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Abstract 
Hereditary fibrosing poikiloderma is an autosomal dominant disorder that is characterised by 
mottled pigmentation and telangiectasia, accompanied by tendon contractures, myopathy and 
pulmonary fibrosis (POIKTMP). Mutations in POIKTMP cases have been shown to harbour 
the Family with sequence similarity 111B (FAM111B) gene. However, its function is 
unknown. The aim of this study was to investigate the causative role of the FAM111B 
mutation (c.1861T>G) in the multi-systemic fibrosis affecting the South African kindred with 
POIKTMP.  
Dermal fibroblasts from two affected siblings and a familial control were reprogrammed into 
induced pluripotent stem cells (iPSCs) via the Sendai virus vector (SeVdp) packaged with 
pluripotency transgenes (OCT4; SOX2; KLF4; C-MYC). The derived iPSCs successfully 
showed a) endogenous expression of pluripotency markers (OCT4; NANOG; TRA-1-60), b) 
in vitro differentiation into the three germ layers (endoderm; mesoderm; ectoderm) and c) 
normal karyotyping. Next, the iPSCs from two patients, a Familial control and a Non-familial 
control were differentiated into mesenchymal stem/stromal cells (iPSC-MSCs) as a cell 
model in this study. Characterisation of derived iPSC-MSCs indicated positive expression of 
MSC markers (CD73; CD90; α-SMA). Differentiation of iPSC-MSCs demonstrated adequate 
osteogenicity but limited adipogenicity. Patient-derived iPSC-MSCs were thereafter analysed 
by qPCR and collagen staining to determine whether the FAM111B mutation alters 
endogenous expression of pro-fibrotic markers as well as collagen synthesis in patient cells 
compared to controls. Messenger RNA expression of pro-fibrotic markers (COL1A1; 
COL3A1; α-SMA) was similar between patient and control iPSC-MSCs. Collagen staining 
and quantification also showed no statistical differences between patient and control cells. 
These results suggest that FAM111B does not directly alter the expression of these pro-
fibrotic genes in this in vitro model system. 
Growth curves were then carried out to investigate if the FAM111B mutation modulates cell 
proliferation and it was found that patient cells proliferated at a higher rate compared to 
controls. To explore the mechanisms underlying the rate change, analyses of FAM111B 
expression during cell cycle progressions were conducted. Extensive optimization 
experiments using the double thymidine block approach were necessary to establish the 
appropriate synchronization protocol, keeping in mind the extended doubling time of iPSC-
MSCs. The results revealed that FAM111B mRNA expression was temporally regulated, 
with a peak at the S-phase and low at the G2/M phase. While there were no pattern 
differences between patient and control cells, FAM111B mRNA expression was significantly 
higher in the patient cells compared to controls at the G1- and S-phase. These results suggest 
that the mutation in FAM111B might affect the stability or perdurance of the mRNA. 
Unfortunately, analysis of the FAM111B protein data was inconclusive. Problems related to 
synchronization of the cells and the specificity of the antibody would have to be rectified in 
order to follow this further. 
The overall findings in this in vitro study reveal that the FAM111B mutation does not alter 
expression of pro-fibrotic markers but does affect the cell proliferation rate of patient cells 
compared to controls. Future work will focus on further optimisation of iPSC-MSCs 
synchronisation to determine correlation of FAM111B mRNA and protein expression during 
cell cycle progression in the patient cells. Furthermore, 3D in vitro cellular models that 
recapitulate some parts of the POIKTMP phenotype will need to be created. Future work will 
also explore the gain-of-function hypothesis to further understand the role of FAM111B in 
fibrosis and cancer phenotype in POIKTMP. 
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Chapter 1 
Literature review 
 
1.1 Introduction 
Hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary 
fibrosis (POIKTMP[MIM#615704) is a rare autosomal dominant genetic disorder. First 
described in a South African family of Dutch descent in 2006, there have been 13 
independent families and 9 sporadic cases of this genetic disorder reported to date (Chasseuil 
et al., 2019). The key features being i) poikiloderma which presents in early childhood and is 
associated with telangiectasia, hypohidrosis and mottled pigmentation, particularly in sun-
exposed areas; ii) muscle contractures of the triceps surae leading to Achilles tendon 
contractures, iii) myopathy with fatty infiltration. and iv) progressive pulmonary fibrosis 
(Mercier et al., 2015; Mercier et al., 2013; Zhang et al., 2019). It also associated with 
exocrine pancreatic insufficiency as well as pancreatic cancer (Chasseuil et al., 2019; Goussot 
et al., 2017; Takeichi et al., 2016). The causative gene has been identified, but the link 
between the mutation and the phenotype has not been elucidated. Therefore, to help 
understand and appreciate the complexity of this condition as it involves dermal sclerosis, 
myopathy and pulmonary impairment, this chapter will address on a broader context the 
phenotype of this condition, focusing on the pathogenesis of fibrosis, which is the cause of 
death in the affected persons. This chapter will also address the aims and objectives of this 
study which will be discussed in detail in the subsequent chapters.      
 
1.2 Hereditary Poikiloderma Syndromes  
Poikiloderma is a dermatological condition that presents with epidermal atrophy, alopecia, 
telangiectasia and mottled pigmentation (Larizza et al., 2010; Nofal & Salah, 2013). 
Hereditary poikiloderma is associated with syndromes such as the Rothmund-Thomson 
(RTS), Kindler, Werner, Weary and Bloom’s syndromes, which are rare autosomal recessive 
disorders (Ellis et al., 1995; Larizza et al., 2010; Lindor et al., 2000; Willis & Lindahl, 1987). 
There have been 300 cases reported for RTS in 2010, and less than 100 cases have been 
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reported for the Kindler syndrome (Fischer et al., 2005; Larizza et al., 2010). From 1916 to 
2002, 1300 cases have been reported for the Werner syndrome (Sert et al., 2009). Bloom’s 
syndrome was reported to have 1:50 000 prevalence persons due to its founder effect, with 
1% of it occurring in the European Ashkenazi Jews (Liu & West, 2008).  
These syndromes present with poikiloderma and overlap in their clinical features. For 
example, the Rothmund-Thomson syndrome (RTS), Werner syndrome and Bloom’s 
syndrome indicate adult progeria, chromosomal instability and predisposition to cancer 
malignancies (Lindor et al., 2000). The Kindler syndrome and Weary syndrome also 
demonstrate similarities, particularly in progressive poikiloderma with blisters and acral 
keratosis (Fig. 1.1). However, there are also clear differences in these syndromes, for 
instance, RTS, Bloom’s syndrome and Kindler syndrome present in early childhood while the 
Werner syndrome presents later in life (see Table 1.1) (Larizza et al., 2010; Lindor et al., 
2000). Due to the overlapping clinical features in some of these syndromes there are no set 
guidelines to properly classify poikiloderma cases. Reliable diagnoses have therefore been 
performed based on genetic and cytogenetic differences (Lindor et al., 2000). For example, 
Bloom’s syndrome which presents with mutations in the RECQ2 gene has a high rate of 
chromatid gaps and breaks that cause genome instability with increased risk of carcinogenesis 
(Ellis et al., 1995). The RTS presents with mutations in the RECQ4 gene and commonly 
presents with cataract and cases of osteosarcoma (Larizza et al., 2010).  
 
 
Figure 1.1: Clinical presentations of Rothmund-Thomson and Kindler syndromes.  
(A) Poikiloderma and bone defects (X-ray) in patients with RTS. (B) Kindler syndrome is shown 
by the crusted lesions of acral bullae (Larizza et al., 2010; Macris et al., 2006)  
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The genes associated with some of these syndromes are well characterised. Most seem to 
be caused by autosomal recessive mutations in the RECQ genes which encode DNA helicase 
enzymes. The human RECQ genes are homologous to the recq gene found in E. coli, and the 
protein has ATPase-dependent helicase activity which functions in unwinding of the DNA 
complementary strand during replication (Ellis et al., 1995; Liu & West, 2008). The RECQ 
proteins are also involved in DNA repair as well as maintenance of genome stability, and 
mutations in these genes produce a truncated protein resulting in loss-of-function and genome 
instability (Bahr et al., 1998; Kitano et al., 2010). Mutations in the RECQ2 gene cause 
chromosomal breakage and increased sister chromatid interchange in somatic cells resulting 
in genome instability and predisposition to cancer (Bahr et al., 1998). Similarly, mutations in 
RECQ3 cause genome instability resulting in malignancy, particularly osteosarcoma (Larizza 
et al., 2010; Macris et al., 2006). Mutations in a different gene, KIND1, are responsible for 
the Kindler syndrome (Lindor et al., 2000). The KIND1 gene encodes the Kindlin-1 protein 
which is involved in the attachment of the actin cytoskeleton to the extracellular matrix at the 
focal adhesion sites, and is expressed in epithelial cells such as keratinocytes (Jobard et al., 
2003; Ussar et al., 2008). Mouse models have shown that loss of function in the Kindlin-1 
protein leads to skin atrophy which is typical of poikiloderma but also causes decreased 
proliferation of keratinocytes and detachment of intestinal epithelia (Ussar et al., 2008).  
 
Table 1.1: Differential Diagnosis of Hereditary poikiloderma syndromes 
Number Syndrome Inheritance Gene Poikiloderma 
Features 
Additional 
Features 
1 Bloom AR RECQ2 Present (when 
exposed to sunlight) 
with telangiectasia 
Excessive sister 
chromatid exchange 
(chromosome 
instability), increased 
risk of cancer 
(myelodysplasia, 
leukaemia) and minor 
immune deficiency 
2 Werner AR RECQ3 Limited to neck & 
upper chest. Onset 
within 1st year of 
life 
Poor dentition, 
Enteropathy 
Chapter 1 
 
4 
 
3 Rothmund-Thomson 
Syndrome 
AR RECQ4 Present (when 
exposed to sunlight) 
Cataract, Dwarfism, 
Hypogonadism, Bone 
abnormalities 
4 Kindler AR KIND1 Widespread, 
Involves Sun 
exposed & Non- sun 
exposed body areas. 
Defective gene 
mapped to 
chromosome 
20p12.3. 
Stenosis of Oesophagus 
Webbing of digits, 
Dental Abnormalities 
Anhidrosis 
5 Weary/Hereditary 
sclerosing 
poikiloderma 
AD  Accentuated in 
flexors with 
sclerotic bands 
Poor dentition, 
Calcinosis cutis 
6 POIKTMP AD FAM111B Widespread with 
telangiectasia, 
hypohidrosis, 
alopecia  
Tendon contractures, 
myopathy with fatty 
infiltration and 
pulmonary fibrosis 
 
 
1.3 Hereditary Fibrosing Poikiloderma (POIKTMP) 
Due to its overlapping features of poikiloderma, alopecia, hypohidrosis and sclerosis, 
hereditary fibrosing poikiloderma (POIKTMP) was first thought to form part of the 
Rothmund-Thomson syndrome or the Weary/Werner syndrome (Khumalo et al., 2006; 
Mercier et al., 2013). Additional clinical features observed in the South African family (Fig. 
1.2) which include myopathy and pulmonary fibrosis thus suggested POIKTMP to be a new 
form of hereditary poikiloderma (Khumalo et al., 2006). There have since been thirteen 
families and nine sporadic POIKTMP cases reported (Kazlouskaya et al., 2018). Genetic 
screening by Whole exome-sequencing (WES) showed that none of the RECQ and KIND1 
genes were involved (Mercier et al., 2013). Mutations were identified in the Family with 
sequence similarity 111, member B (FAM111B) gene which encodes a trypsin-like 
cysteine/serine peptidase (Goussot et al., 2017; Kazlouskaya et al., 2018; Mercier et al., 2013; 
Seo et al., 2016; Takeichi et al., 2016).  
 
 
Table modified from Mahajan et al. (2005) (AD = Autosomal; Dominant, AR =Autosomal Recessive) 
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1.3.1 Clinical presentation of POIKTMP 
This condition in the South African family spans two generations, the second-
generation female, who is the proband presented with poikiloderma, alopecia of the scalp and 
eyebrows, tendon contractures and sclerosis of the digits (Khumalo et al., 2006). The family 
history indicated that the proband’s father, who is deceased presented with similar clinical 
features and died from interstitial pulmonary fibrosis. An autopsy report of the older brother 
who also died from interstitial pulmonary fibrosis indicated that he developed poikiloderma, 
skeletal muscle abnormalities with fatty infiltration and tendon contractures. The surviving 
brother of the proband is also affected and is reported to experience pulmonary restriction 
with high chance of requiring lung transplantation (pers comm, data not shown).  
More POIKTMP cases of similar phenotype as the South African kindred have been 
reported by Mercier et al. (2015; 2013). The affected individuals reported Mercier et al. 
(2013) are of Moroccan, Egyptian, Algerian and of Italian descent, and present with tendon 
contractures, myopathy, and pulmonary fibrosis (Fig. 1.3). Some patients showed evidence of 
growth retardation and anhidrosis which causes heat intolerance. Magnetic resonance 
imaging (MRI) results further indicated that myopathy is caused by fragmentation of the 
skeletal muscle fascicles and increased fatty infiltration (Fig. 1.3D). Skin histology of the 
affected person also indicated formation of elastin globes on the papillary dermis due to 
elastin degeneration (Fig. 1.3C). In their follow-up case report, Mercier et al. (2015) reported 
Figure 1.2: Pedigree of the South African kindred with POIKTMP. The affected individuals 
are represented by solid square (male) or circle (female). The index case (proband) is indicated by 
an arrow (Khumalo et al., 2006) 
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six additional cases of individuals with POIKTMP, with additional phenotype such as 
pancreatic insufficiency and minor liver impairment. The most recent POIKTMP case report 
is of a French family, of whom the proband was a 64-year old male (father) presenting with 
classic poikiloderma, including mottled pigmentation, telangiectasia, marked hypohidrosis 
due to heat intolerance and tendon contractures. The proband did not present with pulmonary 
fibrosis but with pancreatic cancer (Goussot et al., 2017). The proband was reported to have 
none of the risk factors (obesity, smoking and type 2 diabetes) associated with pancreatic 
cancer. The children of the proband, a son and daughter are affected and have been shown to 
carry the mutation indicating autosomal dominance. They also presented in early childhood 
with the same clinical features as their father, except for pancreatic cancer. This is the only 
case to report pancreatic cancer as another feature of POIKTMP. It is unclear at this stage 
whether this is related to POIKTMP. This potential link will be expanded in detail in latter 
chapters, especially because there have been other papers where a link between fibrosis and 
cancer have been posited (Vancheri et al., 2010). The overall analysis of these case reports 
demonstrates that though the onset of POIKTMP is in early childhood, the clinical features of 
this condition vary from patient to patient, with some showing varied muscle atrophy ranging 
from diffuse to severe and pulmonary restrictive patterns beginning in childhood and 
interstitial pulmonary fibrosis or pancreatic cancer occurring in older individuals. (Goussot et 
al., 2017; Mercier et al., 2015; Mercier et al., 2013; Takeichi et al., 2016). 
 
 
Figure 1.3: Clinical presentation of POIKTMP. The images show poikiloderma with 
telangiectasia (A) surgical scars of lengthened Achilles tendon (B), elastin globules in the skin (C) 
myopathy with fatty infiltration (D) and pulmonary fibrosis (Khumalo, 2006; Mercier et al. 2013). 
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1.3.2 Genetic and molecular basis of POIKTMP 
To date, only three familial cases of autosomal dominant inheritance and ten de novo 
cases have been reported globally (Goussot et al., 2017; Khumalo et al., 2006; Mercier et al., 
2015; Mercier et al., 2013; Seo et al., 2016; Takeichi et al., 2016). An autosomal dominant 
mutation was detected in the South African kindred [c.1861T>G (p.Tyr621Asp)] with the 
classic POIKTMP phenotype (Mercier et al., 2013). Another family with an autosomal 
dominant mutation [c.1261_1263del (p.Lys421del)] in the FAM111B gene was reported to 
further show POIKTMP phenotype with pancreatic exocrine dysfunction (Seo et al., 2016). 
In a new case report from Goussot et al. (2017) of autosomal dominant FAM111B mutation 
[c.1884T > A (p.Ser628Arg)] indicated an additional feature of pancreatic cancer. The de 
novo cases reported indicated the same mutations in unrelated individuals (see Table 1.2). 
The most common de novo mutations are c.1883G > A (p.Ser628Asn), c.1879A > G 
(p.Arg627Gly) and c.1289A > C (p.Gln430Pro) (Mercier et al., 2015; Takeichi et al., 2016). 
All mutations were absent in all public genetic variant databases such as 1000 Genomes 
Project, Exome Variant Server and (dbSNP142 (http://www.ncbi.nlm.nih.gov/snp/) (Mercier 
et al., 2015; Seo et al., 2016). Bioinformatic tools (SIFT and PolyPhen) predicted all 
mutations to be deleterious as they affect amino acids that are conserved across mammalian 
species (Mercier et al., 2015; Mercier et al., 2013; Seo et al., 2016). 
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Table 1.2: FAM111B mutations in POIKTMP  
 
Case No. Origin Inheritance Mutation Literature 
1 South Africa AD c.1861T > G 
(p.Tyr621Asp) 
  
  
  
  
  
Mercier et al. 
(2013; 2015) 
2 France De novo c.1874C > A 
(p.Thr625Asn) 
3 Algeria De novo (with 
paternal inheritance) 
c.1879A > G 
(p.Arg627Gly) 
4 France De novo c.1879A > G 
(p.Arg627Gly) 
5 Italy De novo c.1879A > G 
(p.Arg627Gly) 
6 France/Morocco N/A c.1883G > A 
(p.Ser628Asn) 
7 France De novo c.1883G > A 
(p.Ser628Asn) 
8 Ireland De novo c.1883G > A 
(p.Ser628Asn) 
9 Dominican 
Republic 
De novo c.1883G > A 
(p.Ser628Asn) 
10 France N/A c.1289A > C 
(p.Gln430Pro) 
11 United States of 
America 
AD c.1261_1263del 
(p.Lys421del) 
Seo et al. 
(2016) 
12 Kuwait De novo c.1289A > C 
(p.Gln430Pro) 
Takeichi et al. 
(2016) 
13 France AD c.1884T > A 
(p.Ser628Arg) 
Goussot et al. 
(2017) 
 
Although the FAM111B gene encodes a protein with a trypsin-like cysteine/serine 
catalytic domain, its function is currently unknown (Mercier et al., 2013). The FAM111 genes 
(FAM111A and FAM111B) are located on the long arm (q) of chromosome 11, position 
q12.1. The FAM111A gene, which is a paralogue of FAM111B encodes a protein with 611 
amino acid and is located 16 Kb from FAM111B (Fig. 1.4) [provided by RefSeq, Apr 2014]. 
The FAM111B gene spans 3.48 Kb of genomic DNA and consists of 4 exons. It undergoes 
alternative mRNA splicing which gives rise to three transcript variants (http://ncbi.org). 
Transcript variant 1 (NM_198947.3) encodes the longer isoform with 734 amino acids. 
Transcript variants 2 (NM_001142703.1) and 3 (NM_001142704.1) both encode the same 
isoform of 704 amino acids that lacks an exon containing the translational start codon as well 
as a 5’ UTR (transcript variant 3). Both transcript variant 2 and 3 also have a shorter N-
terminus compared to variant 1. 
 AD = Autosomal Dominant; AR =Autosomal Recessive 
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The reported FAM111B mutations are shown to be localised in the loop region of the 
catalytic domain (Goussot et al., 2017; Mercier et al., 2015; Mercier et al., 2013), except for 
the mutation identified in one of the French and a Kuwait patient, which is located on codon 
430 (c.1289A>C) (p. Gln430Pro) upstream of the loop domain (Fig. 1.5).  The mutations 
located in codon 621, 627 and 628 are reported to be associated with early onset POIKTMP 
(Goussot et al., 2017; Mercier et al., 2015; Mercier et al., 2013; Takeichi et al., 2016). 
However, there are also varying poikiloderma features in individuals carrying mutations in 
codons 621, 627 and 628. For example, some patients with c.1879A > G (p.Arg627Gly) 
presented with sclerosis of the digits while others with the same mutation did not (Mercier et 
al., 2015). A mutation in codon 628 [c.1883G > A (p.Ser628Asn)] indicated pancreatic 
impairment (Mercier et al., 2013) and the other [c.1884T > A (p.Ser628Arg)] was associated 
with pancreatic cancer (Goussot et al., 2017). Additionally, it appears that the mutations 
located in codons 621, 627 and 628 are associated with respiratory abnormalities (Mercier et 
al., 2015), except for the case reported by Goussot et al. (2017), which did not present with 
respiratory abnormalities, but rather with pancreatic cancer. The FAM111B mutation c.1289A 
> C (p.Gln430Pro) was reported to present with a mild form of POIKTMP as one of the cases 
Figure 1.4: Chromosomal localisation of FAM111 genes. FAM111 (FAM111A and FAM111B) 
genes are located on the long arm (q) of chromosome 11, position q12.1. ENSEMBL genome 
browser (ensembl.org/index.html).  
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did not present with tendon contractures and myopathy (Takeichi et al., 2016). However, 
pulmonary impairment was detected in an adult (40 years old), while a 14-year old girl with 
the same mutation did not present with pulmonary impairment, thus suggesting that 
pulmonary abnormalities present at adulthood (Mercier et al., 2015; Takeichi et al., 2016). 
Another case of a family with an insertion/deletion (INDEL) mutation c.1261_1263del 
(p.Lys421del), which is located upstream of the loop region presented with pulmonary 
abnormalities and pancreatic exocrine dysfunction affecting persons of different age groups 
(Seo et al., 2016). These FAM111B mutations appear to cause varying severity of the disease 
irrespective of the location of the mutations. The genetic and molecular variation between the 
reported cases therefore highlight the need to understand the function of FAM111B and 
molecular pathogenesis of these mutations in POIKTMP. 
 
 
 
 
 
 
Figure 1.5: FAM111B mutations associated with POIKTMP.  The diagram obtained from the 
database of disordered protein prediction (D2P2) shows amino acids changes (POIKTMP) that are 
conserved across primates. It also shows that mutations c.1861T > G (p.Tyr621Asp); c.1874C > A 
(p.Thr625Asn), c.1879A > G (p.Arg627Gly) and c.1883G > A (p.Ser628Asn) as well as c.1884T > A 
(p.Ser628Arg) are located in the loop region of the catalytic domain. The c.1289A > C (p.Gln430Pro) 
mutation is located upstream of the loop region within the catalytic domain (Mercier et al., 2015). 
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1.4 Functions of FAM1111A and FAM111B proteins 
The microarray database (www.uniprot.org) reports FAM111A and FAM111B to be 
ubiquitously expressed, with FAM111B showing the highest expression in the kidneys, 
skeletal muscle and the skin (Mercier et al., 2013). Both proteins have trypsin-like catalytic 
activity and both seem to play a part in cell cycle regulation, but the link between trypsin-like 
domain and cell cycle regulation is unknown. The STRING network database reports 
FAM111B to have strong interactions with the ATP13A2 and SET proteins (http://string-
db.org/cgi/network). The ATP13A2 protein, which belongs to the ATPase family is reported 
to be involved in regulating the transport of membrane cations as well as maintaining 
neuronal integrity (Ramonet et al., 2012). The SET protein is reported to link the 
transcription complex with chromatin during cellular replication (Fan et al., 2002). This 
suggests that it might play a role in the cell cycle.  
Cell division is essential for embryonic development and cellular function required 
for events such as exercise, immune activation, wound healing and tissue repair, to mention a 
few. Cell cycle entry is tightly regulated by the checkpoints and key regulatory proteins 
which form the dimerization partner, retinoblastoma-like p130 and p107, E2F and MuvB 
(DREAM) complex. The DREAM complex is known to mediate repression of most of the 
cell cycle genes at the quiescent (G0) phase. Phosphorylation of RB-like p130 protein leads 
to its dissociation from E2F (E2F4 and E2F5) repressors and activation of other E2F 
transcription factors such E2F1 and E2F2, which promote cell cycle progression from G0 to 
G1/S (Sadasivam & DeCaprio, 2013); other proteins of the DREAM complex such as MuvB 
bind to the BMYB protein to promote expression of genes required in the G2/M phase 
(Fischer & Müller, 2017; Sadasivam & DeCaprio, 2013). The first phase in cell division is 
DNA synthesis, commonly known as the S-phase. This phase is preceded by gap-1 
(G1)/restriction point, which involves the “sensing” of metabolic, stress and environmental 
cues that determine whether the cell undergoes division, differentiation or death (Massague, 
2004). The cell cycle checkpoints are regulated by cyclin proteins and cyclin-dependent 
kinases (CDKs), which mediate cell cycle progression and division. The G1 phase is 
mediated by phosphorylation of cyclin D and cyclin E by CDK4/6 and CDK2, respectively. 
When cyclin D complexes with CDK4 or CDK6 it hypo-phosphorylates the retinoblastoma 
protein (pRB)- a tumour suppressor and potent inhibitor of G1→S transition (Bertoli et al., 
2013). Hypo-phosphorylation of pRB by cyclin D-CDK4/6 complex keeps it bound to the 
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E2F transcription factor and prevents cell cycle progression into the S-phase. The complexing 
of cyclin E-CDK2 required for S-phase progression is inhibited by the CDK inhibitor (CDKI) 
protein p27. However, with the increase of cyclin D levels, CDK2 dissociates from p27 and 
binds to cyclin E, leading to hyperphosphorylation of pRB and liberation of E2F to initiate 
the transcription of genes required for S-phase progression (Foster et al., 2010; Massague, 
2004).  Mutations in the Rb gene have been shown in cells to escape the G1 checkpoint, 
which increases the risk of oncogenesis (Foster et al., 2010). Once the cell passes the G1 
restriction point it commits to progress into the S-phase for DNA replication. Upon 
completion of chromosome replication, the cell enters the G2 phase which ensures that no 
replication errors are duplicated (Barnum & O’Connell, 2014). This is regulated by the p53 
protein which induces cell cycle arrest and apoptosis should replication errors be detected and 
not corrected. Transition of the cell from G2 to M (mitosis) phase is mediated by the cyclin 
B-CDK1 complex (Kastan & Bartek, 2004). Cellular stress at the G2 phase, leads to 
inhibition of cyclin B-CDK1 interaction via p21, or inhibition of CDC25C phosphatase 
which also prevents CDK1 activation (Foster et al., 2010; Kastan & Bartek, 2004).  At the 
Mitotic (M) phase the cell nucleus membrane is lost (prophase), followed by the centriole 
positioning forming the mitotic spindle required for chromosome metaphase plate. This step 
is followed by the separation of the sister chromatids to the opposite spindle poles of the cell 
(anaphase). Upon separation of the sister chromatids, the nucleoli and nuclear envelopes form 
around the daughter chromosomes followed by cytokinesis which divides the cell into two 
daughter cells.  
There are various ways that a protein could affect the cell cycle. There is an 
interesting link between FAM111A and the ability of a cell to protect itself against 
adenovirus infection in mammalian cells by inducing host cell restriction (Fine et al., 2012). 
Host cell restriction is a process whereby a specific protein prevents virus binding and entry 
in a cell (and thereby the disruption of cell cycle machinery). Adenovirus infection requires 
the Simian Virus 40 (SV40) large T antigen (LT) for replication and cell transformation. The 
study by Fine et al. (2012) indicated that the C-terminus of the SV40 LT physically binds to 
FAM111A for cell cycle entry and replication in the host cell.  Using human osteosarcoma 
epithelial cells (U-2 OS), this study further showed that the SV40 virus hijacks the restriction 
property of FAM111A and uses it for viral replication. Importantly, they demonstrated that 
only FAM111A and not FAM111B interacts with the C-terminus of the SV40 LT antigen. 
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Another study by Alabert et al. (2014), which aimed to understand chromatin dynamics and 
to identify uncharacterised DNA replication factors established that FAM111A contains a 
proliferating cell nuclear antigen (PCNA) interaction motif (PIP box) to which it uses to 
physically bind to PCNA at the early S-phase of the cell cycle. The PCNA is known an 
homotrimeric DNA sliding clamp protein, which encircles double-stranded DNA during 
replication (Dieckman et al., 2012; Moldovan et al., 2007). It also recruits and regulates other 
proteins such as DNA polymerase δ required for replication of the lagging strand during 
DNA synthesis (Moldovan et al., 2007). Its expression levels have been shown to be cell 
cycle dependent, peaking at the G1/S phase and low at the G0 and G2/M phase (Moldovan et 
al., 2007). Proteins that contain PIP motif are reported to enhance the binding affinity of 
PCNA to the DNA strand (Choe & Moldovan, 2017). The binding of FAM111A to the 
PCNA PIP box therefore suggests its involvement during DNA replication. Alabert et al. 
(2014) further showed that knockdown of FAM111A by siRNA delays S-phase entry in 
mammalian cells and inhibits cell proliferation. Furthermore, this study indicated that 
FAM111A localises with PCNA and that its knockdown delays progression of the cell from 
the G1/S to G2/M phase, thus delaying cellular replication.  
Interestingly, a recent study showed that FAM111B is also involved in the cell cycle 
(Aviner et al., 2015). Using an integrative multi-omic study approach, Aviner et al. (2015) 
revealed that the FAM111B expression pattern increases at the mRNA level during the G1 
phase, with protein accumulation at the S-phase in synchronised HeLa cells. This expression 
pattern is reported to follow similar expression to PCNA and MCM2. This link to the cell 
cycle will be expanded in detail in chapter 4, this leads next to the pivotal question of the 
relationship between cell cycle and fibrosis. In order to understand this, a detailed 
appreciation of fibrosis is needed. 
 
1.5 Aetiology and pathogenesis of fibrosis 
Fibrosis is the overproduction, deposition and accumulation of collagen and other 
extracellular matrix (ECM) proteins caused by chronic injury and aberrant tissue repair 
(Krieg et al., 2007; Wynn & Ramalingam, 2012).  Most organ failures result from excessive 
scarring (fibrosis) of the tissue parenchyma which leads to cellular dysfunction and 
eventually death. Fibrosis is responsible for 45% of deaths in the developed world (Usunier et 
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al., 2014). The commonly investigated fibrotic diseases are systemic sclerosis (SSc), hepatic 
fibrosis, interstitial renal failure and idiopathic pulmonary fibrosis (Ley & Collard, 2013; 
Rockey et al., 2015). Systemic sclerosis/scleroderma (SSc) is an autoimmune disease 
characterised by abnormal connective tissue, autoantibody production and fibrosis of the skin 
and other tissues (Maurer & Distler, 2011). The cause of death in SSc patients is commonly 
SSc-related pulmonary fibrosis and myocardial disease (Barnes & Mayes, 2012).  Idiopathic 
pulmonary fibrosis (IPF) is a progressive form of interstitial pneumonia with severe 
prognosis and poor survival rate of 3-5 years from the time of diagnosis (Caminati et al., 
2015). The pathogenesis is poorly understood but is associated with genetic and 
environmental risk factors (Denham & Hauer-Jensen, 2002; Wynn, 2011). Since fibrosis is an 
irreversible disorder, current treatments aim to prevent disease progression and prolong 
survival (Bonella et al., 2015). 
The patients with POIKTMP develop systemic fibrosis primarily in the skin, lungs 
and display fibrosis-associated myopathy (Goussot et al., 2017; Khumalo et al., 2006; 
Mercier et al., 2015; Mercier et al., 2013; Takeichi et al., 2016). While it was initially thought 
that the skin fibrosis in POIKTMP patients was similar to that of SSc patients, the dermal 
features were however distinct as the dermis of POIKTMP patients show elastic globes 
caused by elastin degeneration, as well as sclerosis of the digits. The SSc patients do not 
show elastin degeneration but present with thickening of the hypodermis and anti-
mononuclear antibodies, features that are absent in POIKTMP patients (Khumalo et al., 2006; 
Shi-Wen et al., 1997). This section will therefore focus on collagen synthesis and regulation 
in skin, muscle and lungs to understand wound healing and onset of fibrosis in these tissues 
that are affected in POIKTMP patients. 
 
1.5.1 The role of the ECM in wound healing   
The connective tissue which is composed of the extracellular matrix and fibroblasts, 
provides the microenvironment with structural support and cellular network responsible for 
cell adhesion (Parker et al., 2014). During inflammation the activated inflammatory cells (e.g. 
eosinophils, basophils, mast cells & macrophages) are recruited to the site of injury to prevent 
infection. The release of cytokines, chemokines and growth factors from inflammatory cells 
stimulates activity effector cells, which include resident fibroblasts, pericytes, fibrocytes and 
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mesenchymal cells.  The effector cells are known to be key players in scar formation as well 
as fibrosis. Following the inflammatory phase, resident fibroblasts proliferate and secrete 
matrix metalloproteinases (MMPs) for resorption of the old ECM and deposition of new 
collagen and ECM (see review by (Diegelmann & Evans, 2004)).  
A key feature of wound healing and tissue remodelling is the activation of quiescent 
fibroblasts which are trans-differentiated into contractile myofibroblasts that express high 
levels of alpha-smooth muscle actin (α-SMA), type I and III collagen as well as other ECM 
proteins such as fibronectin, elastin and integrins (Barrientos et al., 2008). Normal wound 
healing is therefore tightly regulated by homeostasis of collagen deposition and degradation 
(summary in Fig. 1.6). 
 
 
 
 
Figure 1.6: Normal wound healing. During injury the damaged cells release chemokines and cytokines 
which activate and recruit platelets and other inflammatory cells to site of injury (haemostasis phase). The 
recruited inflammatory cells (inflammatory phase) also release cytokines (e.g. TGF-β and IL-13) which 
in turn activate fibroblasts to proliferate and differentiate into myofibroblasts for production of collagen, 
ECM and MMPs for tissue repair/remodelling (maturation/remodelling phase). Dysregulation of tissue 
remodelling leads to fibrosis (image illustrated by (Wynn, 2004).     
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1.5.2 Collagen synthesis and turnover  
   Changes in the homeostasis of ECM production, particularly during wound healing 
leads to fibrosis, resulting in overproduction and accumulation of type I and III collagen. 
Therefore, understanding the molecular mechanism of collagen synthesis and regulation 
provides insight into the pathology and approaches that can be used for treatment.  
Collagen constitutes over 30% of the body’s total protein and is essential in human 
physiology as it is involved in structural integrity of tissues (Hulmes, 2002; Minor, 1980). 
The collagen molecule is a triple-helix with a Gly-X-Y motif, where the X is mostly proline 
and Y is often hydroxyproline (Jinnin, 2010; Viguet-Carrin et al., 2006). The transcribed 
collagen mRNA (procollagen) interacts with ribosomes to form procollagen polypeptide 
chains which are imported into the lumen of the rough endoplasmic reticulum for translation 
and post-translational modification initiated by the hydroxylation of proline and lysine 
residues by prolyly-3-hydroxylase, prolyly-4-hydroxylase and lysyl hydroxylase respectively 
(Trackman, 2005). Hydroxylation of proline and lysine residues initiates the cross-linking 
and stable conformation of procollagen chains into triple helices which cannot be 
hydroxylated once formed. Procollagen chains are then chaperoned to the Golgi apparatus by 
the heat shock protein 47 (HSP47) for packaging of procollagen into secretory vesicles and 
exported to the extracellular space for further modification (Sluijter et al., 2004; Trackman, 
2005). In the extracellular space the non-helical pro-peptides are cleaved at the N- and C-
termini by procollagen proteinases. Cleavage of the N- and C-termini leads to the soluble 
collagen becoming insoluble to form collagen fibrils. The final step is the crosslinking of the 
collagen fibrils through a catalytic reaction by the lysyl oxidase (LOX) enzyme (Trackman, 
2005; Viguet-Carrin et al., 2006) (See Fig. 1.7).  
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Collagen turnover in the ECM is regulated by matrix metalloproteinase proteins 
(MMPs) that have a catalytic domain with zinc binding motif that binds to three histidines for 
collagen degradation, and a C-terminus that has the hemopexin domain required for cleavage 
of helical interstitial collagens (Marion & Mao, 2006; Nagase & Woessner, 1999). The 
MMPs are classified into collagenases (MMP-1, -8 and -13) which breakdown collagen type 
I, II, and III; gelatinase (MMP-2 and -9) and membrane-type MMP (MMP 14-16), to mention 
a few. The secretion of MMP collagenase by fibroblasts results in their binding to collagen to 
Figure 1.7: Collagen synthesis. A shematic diagram showing the steps and enzymes involved in 
collagen synthesis. Illustration by (Viguet-Carrin et al., 2006). 
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unwind the collagen triple helix, and the single collagen strands are further degraded by 
gelatinase (MMP-2 & MMP-9) as well as serine proteinases such as cathepsin K (Lauer-
Fields et al., 2009; Laurent, 1987; McKleroy et al., 2013; Nagase & Woessner, 1999). The 
MMP activity is regulated by tissue inhibitors of metalloproteinases (TIMPs), which are 
known to be involved in development and tissue remodelling as well as preventing tumour 
cell invasion (Nagase & Woessner, 1999). There are four known TIMP isoforms (TIMP 1-4) 
whose N- and C-termini contain cysteine residues that form disulphide bonds for interaction 
with the hemopexin domain of MMPs required for downregulating MMP activity (Arpino et 
al., 2015; Baker et al., 2002). 
 
1.5.3 Activation of fibroblasts and transcriptional regulation of collagen synthesis  
Chemokines, growth factors and cytokines such as interferon-gamma (IFN-γ), 
interleukin-6 (IL-6), platelet-derived growth factor (PDGF), connective tissue growth factor 
(CTGF) and transforming growth factors (TGFs) are known to mediate activation and 
regulation of collagen synthesis (Krieg et al., 2007; Narayanan et al., 1989). The TGF-β 
cytokine is a master regulator of this process (Gelse et al., 2003). It is primarily secreted by 
fibroblasts and macrophages during this process (Desmouliere et al., 1993; Leask & 
Abraham, 2004). There are three known protein isoforms of TGF-β, namely TGF-β1, TGF-
β2 and TGF-β3. The TGF-β1 isoform has a higher binding affinity to their receptors (TGF-
βRI and TGF-βRII), and is the major isoform regulating collagen synthesis (Biernacka et al., 
2011; Cheifetz et al., 1990). It is synthesised and secreted into the ECM in its inactive form 
(latent precursor TGF-β). Protease-dependent activation is required Through protease-
dependent conformational modification of LAP, the LAP-bound TGF-β is released into its 
active form. Phosphorylation of TGFβRI receptor activates phosphorylation of SMAD (R-
SMAD2 and R-SMAD3) proteins. Upon phosphorylation the R-SMAD2 or R-SMAD3 form 
a hetero-trimer complex with SMAD4 which translocate to the nucleus to initiate 
transcription of target genes such as type I, III and V collagen, α-SMA and other ECM genes 
(Diegelmann & Evans, 2004; Hall et al., 2003). In addition, the TGF-β pathway is regulated 
by activation of SMAD7 which inhibits the formation of SMAD2/3-SMAD4 complex 
thereby downregulating expression of collagen and other ECM proteins under normal 
conditions (Nagase & Woessner, 1999). 
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1.5.4 Abnormal wound healing and fibrosis 
Chronic inflammation and aberrant tissue repair/remodelling are the common causes 
for the imbalance between synthesis and degradation of collagen and other ECM 
components, which alters the architecture of the stroma resulting in compromised function of 
the affected tissues (Wynn, 2007). Chronic inflammation is due to a persistent immune 
response which maintains the activation of inflammatory cells such as neutrophils, 
mononuclear cells and macrophages, which secrete cytokines and growth factors such as 
TGF-β that stimulate the trans-differentiation of resident fibroblasts into myofibroblasts as 
well as expression of pro-fibrotic genes (Borthwick et al., 2013; Wynn, 2008). The secretion 
of cytokines such as interleukin-4 (IL-4) and IL-13 have been shown to also play key roles in 
fibrosis (Borthwick et al., 2013). Interestingly, both IL-4 and IL-13 have been reported to 
have similar functionality and share common receptors for activation and differentiation of 
stromal fibroblasts and circulating fibrocytes into myofibroblasts (Coward et al., 2010; 
Desmouliere et al., 1993; Wynn, 2008).  
Macrophages have further been shown to be extensively involved in fibrogenesis due 
to their plasticity (Laskin et al., 2011). The plasticity produces two subpopulations that have 
been shown to be active during wound healing; the classic M1 subpopulation is activated by 
proinflammatory cytokines such as tumour necrosis factor-α (TNF-α) and IFN-γ which 
induce an immune response during wound healing. The alternative M2 subpopulation acts to 
downregulate inflammation, thus inducing tissue repair and remodelling by releasing anti-
inflammatory cytokines such as IL-4, IL-10 and IL-13 as well as activating TGF-β expression 
(Laskin et al., 2011; Novak & Koh, 2013). Moreover, studies have reported M2 to interact 
with mesenchymal stem/stromal cells for immune modulation, myofibroblast formation and 
recruitment of pericytes during tissue repair. However, it has been suggested that in aberrant 
tissue repair the MSC-macrophage interaction may lead to fibrosis and maintain the 
hyperactivity of M2 macrophages which contributes to the fibrotic state in affected tissues 
(Chung & Son, 2014).  
The activation of resident fibroblasts and circulating fibrocytes by growth factors such 
as TGF-β and CTGF not only leads to their trans-differentiation but also induces increased 
proliferation of these effector cells (Yang et al., 2015). It been indicated that in conditions 
such as IPF that IPF-derived fibroblasts increase their proliferation by overriding the negative 
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feedback that is mediated by the phosphatase and tensin homolog (PTEN)-a tumour 
suppressor protein that is involved in cell cycle regulation (Xia et al., 2008). Increased 
proliferation of fibroblasts and other effector cells during fibrosis is also reported to be 
caused by modulation of the TGF-β as well as the Wnt/β-catenin signalling pathways which 
will be discussed in section 1.5.6 below. Furthermore, proliferation of these cells during 
fibrosis has been shown to be due to altered cell cycle progression. For instance, aberrant 
induction of integrin proteins activates signalling of Rho kinase pathways which increases 
expression of cell cycle genes such as cyclin D1 (Moreno-Layseca & Streuli, 2014; Watts et 
al., 2006). Due to its importance in fibrosis and in POIKTMP, cell proliferation will be 
discussed extensively in chapter 4.  
 
1.5.5 Origin of myofibroblasts involved in wound healing and fibrosis 
Resident fibroblasts in the injured tissue are the primary source of myofibroblast cells 
as shown in a study by(Gabbiani et al., 1972) using male wistar rats to study the ultrastructure 
of fibroblasts during wound healing. The key feature of myofibroblasts is their high 
expression of α-SMA which provides myofibroblasts their contractile property during tissue 
repair (Darby et al., 1990; Masur et al., 1996). They also produce high levels of type I and III 
collagen and other ECM proteins for wound repair (Ansorge et al., 2017; Hinz, 2007). 
Treatment of corneal or dermal fibroblasts with TGF-β in vitro showed formation of 
myofibroblasts as they were larger than fibroblasts, have a well-developed rough 
endoplasmic reticulum and can revert into fibroblasts upon cell-to-cell contact (Masur et al., 
1996). In normal wound healing, quiescent fibroblasts are activated for differentiation into 
myofibroblasts by TGF-β, CTGF and other cytokines; and upon scar formation they are 
removed either by reverting into fibroblasts or phagocytosed by macrophages. However, in 
chronic inflammation or chronic injury fibroblasts continuously maintain their myofibroblast 
state thus resulting in increased collagen and ECM production which causes fibrosis 
(Desmouliere et al., 1993). 
It has been shown that myofibroblasts can also be derived from other cell sources of 
mesenchymal origin (Wynn, 2008). These include perivascular mesenchymal cells and 
fibrocytes from the bone marrow which serve as myofibroblast progenitors, and have also 
been suggested to contribute to liver cirrhosis in post-hepatic transplants due to excessive 
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scar formation (Forbes et al., 2004; Gabbiani, 2003). In other tissues such as the liver, it has 
been reported that activation of hepatic stellate cells by TGF-β1 and other cytokines also 
leads to their differentiation into myofibroblasts, which further contributes to liver fibrosis in 
aberrant tissue repair (Berardis et al., 2015). In skeletal muscle, mesenchymal progenitor cells 
known as fibro/adipogenic progenitors localised in the intermuscular region and express 
PDGF receptor-α (PDGFRα), have been shown to contribute to muscle fibrosis by 
differentiating into fibrofatty tissue (Uezumi et al., 2014; Uezumi et al., 2011). Interstitial 
cells in the lung septa have also been reported to differentiate into myofibroblasts during lung 
injury and can persist in chronic inflammation (Desmouliere et al., 1993). 
Other sources of myofibroblasts have been suggested to be derived from resident 
endothelial and epithelial cells that undergo a reversible process known as endothelial-to-
mesenchymal transition (EndMT) and/or epithelial-to-mesenchymal transition (EMT) 
respectively (Fig. 1.8) (Kalluri & Neilson, 2003; Willis et al., 2006; Zeisberg et al., 2007).  
Zeisberg et al. (2007) for example, showed that endothelial cells stimulated by TGF-β 
undergo EndMT during cardiac fibrosis for production of the ECM and collagen. Chronic 
injury in the lungs has also been shown to induce metaplasia of type II alveolar epithelial 
cells (AECs) into myofibroblasts, thus activating the EMT process in a TGF-β-dependent 
manner (Coward et al., 2010). The EMT has also been reported in kidney injury, where 
tubular epithelial cells differentiate into α-MSA-positive myofibroblast-like cells during 
tissue repair (Berardis et al., 2015; Strutz & Zeisberg, 2006). The differentiation of these cells 
into myofibroblasts also contributes to fibrosis in chronic wound healing in different tissues. 
Therefore, targeting of these cells to prevent myofibroblast formation could delay or prevent 
fibrosis progression. 
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1.5.6 Molecular pathways involved in fibrosis 
The common pathway in fibrogenesis in many affected tissues occurs via the 
canonical TGF-β1 pathway as TGF-β is a potent profibrotic factor (Pohlers et al., 2009; 
Rockey et al., 2015; Wynn & Ramalingam, 2012). The constitutive secretion of TGF-β1 by 
fibroblasts and macrophages in chronic injury activates the SMAD2/3 and SMAD4 complex, 
which translocate to the nucleus to induce expression of collagen type I, type III and other 
ECM components (Borthwick et al., 2013; Pohlers et al., 2009). In systemic sclerosis (SSc), 
collagen I (COL1A1; COL1A2) levels have been shown to be elevated in dermal fibroblasts 
of SSc patients following analysis of collagen mRNA and quantification of soluble collagen 
protein (LeRoy, 1974; Shi-Wen et al., 1997). In lung fibrosis, activation of TGF-β1 is shown 
to promote apoptosis of epithelial cells as well as EMT resulting in the formation of 
myofibroblasts (Borthwick et al., 2013; Guarino et al., 2009; Iwano et al., 2002). In aberrant 
Figure 1.8: Origin of myofibroblasts.  Besides resident fibroblasts that form myofibroblasts, circulating 
fibrocytes and bone marrow-derived mesenchymal stem cells are also recruited and activated, commonly by 
TGF-β, to form myofibroblasts. Epithelial cells undergo EMT process to form myofibroblasts during wound 
healing. After normal wound healing the myofibroblasts either revert to their original cell type or undergo 
apoptosis or phagocytosis. In abnormal wound healing however, there is excessive proliferation of 
myofibroblasts which increase ECM and collagen production leading to fibrosis. Diagram modified from 
(Chakraborty et al., 2014). 
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skeletal muscle repair, TGF-β1 inhibits proliferation and differentiation of myoblasts and 
satellite cells into myotubes by altering the expression of myogenic proteins such as desmin, 
MyoD and myogenin. Instead, it promotes their differentiation into myofibroblasts (Garg et 
al., 2015; Li et al., 2004; Mann et al., 2011). Other cytokines such as CTGF and PDGF have 
also been shown to act in concert with TGF-β1, further augmenting its activity (Leask & 
Abraham, 2004). 
Signalling pathways that act in a TGF-β-dependent and independent manner have also 
been reported to play a role in fibrogenesis. Additional pathways involved in fibrogenesis are 
the Wnt/β-catenin and Hedgehog pathways (Rosenbloom et al., 2013). Both pathways have 
been shown to be activated in lung, kidney, skin and muscle fibrosis (Akhmetshina et al., 
2012; Clevers & Nusse, 2012; Ding et al., 2012; Nusse, 2005; Stewart et al., 2003). Both 
Wnt/β-catenin and Hedgehog pathways are well characterised in embryonic development as 
they play a role in cell proliferation, body axis formation, stem cell maintenance and cell-fate 
determination (Cerdan & Bhatia, 2010; Ding et al., 2012; Ribes & Briscoe, 2009; van 
Amerongen & Nusse, 2009). The canonical Wnt/β-catenin pathway is activated by the 
binding of the Wnt ligands to the Frizzled transmembrane receptor and low-density 
lipoprotein receptor-related protein 5/6 (LRP5/6) complex, which activates the complexing of 
Disheveled (Dvl), Axin-2 and Adenomatosis Polyposis Coli (APC) proteins. This complex 
leads to the dephosphorylation and accumulation of β-catenin in the cytoplasm and eventual 
translocation into the nucleus where it binds to the T-cell factor/lymphoid enhancer-factor 
(TCF/LEF) for transcriptional activation of target genes (van Amerongen & Nusse, 2009). 
Inhibition of the Wnt/β-catenin pathway is mediated by binding of the Dickkopf-1 (Dkk-1) 
ligand on the LRP5/6 receptor which stimulates the formation of Dvl, axin, APC and 
glycogen synthase kinase-3β (GSK-3β) complex. This complex phosphorylates β-catenin 
thus leading to its degradation via ubiquitination (Nusse, 2005; van Amerongen & Nusse, 
2009). The involvement of the Wnt/β-catenin signalling in fibrosis has been primarily shown 
by the accumulation of β-catenin in the nucleus (Akhmetshina et al., 2012; Carthy et al., 
2011; Chilosi et al., 2003). In human or animal studies where fibroblast cells were treated 
with Wnt-1, Wnt-3a or Wnt-10b there was an observed elevation of pro-fibrotic proteins such 
as type I collagen, α-SMA and MMP-7 (Carthy et al., 2011; Chilosi et al., 2003; Lam & 
Gottardi, 2011a). It was also reported that Wnt/β-catenin signalling induces the EMT process 
for myofibroblasts formation further inducing fibrosis (Gonzalez & Medici, 2014). 
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Furthermore, it was shown that aberrant Wnt/β-catenin signalling results in 60-80% 
downregulation of Dkk-1 in fibrotic diseases such as SSc, lung and liver fibrosis 
(Akhmetshina et al., 2012). Moreover, there is lack of Dkk-1 compensation by other Dkk 
proteins such as Dkk-2, which was observed in mice treated with a neutralising antibody 
against Dkk-1 (Akhmetshina et al., 2012). Furthermore, Akhmetshina et al. (2012) showed 
that TGF-β activates Wnt/β-catenin signalling via the p38 pathway by decreasing the 
expression of Dkk-1 in cultured human fibroblasts. Other studies have also shown that 
Wnt/β-catenin signalling can be activated via the canonical TGF-β pathway through 
phosphorylation of SMAD2/3 (Carthy et al., 2011; Lam & Gottardi, 2011b). These studies 
therefore suggest that the Wnt/β-catenin signalling can be activated in a TGF-β-dependent 
and independent manner, thereby contributing to fibrosis progression. 
Though Sonic Hedgehog (SHH) signalling is active during embryonic development, it 
is reported to be deactivated in healthy adults, but is activated during wound healing and 
tissue repair, as well as in fibrosis (Ding et al., 2012; Jia et al., 2017). The canonical SHH 
pathway involves binding of the SHH ligand to the Patched-1 (Ptch-1) transmembrane 
receptor which induces the de-repression of the Smoothened (Smo) protein that when 
repressed is localised in intracellular endosomes. The de-repressed Smo protein activates the 
Gli-1 transcription factor which translocates to the nucleus for expression of its target genes. 
It was shown that SHH secretion in kidney fibrosis is very high thus resulting in increased α-
SMA, type I collagen and high induction of EMT in tubular epithelial cells, while in a 
knockout model reverses the fibrotic phenotype (Ding et al., 2012). 
 
1.6 Disease models for fibrosis 
1.6.1 In vivo fibrosis models  
In vitro and in vivo models have been developed to study the complexity of fibrosis 
and the pathways involved therein.  Various animal models have been developed to identify 
specific mediators and molecular pathways that drive fibrogenesis. The various mouse 
models that have been developed for studying skin fibrosis include bleomycin-induced 
fibrosis, the tight-skin (Tsk mutant), Graft-vs-Host Disease (GvHD) and the TGFβRI/II (Cre-
Lox) mouse model (Aso et al., 1976; Denton et al., 2007; Do & Eming, 2016; Green et al., 
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1976; Ruzek et al., 2004; Smith & Chan, 2010; Yamamoto et al., 1999). Bleomycin, an anti-
cancer reagent was previously used to block the progression of cancerous cells to the G2 
phase of the cell cycle by causing DNA double strand breaks. The side effects of the 
treatment however, included scleroderma accompanied by lung fibrosis in humans (Aso et 
al., 1999). Bleomycin treatment in mouse skin induces scleroderma at the treated site when 
injected subcutaneously daily for four weeks, and causes an inflammatory response by 
infiltration of mononuclear cells in skin lesions as well as thickening of the dermis 
(Yamamoto et al., 1999). Furthermore, it was shown to cause fibroblast trans-differentiation 
into myofibroblasts leading to increased collagen synthesis and production of anti-
mononuclear antibodies, which mimicked the scleroderma phenotype observed in humans. 
This model has been shown to be effective at identifying the pro-fibrotic mediators which can 
be targets for anti-fibrotic drug treatment. However, the challenge of this model is that the 
skin lesions and thickened dermis are localised at the injected site while the clinical features 
observed in SSc patients are diffused (Do & Eming, 2016). Also, the scleroderma phenotype 
in mouse models is strain-dependent, with the C57/BL6 strain being susceptible to bleomycin 
treatment and the BALB/C strain being resistant (Moore et al., 2013; Beyer et al., 2010; 
Harrison & Lazo, 1988). The BALB/C strain is indicated to be resistant to bleomycin 
injection due to the suppressor T-cells it produces in the spleen that prevent a fibrotic 
response (Schrier & Phan, 1984). 
The Tsk-1 (mutant) model, first discovered in the Jackson laboratory, is a mouse 
carrying a spontaneous autosomal dominant mutation in the Fibrillin gene (Green et al., 
1976). The Tsk-1 mice develop tight-skin two weeks postnatal, and present with hyperplasia 
of the loose connective tissue, bone and cartilage, which are some of the features observed in 
skin fibrosis.  Moreover, the Tsk-1 mouse fibroblasts produce high levels of type I and III 
collagen (Beyer et al., 2010). It was also reported that other growth factors such as CTGF and 
Wnt3a levels are increased in this model (Green et al., 1976). However, the limitation of the 
Tsk-1 model is that it does not induce an inflammatory response, which is one of the primary 
features of scleroderma (Green et al., 1976).  
The Tsk-2 (mutant) model was observed in the offspring of the 101/H mouse strain 
treated with the mutagenic ethylnitrosourea (ENU), which caused an autosomal dominant 
mutation in the alpha-1 propeptide chain of type III collagen (Beyer et al., 2010; Christner et 
al., 1995; Denton et al., 2007). In contrast to the Tsk-1 model, the Tsk-2 mice produce anti-
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mononuclear antibodies and display inflammatory cell infiltration in the affected tissue, 
which is lacking in the Tsk-1 model. However, the Tsk-2 model is less well characterised than 
the Tsk-1 model. Furthermore, both mouse models display thickening of the hypodermis but 
incompletely recapitulate the phenotype observed in SSc humans (Baxter et al., 2005; Beyer 
et al., 2010).  
Although the pathogenesis of pulmonary fibrosis is poorly understood, the animal 
model that is widely used and well established for this disease is the bleomycin model (Aso et 
al., 1976). It is not known how bleomycin specifically induces lung fibrosis, but its systemic 
administration in mice causes destruction of the pulmonary vascular endothelium and 
alveolar epithelial cells by breaking down the basement membrane. This therefore leads to an 
inflammatory response, proliferation and differentiation of resident epithelial and fibroblast 
cells (Moore et al., 2013; Coward et al., 2010). Due to the hyperplasia of alveolar epithelial 
cells (AECs) and metaplasia of the squamous cell, the integrity of the basement membrane 
remains disrupted further increasing the infiltration of myofibroblasts and collagen deposition 
in the stroma. Bleomycin has therefore been used to study the pro-fibrotic pathways and cell-
to-cell interaction for drug targets (Moore et al., 2013).   
 
1.6.2 In vitro fibrosis models 
In vitro fibrosis models that are well established are those where fibroblasts are 
constitutively treated with TGF-β or CTGF to mimic their trans-differentiation into 
myofibroblasts and overproduction of collagen as well as other ECM proteins (Desmouliere 
et al., 1993). Some in vitro SSc studies have shown that fibroblasts obtained from SSc 
patients maintain their myofibroblast phenotype and express high levels of type I collagen 
without TGF-β induction (LeRoy, 1974). Two-dimensional (2D) co-culture systems have 
also been used to determine the effect of cell signalling and cell-to-cell interaction during 
fibrosis. For example, Holt et al. (2010) performed a fibroblast-macrophage co-culture to 
determine the effect of cell signalling via the paracrine (non-contact) effect using 
macrophage- or fibroblast-conditioned medium and by juxtacrine (co-culture) mechanism. 
They observed that fibroblasts cultured in macrophage-conditioned medium increased the 
production of pro-inflammatory cytokines such as IL-6, while macrophages maintained in 
fibroblast-conditioned medium produced reduced levels of pro-inflammatory cytokines. This 
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study therefore indicated the role of paracrine and juxtracrine mechanisms that influence 
changes in cellular activity and response during the inflammatory and remodelling phases of 
wound healing.  While in vitro monocellular or co-culture systems have yielded invaluable 
knowledge in understanding some the mechanisms involved in fibrosis, their limitation 
involves the inability to create a cell culture model where most, if not all the cell types 
involved in fibrosis are included. This is also due to the complexity of mimicking the in vivo 
microenvironment in vitro. For example, macrophages have been shown to undergo 
alternative activation to secrete anti-inflammatory cytokines such as IL-10 and TGF-β, 
induced by autocrine effect and/or by secretion of IL-4 or IL-6 by epithelial or endothelial 
cells (Ayaub et al., 2017; Laskin et al., 2011). Alternatively-activated macrophages (M2) 
together with endo/epithelial cells further induce fibroblast proliferation and trans-
differentiation into myofibroblasts, which further drives overproduction of collagen and other 
ECM proteins that are involved in fibrosis. Also, it is difficult to determine the positive or 
negative feedback signals of such systems in 2D in vitro cell culture. Furthermore, 
exogenously activated cells can induce an attenuated response in vitro, which does not 
adequately mimic the effects observed in vivo (Holt et al., 2010). Furthermore, fibrosis is a 
progressive condition and its effects manifest over a long period, therefore, to circumvent 
some of these limitations better in vitro models need to be further developed. 
 Three-dimensional (3D) culture systems have since been established and demonstrate 
great promise in mimicking the in vivo fibrosis milieu.  The 3D culture system uses collagen 
gels or hydrogels to construct matrix scaffolds which can be used to study cell migration, 
invasion, remodelling and cell-to-cell interaction as well as signalling (Smithmyer et al., 
2014; van Spreeuwel et al., 2017). Furthermore, the 3D matrix composition can be adjusted 
to mimic the matrix stiffness observed in fibrosis, thus making it possible to study changes in 
cellular response in such conditions.  For instance, hydrogels have been used to mimic the 
ECM and induce a fibrotic state in cardiac fibrosis studies where the stiffness of the matrix 
determined differentiation of fibroblasts into myofibroblasts, thus mimicking key fibrotic 
processes that occur in vivo (Smithmyer et al., 2014; Zhao et al., 2014). 3D culture systems 
hold great promise in further understanding the involvement of specific cell types in fibrosis 
as well as using them as screening potentials for anti-fibrotic drugs. Moreover, with 
increasing application of pluripotent or multipotent stem cells, there is a greater avenue for 
developing better in vitro disease models.    
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1.7 Using stem cells for disease-modelling  
Stem cells have been used for decades to study and understand animal and human 
development as well as genetic disorders. They have also been used where animal models 
failed to recapitulate the phenotypes observed in specific human diseases (Avior et al., 2016). 
Stem cells have been advantageously used in vitro because of their capacity to self-renew and 
differentiate into different cell lineages (Lewandowski et al., 2017). Totipotent stem cells 
have an infinite spectrum of differentiation and can form both the embryo and placenta. 
Pluripotent stem cells have the capacity to self-renew and differentiate into the three 
embryonic germ layers. Multipotent stem cells have a limited capacity to self-renew and 
differentiate into other cell lineages (Lewandowski et al., 2017). Stem cells can be derived 
from adult tissues such as the bone marrow, blood, skin, muscle and liver (Boisset & Robin, 
2012).  Adult stem cells, which are primarily active during wound healing and tissue 
remodelling are multipotent and therefore have a limited capacity to self-renew and 
differentiate into various cell lineages (Blanpain et al., 2004; Seaberg & van der Kooy, 2003). 
They are most commonly found in a specific microenvironment or niche as stem cell 
precursors; for example, satellite cells found in skeletal muscle are localised in the 
sublaminar regions, stellate cells are localised between hepatic lobules, and haematopoietic 
stem cells are found in the bone marrow (Blanpain et al., 2004; Lewandowski et al., 2017). 
Due to their limited number and capacity to self-renew, especially in vitro, it is challenging to 
use adult stem cells for therapeutic applications (Blanpain et al., 2004; Potten & Loeffler, 
1990).  
Pluripotent stem cells are therefore an excellent source to study embryonic 
development, various diseases as well as the development of regenerative medicine due to 
their limitless self-renewal as well as the potential to differentiate into the three germ layers 
(Lewandowski et al., 2017; Thomson et al., 1998; Xu et al., 2015).  Embryonic stem cells 
(ESCs) which were first derived by Thomson et al. (1998) from the inner cell mass of a 5-day 
old blastocyst fertilised in vitro are pluripotent cells and have been used to further study 
embryonic development, human diseases as well as the development of potential cell 
therapies and drug discovery (Avior et al., 2016; Merkle & Eggan, 2013; Stadtfeld & 
Hochedlinger, 2010). Embryonic stem cells have also been derived by the somatic cell 
nuclear transfer (SCNT) method, where a somatic cell nucleus is transferred into an 
enucleated oocyte (Gurdon, 1962; Wilmut et al., 1997) to create ESC-like cells by the 
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electrical impulses and extraction and culture of the inner cell mass (Wilmut et al., 1997). 
This method has been successful in animal models but not in human cells due to challenges 
such as abnormal gene expression, incomplete reprogramming and dysregulation of 
epigenetics during “reprogramming” (Lewandowski et al., 2017; Stadtfeld & Hochedlinger, 
2010; Tachibana et al., 2013; Wakayama & Yanagimachi, 1999). Other challenges in using 
ESCs or SCNT-derived ESCs include lack of cell therapy development due to immunogenic 
response. Furthermore, SCNT-derived ESCs are less viable in culture and only contain two 
types of DNA, the mitochondrial DNA from the egg donor and separate DNA from the 
somatic nuclear donor (Lewandowski et al., 2017).  Moreover, there are ethical concerns with 
the use of ESCs or SCNT-derived ESCs. Embryonic stem cells are derived from spare 
embryos fertilised through IVF and/or aborted foetuses. The ethical debate thus includes the 
argument that the inner cell mass used to derive ESCs is obtained from a viable embryo and 
that once extracted it is a non-viable embryo (de Wert & Mummery, 2003). The SCNT-
derived ESCs are derived from donated oocytes which has been met with social resistance as 
well as unclear boundaries on reproduction and cell therapy (Lewandowski et al., 2017). 
The derivation of induced pluripotent stem cells (iPSCs) from animal and human 
somatic cells such as dermal fibroblasts, a technique pioneered by Yamanaka and colleagues 
(Takahashi, 2007; Takahashi & Yamanaka, 2006) has overcome mainly the ethical 
challenges of using pluripotent stem cells for drug discovery, regenerative medicine and 
potential cell therapies (de Wert & Mummery, 2003; Stadtfeld & Hochedlinger, 2010). This 
technology further advanced development of patient-specific pluripotent stem cells to study 
rare diseases as well as creating cell-based disease models that be studied in vitro. Moreover, 
this technology has made possible the elimination of immunogenic responses for future cell 
transplantations in patient-specific treatments.  
 
1.7.1 iPSC-derived disease models 
Due to the limitation of animal models to faithfully recapitulate the phenotype of 
many human disease conditions, establishing a culture system using human cells to mimic the 
microenvironment and cellular interactions will advance future work of drug screening and 
clinical trials (Guo et al., 2013). However, the use of primary somatic cells limits long-term 
in vitro experiments required for disease modelling as primary cells have limited proliferation 
Chapter 1 
 
30 
 
capacity (Trounson & DeWitt, 2016). Therefore, using iPSCs firstly, eliminates this 
limitation by providing an endless source of cells, which further reduces the need for tissue 
biopsies that are obtained by a painful and invasive procedure. Secondly, iPSCs can be 
differentiated into the different lineages, thus providing the ability to create improved disease 
models in vitro. And thirdly, iPSCs provide the means of personalised medicine and future 
autologous cell therapies. Recent studies have demonstrated that iPSCs can be differentiated 
into neuronal progenitors, cardiomyocytes and pancreatic islet-like cells (Arber et al., 2015; 
Kunisada et al., 2012; Oh et al., 2012). Recent studies have demonstrated that using iPSCs to 
model diseases such as Parkinson’s disease, Alzheimer’s and Huntington’s diseases (HD) has 
opened avenues to understanding the molecular events involved in the onset of these diseases 
(Arber et al., 2015; Hossini et al., 2015; Ryan et al., 2013; Yang et al., 2016; Zhang et al., 
2016). For example, the iPSCs derived from a patient with Parkinson’s disease caused by an 
autosomal dominant mutation in the LRRK2 gene were differentiated into dopaminergic 
precursors and demonstrated that the mutation leads to increased oxidative stress causing 
degeneration of dopaminergic neurons (Nguyen et al., 2011). Furthermore, iPSCs can be used 
to study cardiomyopathies such as arrhythmogenic right ventricular cardiomyopathy (ARVC) 
and long-QT syndrome (Kim et al., 2013; Ma et al., 2013; Miller et al., 2013; Moretti et al., 
2013). A study by Kim et al. (2013) for example, showed that iPSCs derived from fibroblasts 
of patients affected with ARVC caused mutations in the PKP-2 gene can be differentiated 
into cardiomyocytes. They further showed that the iPSC-derived cardiomyocytes can 
recapitulate the disease phenotype by inducing dysregulated lipogenesis and abnormal PKP-2 
translocation into the nucleus.  
 
1.7.2 Using iPSC-derived models to study fibrosis 
Studies have shown that iPSC can be differentiated into different cell types to perform 
in vitro studies. There are emerging studies that have explored modelling of renal, cardiac 
and skin fibrosis using iPSC models. For instance, a study by Itoh et al. (2013) successfully 
differentiated iPSCs into keratinocytes and fibroblasts, which produce COL7A1 to study 
recessive dystrophic epidermolysis bullosa (RDEB), a genetic disorder caused by mutations 
in the COL7A1 gene which encodes a protein that anchors the fibrils on the basement 
membrane zone. This study further created a 3D culture model by layering iPSC-derived 
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keratinocytes onto iPSC-derived fibroblasts polymerised in collagen type1 matrix to mimic 
the skin layer. The 3D model by Itoh et al. (2013) thereby indicates the potential of iPSCs to 
create models that can be used and improved to model skin fibrosis. Furthermore, patient-
specific iPSCs can be used in rare genetic disorders such as POIKTMP to determine some of 
the molecular changes that may contribute to the phenotype observed in affected individuals.  
Another study showed that iPSC-derived alveolar epithelial cells (type II), which are 
activated to form myofibroblasts during pulmonary fibrosis can be used for future therapeutic 
interventions such as cell replacement therapy to treat cystic fibrosis as well as pulmonary 
fibrosis (Ghaedi et al., 2013; Snoeck, 2015).   
In addition, the recent emergence of iPSC-derived organoids has made it possible to 
study organ development as well as disease pathologies. For example, (Przepiorski et al., 
2018) generated kidney organoids which developed tubular epithelia after 14 days in culture 
and revealed that at 26 days of culture the kidney organoids showed increased ECM 
production and high levels of α-SMA which are features of fibrosis. Another recent study 
created cardiac spheroids using iPSC-derived cardiomyocytes, fibroblasts and endothelial 
cells in order to study the physiology and microenvironment of these cells in cardiac tissue 
(Polonchuk et al., 2017). 
The present study focuses on the development of an in vitro system to investigate the 
link between mutations in the FAM111B gene and the fibrotic phenotype seen in POIKTMP 
patients. In particular, the rationale in this study is that in order to investigate the cells that 
might be playing a role in fibrosis, one needs large numbers of such cells, an ability to drive 
them along a particular line of differentiation, and in so doing, investigate basic cellular 
processes by comparing normal cells versus patient-derived cells. 
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1.8 Aims and Objectives 
1.8.1 Aim 
To evaluate the role of FAM111B in multi-systemic fibrosis, we asked whether the 
creation of iPSCs might enable us to model some components of the phenotype, and in doing 
so, contribute to the understanding of the causes of hereditary fibrosing poikiloderma. 
 
1.8.2 Objectives 
The overall objectives of this study are to:  
i. derive patient-specific iPSCs containing the FAM111B mutation (c.1861T>G) (p. 
Tyr621Asp). 
ii. differentiate the iPSCs into mesenchymal stem/stromal cells to investigate if the 
pro-fibrotic markers are elevated in patients compared to controls.  
iii. determine if FAM111B expression is altered in patient cells compared to controls 
iv. determine if cell proliferation and the cell cycle are dysregulated in some way in 
patient-derived cells compared to controls.  
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Chapter 2 
Derivation and characterisation of patient-specific induced 
pluripotent stem cells (iPSCs) 
 
2.1 Introduction  
It has been a decade since the pioneering of induced pluripotent stem cells by the Yamanaka 
group. Yamanaka and colleagues (Takahashi, 2007; Takahashi & Yamanaka, 2006) observed 
that a combination of OCT3/4, SOX2, KLF-4 and C-MYC (OSKM) transcription factors from 
a panel of 24 candidate genes activated the reprogramming of mouse and human fibroblasts 
into iPSCs with ESC-like phenotype. Of the four transcription factors selected for 
reprogramming, octomer-binding protein 3/4 (OCT 3/4) was previously shown to be the 
master regulator of pluripotency, self-renewal and regulates other key pluripotency-
associated genes such as NANOG in embryonic stem cells (ESCs) (Loh et al., 2006; Mitsui et 
al., 2003; Saxe et al., 2009; Takahashi & Yamanaka, 2006). Similarly, the SOX2 
transcription factor is also reported to regulate the expression of other pluripotency-
associated genes (Okumura-Nakanishi et al., 2005; Schmidt & Plath, 2012). Furthermore, 
both OCT 3/4 and SOX 2 also act as autoregulators of their respective genes by a positive 
feedback loop (Schmidt & Plath, 2012). The Kruppel-like factor 4 (KLF-4), also a 
transcription factor, was first demonstrated to actively bind to nanog in mouse ESCs to 
maintain pluripotency and self-renewal as well as preventing ESC differentiation (Chan et al., 
2009; Zhang et al., 2010). The C-MYC oncogene is known to promote cell proliferation and 
survival. Furthermore, it has been reported that C-MYC promotes opening of chromatin into 
an active state during cell reprogramming (Nie et al., 2012; Rahl et al., 2010; Schmidt & 
Plath, 2012). However, the use of factors such as C-MYC, which is a well-known oncogene 
poses a challenge in that its proliferative property can also induce oncogenesis, thus limiting 
the future potential of iPSCs (Nie et al., 2012; Takahashi & Yamanaka, 2006). To circumvent 
this limitation, other studies have since shown that substitution of factors such as C-MYC and 
KLF-4 with NANOG, LIN28 and oestrogen-related receptor-β (ESRRβ) can induce stem cell 
reprogramming (Feng et al., 2009; Yu, 2007). Furthermore, studies have demonstrated that 
other MYC proteins such as L-MYC and N-MYC can perform similar function as C-MYC, 
with L-MYC indicating minimal oncogenic activity (Nakagawa et al., 2008). C-MYC has also 
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been suggested to be responsible for induction of partially reprogrammed cells which do not 
fully express endogenous stem cell genes due to its high activity during the early stages of 
reprogramming (Wernig et al., 2008). Therefore, its substitution reduces the yield of partially 
reprogrammed cells thus increasing reprogramming efficiency. Reprogramming enhancers 
such as Gli-like transcription factor (GliS1) have also been suggested as effective substitutes 
of C-MYC for increasing reprogramming efficiency and reducing partial reprogramming 
(Ebrahimi, 2015; Schmidt & Plath, 2012; Seki & Fukuda, 2015). Like MYC, other KLF 
proteins such as KLF-2 and KLF-5 can be used to substitute KLF-4 as they have also been 
shown to activate expression and activity of NANOG (Zhang et al., 2010).  
It has become evident in recent years that there is an order to the reprogramming 
process (Polo et al., 2012). A few models were hypothesised to explain the reprogramming 
process; the first model was thought to be the “Elite” model which suggested that some of the 
somatic cells that undergo complete reprogramming are stem cell progenitors which can be 
more readily reprogrammed into iPSCs compared to terminally differentiated somatic cells 
(Smith et al., 2016). This theory, however, was disproved when terminally differentiated T 
and B lymphocytes were successfully reprogrammed into iPSCs, thus indicating that any cell 
type can be reprogrammed into iPSCs (Hanna et al., 2008; Stadtfeld et al., 2008; Takahashi & 
Yamanaka, 2016). The second hypothesised model was the “Deterministic” model in which it 
was hypothesised that every cell that is exposed to the overexpression of ectopic pluripotency 
transcription factors will be reprogrammed in a fixed and synchronised manner. However, 
due to the findings of partial reprogramming this hypothesis was modified to describe a 
“Stochastic” model, which states that all somatic cells have the potential to become iPSCs at 
different time points of reprogramming (Polo et al., 2012; Yamanaka, 2009). The stochastic 
model further proposes that cell reprogramming is a two-stage process which begins with cell 
proliferation followed by gene activation due to the epigenetics events that occur during 
reprogramming (Polo et al., 2012; Zunder et al., 2015). The cellular changes that have been 
shown to occur during the proliferative stage of reprogramming include mesenchymal-to-
epithelial cell (MET) transition that is characterised by expression of E-cadherin which is an 
epithelial marker, and by the metabolic switch from the oxidative to the glycolytic pathway. 
The late phase is the epigenetic modification phase which is characterised by demethylation 
of stem cell genes (Kim et al., 2014; Maherali et al., 2007; Pasque et al., 2014; Polo et al., 
2012).  
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Epigenetic modifications are reported to be the driving force to cellular and molecular 
changes that somatic cells undergo in the stochastic model (Yamanaka, 2009; Zhang et al., 
2012). Cell reprogramming from mature lineage-specific somatic cells to pluripotent cells 
requires chromatin conformation from heterochromatin to euchromatin for the ectopic 
reprogramming factors to access DNA regions that have been inactivated. Conformation of 
chromatin from heterochromatin to euchromatin requires the acetylation and/or methylation 
of histones at specific sites (Gładych et al., 2015; Maherali et al., 2007). Acetylation of 
histones occurs when acetyl groups are bound to the lysine groups at the N-terminus of 
histone tails, a process facilitated by histone acetyltransferases (HATs), resulting in a 
negative histone charge that leads to conformational changes and active chromatin (Gładych 
et al., 2015; Handy et al., 2011; Srinageshwar et al., 2016). Histone methylation at specific 
sites has also been shown to change the chromatin state to euchromatin. The commonly 
reported methylated sites in a heterochromatin state are H3K4me3 and H3K27me3, but the 
ectopic expression of OSKM factors initiates trimethylation of lysine 9 and 36 in histone H3 
(H3K9me3 and H3K36me3) regions leading to gene activation (Buganim et al., 2013; 
Srinageshwar et al., 2016). Overexpression of ectopic OCT3/4 and SOX2 during 
reprogramming appears to similarly induce DNA demethylation at OCT3/4 and NANOG 
promoter regions. Kruppel-like factor-4 (KLF4) and C-MYC have also been shown to induce 
histone acetylation and methylation for accessibility of the OCT3/4 and NANOG promoter 
regions (Evans et al., 2007; Lunyak & Rosenfeld, 2008). The early phase of reprogramming 
which is characterised by the MET transformation occurs following binding of ectopic factors 
to the promoter regions of their target pluripotency genes, followed by the late phase where 
the expression of endogenous stem cell genes leads to the complete reprogramming of cells 
that pass the partially reprogrammed state (Buganim et al., 2012).   
Another key epigenetic modification which is observed in reprogrammed female 
somatic cells is the reactivation of inactive X-chromosome (Xi) (Kim et al., 2015). As 
mammalian females have two X chromosomes, their somatic cells undergo random 
inactivation of the second X-chromosome for dosage compensation, which maintains normal 
genomic copy number between male and female cells (Barakat et al., 2015; Ercan, 2015). 
This process is regulated by the expression of a long non-coding RNA known as x-inactive 
specific transcript (Xist) for heterochromatin formation (Cantone et al., 2016; Kim et al., 
2015; Panning et al., 1997). The Xist RNA transcript induces silencing of the second X-
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chromosome by creating a nuclear compartment that is devoid of RNA polymerase II, which 
leads to the recruitment of the Polycomb Recessive Complex 2 (PRC2) that induces the 
trimethylation of lysine 27 on histone H3 (H3K27me3) as well as 5-methyl-cytosine 
incorporation on the Xi gene for stable silencing (Cantone et al., 2016). During somatic cell 
reprogramming however, the Xi chromosome is reactivated by downregulation of Xist RNA 
as well as the removal of heterochromatin marks by downregulation of PRC2 (H3K27me3 
and DNA methylation) (Pasque et al., 2014). This process has been shown to occur at the late 
phase of reprogramming where Xist RNA is downregulated by the activation of its anti-sense 
strand which encodes Tsix RNA on the Xi domain. Furthermore, X-chromosome reactivation 
(XCR) occurs post-endogenous expression of OCT4, which has been shown to actively bind 
onto Tsix RNA (Donohoe et al., 2009; Maherali et al., 2007; Pasque et al., 2014). 
Interestingly, XCR has revealed more insight into the epigenetic modifications that occur 
during reprogramming and made possible detailed tracking of reprogramming stages thus 
expanding the understanding of cell reprograming (Pasque et al., 2014).  
 
2.1.1. Gene-delivery system for reprogramming 
The transduction of fibroblasts into iPSCs was first performed with the use of 
integrating retroviral plasmids (Nishimura et al., 2011; Takahashi & Yamanaka, 2006; 
Takahashi & Yamanaka, 2016) due to their high infection efficiency. Since the first 
demonstration that iPSC generation was possible, subsequent work in this field focused on 
improving the reprogramming method for clinical application. One of the primary issues with 
the original iPSC reprogramming method was the use of retroviral vectors, which are 
genome-integrating vectors and randomly integrate into the host genome (Han & Yoon, 
2011). Therefore, the use of retroviral vectors for derivation of human iPSCs for translational 
purposes posed a risk of retroviral integration into the host genome, which may cause 
insertional mutagenesis that can lead to tumorigenicity (Higuchi et al., 2014; Kagawa et al., 
2009). Scientific advances have since been applied to circumvent this challenge and generate 
human iPSCs using non-integrating vectors. One of the early strategies applied was replacing 
retroviral vectors with lentivirus vectors as they do not integrate near the host genome 
transcription sites (Han & Yoon, 2011; Wu et al., 2003). Lentivirus vectors were replaced by 
adenoviruses which do not integrate into the host cell genome. However, transient 
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transfections with the adenovirus greatly reduces reprogramming efficiency (Yu et al., 2011).  
Other non-integrating vectors such as cosmids, Sendai virus, RNA molecules, transposons, 
small and large protein molecules as well as episomal vectors have been investigated and 
showed promise compared to previous systems (Chou et al., 2011; Fusaki et al., 2009b; Malik 
& Rao, 2013; Stadtfeld & Hochedlinger, 2010). The use of RNA molecules and other 
molecules such as episomes, are promising non-integrating viral approaches for delivery of 
pluripotency transgenes. For example, Yu et al. (2011) demonstrated that cells can be 
reprogrammed with episomal vectors that do not require transgene packaging or repeated 
transfections and are easily silenced due to their low copy number once transfected into 
somatic cells. However, they demonstrated that episomal vectors yielded very low 
reprogramming efficiency, and reprogramming enhancers were required to increase 
efficiency. Similarly, cosmid plasmids and synthetic modified mRNA molecules 
demonstrated low reprogramming efficiency and required repeated cycles of infection 
(Higuchi et al., 2014). While these methods show promise in developing clinical-grade 
iPSCs, more improvements are required to ensure efficient gene packaging, stable 
transfection with reduced cellular stress as well as improved reprogramming efficiency. Some 
studies have suggested that the use micro-RNA 302 (miRNA-302), which endogenously 
increases OCT4 expression by targeting its inhibitors such as the Nuclear receptor subfamily 
2, group F, member two (NR2F2) in ESC and iPSCs, can enhance reprogramming efficiency 
when used in combination with these non-integrating vectors (Hu et al., 2013). Valproic acid 
has also been identified to be one of the reprogramming enhancers which can increase 
reprogramming efficiency. It is a histone deacetylase (HDAC) inhibitor commonly used to 
treat epilepsy, bipolar mania and migraine prophylaxis which has been shown to promote 
global increase of H3K9 acetylation in ESCs (Hezroni et al., 2011). Furthermore, it has been 
shown to prevent senescence and promote cell proliferation of reprogrammed cells (Chen et 
al., 2016; Huangfu et al., 2008). The p53 tumour suppressor protein or its suppression 
pathway has also been reported to improve reprogramming efficiency (Menendez et al., 
2010). Studies have indicated that ectopic expression of C-MYC and KLF-4 activates p53 due 
to high expression of the CDK inhibitor p21 which halts cell cycle progression (Kawamura et 
al., 2009; Li et al., 2013). Therefore, knockdown of p53 increases induction of iPSCs, 
however, knockdown of p53 causes genomic instability therefore, other studies have 
suggested that targeting the p53-upregulated mediator of apoptosis (PUMA) protein which is 
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part of the p53 suppressor pathway can improve iPSC reprogramming without inducing 
genomic instability (Li et al., 2013).  
To date the most promising vector which is used by most researchers in iPSC-based 
and drug discovery studies is the Sendai virus (Beers et al., 2015; Fusaki et al., 2009b). The 
Sendai virus (SeV) belongs to the Paramyxoviridae family of viruses and is non-pathogenic 
to humans (Nishimura et al., 2011). It is a negative-strand RNA virus that replicates in the 
cytoplasm and does not integrate with the host genome (Li et al., 2000; MacArthur et al., 
2012; Nishimura et al., 2011). Nishimura et al. (2017) demonstrated that stable transfection 
for reprogramming can be generated with the Sendai virus, moreover, they also demonstrated 
that the coding region of the SeV Cl. 151 strain can be replaced with all four pluripotency 
transgenes (Oct4; Sox2; Klf4; c-myc) and the viral persistence can be eliminated with siRNA. 
Furthermore, Nakanishi & Otsu (Nakanishi & Otsu, 2012) demonstrated that the replication-
defective and persistent Sendai virus (SeVdp) can be silenced by using siRNA and 
endogenous miRNA (mir-302a) that is expressed by human and mouse ESCs and established 
iPSCs (Nishimura et al., 2017; Nishimura et al., 2011). Nishimura et al. (2011) demonstrated 
that the L gene effectively silenced the SeVdp vector after treatment with small interfering 
mRNA (siRNA). The mechanism by which it is silenced, briefly, is by targeting RNA-
dependent RNA polymerase L subunit which contains miRNA-302a sequence at the 3’ UTR 
(Nishimura et al., 2017).The mir-302a target sequences were added to the non-coding region 
of the L gene to silence the SeVdp vector when pluripotent stem cells have been established 
(Nakanishi & Otsu, 2012). The expression of mir-302a occurs once the iPSCs have been fully 
established, therefore, removal of SeVdp genome can be analysed between 10-19 passages in 
newly derived iPSCs (Miller et al., 2013; Nishimura et al., 2017). Therefore, the SeVdp is an 
ideal vector for iPSC reprogramming to advance iPSC research studies for future clinical 
applications.  
 
2.1.2. Feeder and feeder-free culture of iPSCs 
Embryonic stem cells (ESCs) and iPSCs have been demonstrated to maintain 
pluripotency and self-renewal when cultured on inactivated mouse embryonic fibroblasts and 
human foreskin fibroblasts (Pekkanen-Mattila et al., 2012; Richards et al., 2002; Takahashi & 
Yamanaka, 2006; Thomson et al., 1998). Mouse and human Feeder cells are known secrete 
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high levels of activin-A and basic fibroblast growth factor respectively (bFGF) (Warren et al., 
2012). Mouse embryonic fibroblasts (MEFs) are most commonly used for culture and 
maintenance of iPSC pluripotency as they are more accessible compared to human cells. 
However, the disadvantage of using MEFs is xeno-contamination with animal genome and 
exogenous antigens which can contaminate human iPSCs thus limiting their future clinical 
use (Chou et al., 2011; MacArthur et al., 2012). Human feeder cells such as foreskin 
fibroblasts and epithelial cells have recently been used to replace MEFs, but the 
contamination of differentiated cells on pluripotent stem cells further indicate a barrier for 
obtaining clinical-grade iPSCs (Pekkanen-Mattila et al., 2012). Therefore, several studies 
have tested and shown that human somatic cells can be reprogrammed under feeder-free 
conditions using extracellular matrix substrates such as collagen type I, gelatin, fibronectin 
and vitronectin (Yamasaki et al., 2014). Mouse ESCs were shown to grow efficiently on 
gelatin and collagen matrices. Furthermore, human ESCs and iPSCs were demonstrated to 
maintain their pluripotency on matrix substrates such as fibronectin and vitronectin 
(Yamasaki et al., 2014). Feeder-free reprogramming was shown to further require specific 
matrix substrates and growth factors. For example, a study by Yamasaki et al. (2014) 
demonstrated that iPSCs can be derived and maintained in an undifferentiated state on 
fibronectin-coated dishes using serum-free hESC medium that is supplemented with TGF-β1. 
However, they indicated that TGF-β1 induces pluripotency in the early stages of 
reprogramming and inhibits the emergence of iPSCs colonies when maintained in the late 
stages of reprogramming.  
Since the breakthrough of iPSC technology, studies have focused on circumventing 
challenges that hinder the production of clinical grade iPSCs for regenerative medicine and 
cell therapy. Recent advances in producing clinical-grade iPSCs include the use of non-
integrating vectors such as the Sendai virus and episomal vectors for delivery of 
reprogramming factors (Wang et al., 2015). There is also use of the two-factor system (OCT4 
and SOX2) and enhancers to eliminate the use of oncogenes such as C-MYC and KLF-4 to 
improve reprogramming efficiency (Baghbaderani et al., 2015; Wang et al., 2015). Other 
studies have also indicated the development of xeno-free reagents to avoid contamination of 
reprogrammed cells (Wang et al., 2015). However, more approaches are required for robust 
induction of clinical-grade iPSCs which can also be used to develop in vitro disease models 
for translational studies. 
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2.1.3 Using induced pluripotent stem cells to study FAM111B in vitro 
The dawn of iPSC technology has broadened the scope of studying genetic and 
sporadic diseases beyond the use of animal models, which often do not faithfully recapitulate 
the disease phenotype. Diseases mechanisms can be studied and further understood by 
modelling them in vitro using iPSCs (Grskovic et al., 2011). Furthermore, their pluripotent 
state makes them an ideal cell type to use for studying disease conditions that affect more 
than one organ in the body as they can be differentiated into different cell lineages in vitro 
(Takahashi, 2007). 
Since hereditary fibrosing poikiloderma is a rare autosomal dominant genetic disorder 
with no animal model available to study the function of FAM111B and disease phenotype in 
vivo, the chosen approach for elucidating the role of FAM111B mutation in this study was the 
use of iPSCs to model the disease phenotype. This chapter will focus on the derivation and 
characterisation of control and patient-specific iPSCs. I will also discuss the challenges 
experienced during the generation and characterisation of iPSCs. The next chapter will focus 
on the differentiation of the patient-specific iPSCs into the affected cell lines in this 
condition.  
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2.2 Materials & methods 
 
2.2.1 Ethics Approval 
Ethics approval for the study was granted by the University of Cape Town (UCT) Faculty of 
Health Sciences Human Research Ethics Committee (REC Ref. 492/2007) and was renewed 
in accordance with REC rules. Informed consents were obtained from the South African 
Kindred, two affected siblings (brother and sister) and their unaffected mother as shown by 
the pedigree in Figure 2.1 (Khumalo et al., 2006) to obtain skin biopsies for extraction of 
dermal fibroblasts.  
 
 
2.2.2 Cell culture 
Skin biopsies were collected from the two affected South African siblings carrying the 
FAM111B gene mutation (c. 1861 T>G) and from their unaffected mother, who was the 
familial control for this study.  Fibroblasts were previously isolated from the dermal explants 
according to the protocol described by Normand & Karasek (1995). Fibroblasts for the non-
familial control were kindly donated by Dr. Robea Ballo (Department of Human Biology, 
University of Cape town). The dermal fibroblasts were expanded in Dulbecco’s Modified 
Eagle’s medium (DMEM (Sigma-Aldrich, St Louis, MO); 10% (v/v) supplemented with 
heat-inactivated foetal bovine serum (FBS) (Biochrom, Merck-Millipore, Germany) and 
penicillin (100 U/ml) & streptomycin (100 µg/ml) antibiotic (hereafter 1% Pen-strep) 
(Sigma-Aldrich, St Louis, MO). The cells were placed in a 37 °C incubator at 5% carbon 
Figure 2.1: Pedigree of South African kindred. The boxed figures indicate individuals from whom 
informed consents were obtained for this study. The proband is indicated by the arrow.  
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dioxide (CO2) during culture. The cells were maintained in growth medium which was 
changed every 2-3 days until the cells reached 95% confluence. Mouse embryonic fibroblasts 
(MEFs) purchased from ATCC (Virginia, USA) were mitotically-inactivated by treatment 
with Mitomycin-c at passage 6. Following inactivation, the iMEFs were cultured in DMEM 
supplemented with 10% FBS, 1% (v/v) Pen-strep and 0.05 mM β-mercaptoethanol and used 
as feeder cells for reprogramming of dermal fibroblasts into iPSCs. Induced pluripotent stem 
cells (iPSCs) were derived and maintained in human stem cell (hESC) medium that is 
composed of knockout DMEM (KO-DMEM) supplemented with 20% (v/v) Knockout Serum 
Replacement (KO-SR), 1% (v/v) non-essential amino acids (NEAA), 1% (v/v) GlutaMax 
solution, 10 ng/ml basic Fibroblast Growth Factor (bFGF) (Miltenyi Biotec) and 0.05 mM β-
mercaptoethanol (all hESC components were purchased from Life Technologies).  
 
2.2.3 Reprogramming of dermal fibroblasts  
2.2.3.1 Infection of dermal fibroblasts with SeVdp 
Control and patient dermal fibroblasts (P6) were seeded 2 x 105 cells per well in a 6-
well culture plate overnight in DMEM medium supplemented with 10% (v/v) FBS.  The 
replication-defective and persistent Sendai virus (SeVdp) vector, which simultaneously 
delivers the four pluripotency factors (OCT4; SOX2; KLF4; C-MYC) for reprogramming was 
kindly provided by Nakanishi (Research Centre for Stem Cell Engineering, National Institute 
of Advanced Industrial Science and Technology, Tokyo, Japan). When the cells reached 80-
90% confluence they were infected with the SeVdp vector at a MOI of 3, per the protocol 
previously described by Fusaki et al. (2009a) and Nishimura et al. (2011). Briefly, the 
infected cells were incubated at room temperature for 2 hours (h) before incubating overnight 
in a 37° C & 5% CO2 incubator. On the same day, 0.3 x 106 iMEFs were seeded onto 
gelatine-coated wells (35-mm) of a 6-well plate and incubated in 37 °C with 5% CO2 
overnight and thereafter rinsed with twice with 1X phosphate buffered saline (PBS) and 
maintained in hESC medium. Following overnight incubation, the infected dermal fibroblasts 
were rinsed twice with 1x PBS and incubated for five minutes with 0.25% trypsin/EDTA at 
37° C. The trypsin/EDTA was deactivated by adding growth medium and the cells were 
centrifuged for five minutes at 450 x g at room temperature. Following centrifugation, the 
supernatant was removed, and the cell pellet resuspended in 1 ml of growth medium and 
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counted. The SeVdp-infected dermal fibroblasts were seeded at 1 x 104 and 2 x 104 cells/ml 
densities onto the previously prepared ATCC iMEFs and maintained in hESC medium. The 
hESC medium was changed every 2nd day until the iMEFs were nine days old. After nine 
days, the SeVdp-infected dermal fibroblasts were maintained in iMEF-conditioned 
conditioned medium (MCM) till iPSC colonies appeared on the iMEF feeder layer. The 
MCM was prepared by culturing 4 x 106 iMEF cells in a T75 cell-culture flask, maintaining 
them in hESC medium without bFGF and collecting the medium daily till the iMEFs were 
nine days old. The MCM was filter-sterilised and supplemented with 10 ng/ml bFGF before 
adding to the cells undergoing iPSC reprogramming. Figure 2.2 shows the reprogramming 
timeline used in this study.  
 
 
 
 
 
 
2.2.3.2 picking and expansion of reprogrammed iPSC clones 
After 4-5 weeks, the reprogrammed cells that successfully formed embryonic stem 
cell-like colonies (see results) were isolated and cultured onto different wells of a 6-well plate 
that contained with fresh iMEF feeder cells and expanded for characterisation. Each colony 
that was picked and transferred into a separate well is referred to as a clone. A minimum of 
Figure 2.2: iPSC Reprogramming timeline. Mitomycin-inactivated MEFs (iMEFs) were cultured on 
the same day as patient and control fibroblasts (d0). Fibroblasts were infected with SeVdp vector on day 1 
and transferred onto iMEF feeder layer after 24 hours. Between d0 and d3 cells were maintained in 
DMEM supplement with 10% FBS and 1% Pen-strep. On d2 infected fibroblasts were transferred onto 
the iMEF feeder layer and maintained in hESC media from d3-d11 for iPSC reprogramming. 
Reprogrammed cells were thereafter maintained on iMEF-conditioned medium until iPSC clones were 
picked for expansion.  
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five clones per cell line were picked and expanded or frozen in liquid nitrogen for later use. 
For expansion, the newly derived iPSCs were cultured on iMEF feeder cells and maintained 
in hESC medium, with a daily 50% medium change till the cells were ready for manual 
passaging. The iPSC colonies were passaged every 4-6 days by manual passaging using a 
sterile 29-gauge syringe needle. The iPSC colonies were dissected to 8-12 patches that were 
then transferred onto a 35-mm well of a 6-well plate that contained newly seeded iMEFs and 
maintained in hESC medium until the next passage.  
 
2.2.3.3 Feeder-free iPSC culture 
The iPSCs were cultured using a feeder-free method to remove contamination of 
iMEFs prior to characterisation and further analysis. Briefly, 35 mm or 6-well culture plates 
were coated with Geltrex (Life Technologies), a basement membrane matrix by incubation at 
37° C for 1 h and a further hour at room temperature before use. The iPSC colonies on iMEF 
feeder cells were aspirated of hESC medium, washed once with 1x PBS and enzymatically 
passaged with 0.5 mM EDTA (Life Technologies) in 1x PBS by incubation at 37° C for five 
minutes. Thereafter, the EDTA solution was gently removed using a pipette. The iPSCs were 
transferred onto a Geltrex-coated 35 mm dish or well that contained feeder-free culture 
medium prepared in DMEM/F12 supplemented with StemPro hESC supplement, 8 ng/mL 
bFGF, 25% bovine serum albumin (BSA) and 0.1 mM β-mercapto-ethanol (all feeder-free 
components were purchased from Life Technologies). The iPSCs were EDTA-passaged 
every 3-4 days and split in a 1:3 ratio until next passage. To prevent dissociation-induced 
apoptosis, which occurs when ESCs or iPSC colonies are dissociated into single cells 
(Watanabe et al., 2007), 10 µM of Rho-associated protein kinase (ROCK) inhibitor (Y-
27632) (Sigma-Aldrich, St Louis, MO) was added to the culture dish and incubated overnight 
at 37° C and 5% CO2. Feeder-free medium was changed daily, and the cells were passaged 
every 3-4 days. Furthermore, the iPSCs were maintained in feeder-free culture for 3-10 
passages for gene expression assays and further analysis.  
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2.2.4 Characterisation of derived iPSCs 
Two iPSCs clones per cell line from the two patients and one familial control were 
characterised for pluripotency by firstly determining the expression of stem cell genes (i.e. 
OCT4; NANOG, SOX2; KLF4); secondly, for the potential to differentiate into the three germ 
layers (endoderm; mesoderm; ectoderm) by in vitro differentiation; and thirdly, for normal 
karyotyping following reprogramming. The iPSCs were characterised between passages eight 
and 12 (after SeVdp vector was silenced) by quantitative polymerase chain reaction (qPCR) 
and immunocytochemistry (ICC). The silenced SeVdp in the reprogrammed iPSCs was 
validated qPCR. A population control iPSC line (Non-familial control), which was used as a 
positive control for the newly derived iPSCs was previously characterised in our lab by Dr. 
Robea Ballo. 
 
2.2.4.1 Expression of pluripotency markers in derived iPSCs  
2.2.4.1.1 RNA extraction and cDNA synthesis 
To determine the pluripotency of derived iPSCs by qPCR the cells were cultured 
under feeder-free conditions as previously described and lysed for RNA extraction by adding 
1 ml Tripure Isolation Reagent (Roche) per 60 mm dish. Total RNA isolation was extracted 
using the High Pure RNA Isolation Kit (Roche) per the manufacturer’s instructions. Briefly, 
0.2 ml of 100% chloroform was added to every 1 ml of the cell lysates, vigorously mixed by 
inverting for 15 seconds (s) and incubated at room temperature for 15 minutes. The lysates 
were thereafter centrifuged at 4° C and 12 000 x g for 15 minutes. After centrifugation, the 
aqueous phase which contained RNA was transferred into new microfuge tube and equal 
volume of 70% ethanol was added to aqueous phase and mixed 10 times by pipetting up and 
down. The aqueous mixture was then transferred into a High Pure filter tube and 2 ml 
collection tube and thereafter centrifuged at 10 000 rpm for one minute. The flow-through 
was discarded and each sample was treated with 100 µl of DNase I for removal of genomic 
DNA contamination and incubated at room temperature for 15 minutes. Following DNase I 
treatment, the samples were washed by adding 500 µl of Wash Buffer I and centrifuged at 10 
000 rpm for one minutes. The flow-through was discarded and the samples were washed 
again with 200 µl of Wash Buffer I and centrifuged as before. Following washes with Buffer 
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I the samples were washed by adding 500 µl of Wash Buffer II and centrifuged at 10 000 rpm 
for one minute. The flow-through was discarded and washed again with 200 µl of Wash 
Buffer II and thereafter centrifuged at 13 000 rpm for two minutes. The flow-through was 
discarded and the samples were opened and incubated at room temperature for five minutes 
to allow evaporation of ethanol from the wash buffers. After five minutes incubation, 30-50 
µl of the Elution buffer were added to each sample and total RNA was measured using a 
nanodrop spectrophotometer (ND-1000, Thermo Fisher). RNA purity was measured at 
A260/A280 ratio. To determine RNA integrity one µg RNA was run on a non-denaturing 1% 
agarose gel containing ethidium bromide and electrophoresed at 100 volts (V) for 45 minutes. 
The gel was viewed under UV light for detection of 28S and 18S ribosomal RNA bands. 
For cDNA synthesis, 0.5-1 µg RNA from each sample was reverse transcribed by 
addition of Oligo (dT) primers and running the reaction in the PCR machine at 42° C for five 
minutes, followed by adding the cDNA mastermix (1 mM dNTPs; 2.5 mM MgCl2; 1X RT 
Buffer; 1 U/µl RNase inhibitor; 20 U M-MLV Reverse Transcriptase) [all reagents purchased 
from Promega except for dNTPs (Bioline)].  
 
2.2.4.1.2 Quantitative real-time PCR (qPCR)  
The quantitative PCR (qPCR) mastermix constituted of 200 ng of cDNA, 0.2 µM of 
forward and reverse primers, 1X (5 µl) SYBR Green I Mastermix (Life Technologies) and 
water to the final volume of 10 µl per sample. The qPCR reaction was performed using the 
StepOne Plus machine (Applied Biosystems, Life Technologies) at 95° C denaturation for 15 
s, the annealing and extension steps were at 60° C for one minute respectively for 40 cycles. 
The results were analysed by relative quantitation using the delta delta (ΔΔ) Ct method, where 
samples were first normalised to β-glucuronidase (GUSβ) and/or β-actin housekeeping genes. 
Fold change (2-ΔΔCt) was analysed by determining differences between the normalised target 
sample and normalised calibrator (control sample). Human dermal fibroblasts (HDFs) were 
used as negative controls for the expression of pluripotency markers.  
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Table 2.1: Primer sequences for stem cell genes 
Gene Primer sequence NM 
Sequence 
Size 
(bp) 
hOCT3/- F 5'-GAC AGG GGG AGG GGA GGA GCT AGG-3’ NM_00128598
7.1 
144 
hOCT3/4-R 5'-CTT CCC TCC AAC CAG TTG CCC CAA AC-3’ 
hNanog-F 5'-CAG CCC CGA TTC TTC CAC CAG TCC C-3’ XM_01152085
2.1 
391 
hNanog-R 5'-CGG AAG ATT CCC AGT CGG GTT CAC C-3’ 
hSox2-F 5'-GGG AAA TGG GAG GGG TGC AAA AGA GG-3’ NM_003106.3 151 
hSox2-R 5'-TTG CGT GAG TGT GGA TGG GAT TGG TG-3’ 
hKLF4-F 5'-ACG ATC GTG GCC CCG GAA AAG GAC C-3’ NM_00131405
2.1 
397 
hKLF4-R 5'-TGA TTG TAG TGC TTT CTG GCT GGG CTC C-3’ 
hMYC-F 5'-GCG TCC TGG GAA GGG AGA TCC GGA GC-3’ NM_002467.4 328 
hMYC-R 5'-TTG AGG GGC ATC GTC GCG GGA GGC TG-3’ 
 
2.2.4.1.3 Detection of pluripotency markers by immunocytochemistry (ICC) 
 For detection of pluripotency markers by immunofluorescence, the reprogrammed 
iPSC lines were manually passaged onto 0.15 x 106 iMEFs plated onto gelatine-coated 
coverslips per well in a 12-well culture plate. The iPSCs were cultured for two days in hESC 
medium and analysed for the presence of OCT4, NANOG and/or TRA-1-60. Briefly, the 
hESC medium was removed and the cells were gently washed three times for three minutes 
per wash with 1x PBS. Following the PBS washes, the cells were fixed with 4% (wt/vol) 
paraformaldehyde for 15 minutes at room temperature. After fixing, the cells were 
permeabilized in ice-cold methanol and incubated at -20° C for five minutes for 
permeabilization of the nuclear membrane. For detection of surface markers such as TRA-1-
60, the permeabilization step was omitted. After permeabilization, the cells were rinsed 3 x 5 
minutes with 1X PBS, followed by incubation with the blocking solution (5% FBS; 0. 01% 
Triton X-100) in 1X PBS for 1 h at room temperature. Following the blocking step, the cells 
were incubated overnight at 4° C with either OCT3/4 anti-rabbit (1:200), NANOG (1:200) 
(both OCT3/4 and NANOG were purchased from Abcam, UK) or TRA-1-60 (1:200) (cat 
#MAB4360A4; Millipore, Germany) antibodies. The cells used as controls were incubated in 
blocking solution only.  Following overnight primary antibody incubation, the cells were 
rinsed 3 x 5 minutes with 1X PBS. Cells labelled with OCT 3/4 and NANOG were incubated 
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with donkey anti-rabbit Cy3-fluor secondary antibody (1:1000) for 2 h at room temperature 
in the dark. No secondary antibody was added to cells labelled with TRA-1-60 as the primary 
antibody is conjugated to the ALEXA-Fluor 488 tag. The ICC control cells were either 
incubated with donkey anti-rabbit Cy3-Fluor (Invitrogen, Thermo Fisher) or Alexa-Fluor 488 
(Invitrogen, Thermo Fisher) at 1:500 dilution to correct for background fluorescence. After 
the 2 h incubation with the secondary antibodies, the cells were washed 3 x 5 minutes with 
1X PBS. The cells were incubated with Hoechst 33342 (1 µg/ml) for 15 minutes in the dark 
at room temperature for nuclear staining. The cells were thereafter washed 2 x 5 minutes with 
1X PBS and the coverslips were mounted onto slides using mounting fluid (Mowiol) and 
were stored overnight at 4° C in the dark for the mounting fluid to dry prior to viewing. 
Images were acquired using a Zeiss Axiovert 200M fluorescence microscope with Axiocam 
HR charge-coupled device camera and Axiovision 4.7 software.  
 
Table 2.2: Primary and secondary antibodies for pluripotency markers  
Antibody 
  
Host species Antibody 
dilution  
Secondary Ab Localisation 
OCT 3/4 
  
Rabbit pAb 1:200 Cy3-Fluor  
(Donkey anti-rabbit) 
(1:1000) 
Nuclear 
NANOG 
  
Rabbit pAb 1:200 Cy3-Fluor 
(Donkey anti-rabbit) 
(1:1000) 
Nuclear 
 TRA-1-60 Mouse pAb 1:200 Alexa-Fluor 488 
conjugate 
Cell surface 
 
2.2.4.2 In vitro differentiation of iPSCs into the three germ layers 
For mesoderm differentiation, the EBs were maintained in EB medium supplemented 
with 0.5 mM ascorbic acid (Sigma-Aldrich, St Louis, MO) for 3 days. Thereafter, the EBs 
were transferred onto gelatine-coated coverslips in a 12-well plate and maintained in EB 
medium supplemented with 0.5 mM ascorbic acid for 15-20 days, with medium change every 
2-3 days till immunofluorescence analysis. For ectoderm differentiation, the EBs were 
maintained in 50% neural basal and 50% DMEM/F12 medium supplemented with 1% 
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GlutaMax, 1% Pen-strep as well as 0.5% (v/v) N2 and 1% (v/v) B27 supplements (Life 
Technologies) for 3 days. The EBs were thereafter transferred on a monolayer of PA6 feeder 
cells cultured on gelatine-coated coverslips previously maintained in MEM-alpha medium 
supplemented with 10% FBS, 1% GlutaMax and 1% Pen-strep until addition of EBs to the 
monolayer. Once transferred, the EBs were maintained in ectoderm medium for 14-16 days. 
Fresh medium added every 2-3 days till immunofluorescence analysis. 
Analysis of in vitro differentiation was performed as described in section 2.2.4.1.3. 
For detection of the endoderm cells were incubated with FOXA2 (1:1000), for the mesoderm 
they were incubated with alpha-smooth muscle actin (α-SMA) (1:100) and for ectoderm 
detection the cells were incubated with β-III tubulin (1:300) antibody (all primary antibodies 
were purchased from Abcam). The secondary antibodies used for fluorescence staining are 
shown in Table 2.3.      
 
Table 2.3: Primary and secondary antibodies for germ layer markers 
Antibody 
  
Host species Dilution  Secondary Ab Germ layer 
  
Alpha SMA 
Mouse mAb 1:100  Alexa Fluor-488 
(Goat anti-mouse) 
(1:500)  
Mesoderm 
  
β-III tubulin 
Mouse mAb 1:300  Alexa Fluor-488  
(Goat anti-mouse) 
(1:500)  
Ectoderm 
neuronal 
 FOXA2 Rabbit pAb 1:1000 Cy3-Fluor 
(Donkey anti-rabbit) 
(1:1000) 
Endoderm 
  
2.2.4.3 Karyotyping of newly derived iPSCs 
To determine if the derived iPSCs maintained normal chromosomal number and 
integrity post-reprogramming, the iPSCs were cultured using the feeder-free method until the 
third passage, where after they were sent to the National Health Laboratory Services (NHLS) 
lab for karyotyping. Karyotyping analysis was performed using the Giemsa staining (G-band) 
method.  Briefly, the cells were arrested at the metaphase of the mitotic stage by treating with 
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colchicine or colcemid. The cells were thereafter fixed with Carnoy’s fixation solution (3:1 
methanol to glacial acetic acid), trypsinised and collected by centrifugation followed by 
staining with Giemsa staining solution (Bickmore; Francke & Oliver, 1978).  
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2.3 Results 
 
2.3.1 Derivation, isolation and expansion of iPSC clones 
Control and patient dermal fibroblasts were infected with the SeVdp vector that contains the 
pluripotency factors (OCT4; SOX2; KLF4, C-MYC). The infected fibroblasts were cultured 
on iMEF feeder layer in hESC medium as described in the methods. Eight to 10 clones per 
iPSC line were picked and expanded or frozen in liquid nitrogen for later use. Two patient 
fibroblasts (Patient A and Patients B) and familial Control fibroblast line were reprogrammed 
into iPSCs. Ten clones were picked for both the familial Control and Patient A were 
successfully expanded up to passage 3. Two clones from each line were characterised (Table 
2.4). The selected clones for the familial Control and Patient A were successfully 
characterised (Fig. 2.2 A-D). Eight iPSC clones were picked for Patient B and two clones 
were initially selected for characterisation. The third clone was expanded for characterisation 
as the second clone indicated poor cell growth and lack of ESC-like morphology up to 
passage 6 (P6). Similarly, the third clone indicated partial reprogramming. Therefore, only 
one out of three clones for Patient B were successfully characterised (Fig. 2.2E). Partially 
reprogrammed clones showed a difference in their morphology compared to fully 
reprogrammed cells. They appeared slightly dome- or flat-shaped with no clear edge around 
each colony compared to the normal flat shape. The colonies were small and differentiated at 
faster rate than the fully reprogrammed cells on a MEF feeder layer (Fig. 2.3E). Although 
partially reprogrammed cells expressed stem cell markers such as OCT4 and TRA-1-60, they 
were difficult to maintain in culture and did not differentiate into the three germ layers as 
they tended to disintegrate at the EB stage, or they maintained their epithelial-like 
morphology after re-adherence of EBs during differentiation. Figure 2.3A-C indicates 
difference in morphology between iPSCs during day 11 and day 20 of reprogramming. The 
selected clones indicated ESC-like morphology at P2, a flat ESC-like morphology with an 
edge around the colony and a 2:1 nuclear to cytoplasm ratio as previously described by 
Takahashi et al. (2007).  iPSCs cultured under feeder-free conditions (Fig. 2.3D) display a 
monolayer compared to the colonies observed on a feeder layer. 
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TABLE 2.4: Patient and control iPSC clones characterised in this study 
Sample iPSC 
clones (C) 
Expression of stem cell 
genes (ICC & RT-PCR) 
Karyotyping in vitro 
differentiation 
to 3 germ layers 
Familial 
Control 
FAM_C1         
FAM_C2         
Patient A Pt A_C1         
Pt A_C2         
Patient B Pt B_C1          
Pt B_C2  Characterisation was discontinued for C2 and C3 due to 
partial reprogramming observed at P6. 
Pt B_C3 
 Familial control (FAM); Patient A (Pt A); Patient B (Pt B); Clone (C) 
Figure 2.3 Morphology of reprogrammed iPSCs. (A) Cells undergoing reprogramming on day 11 post-
infection showing a MET morphology. (B) Reprogrammed cells on day 20 showing formation of a colony with 
ESC-like defined border. (C) iPSC colony at passage 2 (P2) post-reprogramming. (D) iPSCs cultured under 
feeder-free conditions proliferate as a monolayer. (E) The flattened colony indicates a partially reprogrammed 
cell after six passages. 
   100 µm     100 µm      100 µm 
A B C 
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2.3.2 Expression of stem cell genes in derived iPSCs 
To determine whether the derived iPSCs express stem cell genes, feeder-free cell culture was 
performed (section 2.2.3.3) and mRNA expression was analysed by qPCR. Expression levels 
of the stem cell markers (OCT4, NANOG and SOX2) were higher in derived iPSC lines 
compared to control dermal fibroblasts (Fig. 2.4A). The expression levels of KLF-4were 
notably similar to the levels observed in control dermal fibroblasts (Fig. 2.4A). KLF-4 is 
reported to regulate NANOG expression (Zhang et al., 2010), and KLF-2 and KLF-5 can also 
regulate NANOG expression (Chan et al., 2009). Therefore, the low KLF-4 levels in derived 
iPSCs may be due the redundancy with other KLF proteins which also bind to NANOG to 
maintain pluripotency and self-renewal. Immunocytochemistry (ICC) was also performed to 
determine protein expression of pluripotency markers in derived iPSCs. Figure 2.4B indicates 
that the iPSCs stained positive for OCT3/4 which localises in the nucleus, and TRA-1-60 
which is a surface marker found in pluripotent stem cells. The results indicate that 
reprogramming of dermal fibroblasts with the SeVdp vector induced endogenous expression 
of stem cell genes. Analysis for clearance of SeVdp backbone was determined and indicated 
that SeVdp was silenced in the iPSC lines used in this study (data not shown).  
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2.3.3 In vitro differentiation of derived iPSCs    
To determine the pluripotency of derived iPSCs, in vitro differentiation via EB formation was 
performed. Figure 2.5 shows images of well-formed EBs cultured in suspension (A) and EBs 
that have been cultured in adherent culture plate with outgrowths of differentiating cells (B). 
Figure 2.5C shows the presence of nuclear-localised FOXA2 protein expressed in the 
endoderm. Figure 2.5D shows positive staining of α-SMA which is a mesoderm marker that 
is prevalent in cells of mesenchymal origin. Figure 2.5E shows detection of β-III tubulin 
which is a neuronal marker demonstrating successful differentiation of iPSCs into the 
ectodermal lineage.  
Figure 2.4 Expression of pluripotency markers. (A) qPCR analysis indicating high mRNA expression 
of stem cell genes (OCT4, NANOG, SOX2 and KLF-4) in derived iPSCs compared to dermal fibroblasts of 
control samples. n=3 (SEM). (B) immunocytochemistry results show a representation of iPSCs that stain 
positive for OCT3/4 and TRA-1-60 pluripotency markers (scale bar = 100 µm). 
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Figure 2.5 in vitro differentiation of derived iPSCs. (A) Embryoid bodies (EBs) in suspension culture.  
(B) Re-adhered EBs with cell outgrowths during in vitro differentiation. (C) Immunocytochemistry 
showing Positive staining of FOXA2 expressed in the endodermal germ layer (scale bar = 20 µm), (D) α-
SMA expressed in the mesodermal germ layer (scale bar = 50 µm) and (E) β-III tubulin expressed in the 
ectodermal germ layer (scale bar = 100 µm).  
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2.3.4. Karyotyping of derived iPSCs 
All the fully reprogrammed iPSC clones were further characterised by determining whether 
they maintained normal karyotype after reprogramming. The iPSC lines demonstrated normal 
karyotyping and no chromosomal aberrations (see appendix).  
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2.4 Discussion 
 
Dermal fibroblasts from two affected siblings and familial control (i.e. genetically related) of 
the South African kindred, were successfully reprogrammed into iPSCs using the Sendai 
virus vector containing four of the pluripotency factors (OCT4; SOX2; KLF-4; c-MYC). Two 
clones per iPSC line were selected for characterisation. Both clones for Patient A and the 
familial control expressed ESC markers (OCT4, NANOG, SOX2 and TRA-1-60) either by 
qPCR or ICC assay (Fig. 2.4A-B) and were further demonstrated pluripotency by 
successfully differentiating (in vitro) into the three germ layers (i.e. endoderm, mesoderm and 
ectoderm) (Fig. 2.5C-E). Moreover, karyotype analysis indicated that the selected iPSC 
clones indicated genome stability with no chromosomal aberrations (Appendix). Only one 
clone for Patient B was fully characterised as two out of three selected clones demonstrated 
partial reprogramming. The morphology of partially reprogrammed iPSCs did not fully 
resemble that of ESCs and were not further characterised, although they expressed all the 
ESC markers. The reprogramming efficiency in these cells was therefore low despite the use 
of the SeVdp vector. Some studies suggest that reprogramming efficiency can be improved 
by 80% if repeated cycles of SeVdp infection are performed (Nishimura et al., 2011). It 
should be noted that a single round of SeVdp infection was performed in this study. 
Interestingly, other studies contest the notion that partially reprogrammed iPSCs are not 
pluripotent (Tonge et al., 2014; Vidal et al., 2015). A study by Tonge et al. (2014) indicated 
that partially reprogrammed derived iPSCs from mouse fibroblasts, which they labelled “F-
Class cells” are at an alternative pluripotent state as they expressed Oct4 and Nanog as well 
as other pluripotent genes such as Sall4. They also showed that the F-class cells had a 
different morphology as they did not express E-cadherin 1, which is highly expressed in 
ESCs. They further suggested that continuous infection cycles with exogenous OSKM factors 
can drive “F-Class cells” into complete reprogramming. Another study showed that partially 
reprogrammed mouse iPSCs that remained in the intermediate state for up to 20 passages 
could progress to a fully reprogrammed state by maintaining them in serum-free medium 
supplemented with bFGF compared to the serum containing medium supplemented with the 
Leukemia inhibitory factor (LIF) (Kim et al., 2014). This study further supports that partially 
reprogrammed cells can be induced to progress into a fully reprogrammed state under 
specific conditions. The use of enhancers such as valproic acid, ascorbic acid and butyrate 
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have been shown to improve reprogramming efficiency (Chen et al., 2016; Ebrahimi, 2015; 
Liang et al., 2010). These studies therefore indicate that partially reprogrammed clones can 
be converted to fully reprogrammed iPSCs by using enhancers and repeated treatment with 
the SeVdp vector containing the stem cell genes. Therefore, future work will include 
enhancing the reprogramming efficiency of partially reprogrammed in this study, especially 
for Patient B clones.  
Although KLF-4 is used for iPSC reprogramming, its endogenous expression in fully 
reprogrammed iPSCs was shown to be similar to fibroblasts (Takahashi, 2007), a finding 
which was also observed in this study. The role of KLF-4 is reported to maintain pluripotency 
and self-renewal in pluripotent stem cells. A study by Zhang et al. (2010) demonstrated that 
KLF-4 expression in mouse ES cells prevents terminal differentiation. Most importantly, they 
indicated that KLF-4 binds to NANOG to maintain pluripotency in mouse ES cells via the 
LIF-STAT3 pathway. Other studies have also suggested that KLF-4 acts as an enhancer of 
pluripotency genes (e.g. OCT3/4 and SOX2) during reprogramming (Guo et al., 2010; 
Takahashi, 2007). Furthermore, KLF-4 is suggested to be involved in chromatin remodelling 
during reprogramming for activation of stem cell genes. There is also functional redundancy 
of the KLF family of proteins, where KLF-2 and KLF-5 also bind to the NANOG promoter 
region (Chan et al., 2009). It is therefore plausible that the low KLF-4 levels detected in 
derived iPSCs for this study may have been due to the redundancy with other KLF proteins.  
The iPSC technology is a promising tool for patient-specific disease modelling, cell 
replacement therapy and regenerative medicine. However, there is also a need to overcome 
some of the challenges experienced during iPSC reprograming such as low reprogramming 
efficiency and partial reprogramming. Furthermore, genetic and clone variation are hurdles 
that still need to be addressed (Ohnuki & Takahashi, 2015; Rouhani et al., 2014). 
Recognising some of these challenges in this study, future work will require that more clones 
be further characterised, particularly for Patient B. Nevertheless, derivation of patient-
specific iPSCs in this study has thus produced a platform to further derive tissue-specific cells 
types that are affected in POIKTMP, and to explore the mechanism(s) by which the 
FAM111B mutation induces POIKTMP, focusing on the fibrosis phenotype which is the 
primary cause of death in the South African family (Khumalo et al., 2006; Mercier et al., 
2013).     
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Chapter 3 
Using iPSC-derived mesenchymal stem/stromal cells (iPSC-MSCs) to 
explore the role of FAM111B in the expression of genes involved in 
fibrogenesis 
 
3.1 Introduction  
Wound healing is a tightly regulated process, its dysregulation causes extensive deposition of 
the ECM causing fibrosis which leads to impaired tissue remodelling and ultimately organ 
failure (Henderson & Iredale, 2007; Krenning et al., 2010; Wynn, 2008). In some disease 
conditions such as chronic kidney disease, cardiac fibrosis and liver cirrhosis, the onset of 
fibrosis can be traced to an acute injury, which progresses to become chronic thus leading to 
fibrosis.  In hereditary fibrosing poikiloderma (POIKTMP) which is caused by mutations in 
the FAM111B gene, it has not been elucidated how these mutations result in the onset or 
progression of fibrosis. As a first approach to investigating this problem, this chapter explores 
the question of whether the FAM111B mutation activates the fibrotic process by altering the 
expression key pro-fibrotic molecules. As previously described (chapter 1), the primary 
effector cells in wound healing are fibroblasts, which break down the damaged extracellular 
matrix via matrix metalloproteinases and deposit newly synthesised type I and type III 
collagen required for wound healing and tissue repair (Fig. 1.6). There is also recruitment of 
pericytes, macrophages and mesenchymal cells/stromal which are activated to form 
myofibroblasts that produce new collagen and other ECM proteins. Epithelial cells which 
undergo EMT, are also activated and recruited for collagen deposition, and also contribute to 
fibrogenesis in impaired tissue repair (Rockey et al., 2015; Talele et al., 2015; Wynn, 2007, 
2010).  
It was observed that most of the affected tissues in POIKTMP are of mesenchymal 
lineage (e.g. tendons, skeletal muscle and connective tissue). Mesenchymal stem/stromal 
cells have notably been implicated in augmenting fibrosis as they are also recruited and 
activated by TGF-β and/or CTGF cytokine to differentiate into myofibroblasts during wound 
healing and fibrosis (LeBleu et al., 2013; Tan et al., 2011). Furthermore, MSCs have also 
been indicated to either attenuate fibrosis. For example, during tissue injury MSCs home to 
the site of injury and induce immunomodulation which results in the inhibition of T-cell and 
B-cell lymphocyte proliferation as well as stimulating an anti-inflammatory response 
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(Corcione et al., 2006; Di Nicola et al., 2002). Due to their role in immunomodulation and 
fibrosis, it is suggested that timing of MSC treatment for clinical application is critical for 
effective immunomodulation and anti-fibrotic response (Hayes et al., 2015). It has been 
suggested in some studies that for effective MSC treatment in lung injury, for example, 
treatment must be performed 48 hours post-injury to prevent fibrogenesis. Late MSC 
treatment is suggested to induce fibrosis as it overlaps with tissue remodelling which is 
associated with high levels of anti-inflammatory cytokines (e.g. TGF-β) which activate 
myofibroblasts. Treatment with MSCs during tissue remodelling therefore results in their 
differentiation into myofibroblast thereby contributing to an increased number of 
myofibroblasts and their activity leading to fibrosis (Popova et al., 2010).  
In systemic sclerosis (SSc), MSCs have been shown to express high levels of α-SMA 
and type I collagen, suggesting that baseline expression of these pro-fibrotic markers is 
elevated in this condition. This is further suggested by the finding that they have low 
potential to differentiate into vascular smooth muscle cells (Hegner et al., 2016). Hegner et al. 
(2016) showed by RNA and protein expression assays that MSCs from SSc patients 
particularly do not express high levels of connective tissue growth factor (CTGF) and bFGF, 
which are required for vascular smooth muscle differentiation. Furthermore, it is proposed 
that in familial disorders such systemic sclerosis, precursor cells such as MSCs could be the 
source of the disease phenotype (Hegner et al., 2016; Larghero et al., 2008).  
In this chapter, to test whether the FAM111B mutation results in increased levels of 
pro-fibrotic markers, mesenchymal stem/stromal cells were derived from patient and control 
iPSCs, and tested for changes in expression of pro-fibrotic markers α-SMA, type I and type 
III collagen  
Different protocols have been used for derivation of MSCs from iPSCs (iPSC-MSCs), 
and though there is no standardised method of derivation, characterisation of derived MSCs 
has been done by comparing iPSC-MSC gene expression profile and multi-lineage 
differentiation to that of bone marrow-derived MSCs, which are used as bona fide MSCs 
(Bianco et al., 2008). Mesenchymal stem/stromal cells previously derived from human ESCs 
were shown to be derived by treating hESCs with small molecules such as Rho-associated 
kinase (ROCK) inhibitor for 10 days (Tan et al., 2011), or TGF-β/BMP inhibitor for 28 days 
(Sánchez et al., 2011). Derivation of iPSC-MSCs by other investigators has also been shown 
to further require a variation of small molecules such as TGF-β, activin-A, retinoic acid, 
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ascorbic acid, platelet-derived growth factor (PDGF) and MSC-specific medium (Diederichs 
& Tuan, 2014; Kang et al., 2015; Lian et al., 2010; Moslem et al., 2015; Zou et al., 2013). 
Moreover, other studies have demonstrated effective differentiation of iPSCs into MSCs via 
standard embryoid body (EB) formation, while others showed direct iPSC to MSCs 
differentiation to be effective (Diederichs & Tuan, 2014; Lian et al., 2010). Interestingly, 
derivation of fibroblast-like cells from iPSCs required similar differentiation molecules used 
to derive iPSC-MSCs. However, due to the heterogeneity of these cells (Itoh et al., 2013), it 
is difficult to fully distinguish whether iPSC-derived fibroblasts are true fibroblasts or MSCs 
as these cell lines both exhibit the same morphology and phenotypic profile. It is therefore 
reasonable to identify these cells as mesenchymal stem/stromal cells.  
 
To investigate the role of the FAM111B mutation in the expression of pro-fibrotic markers in 
POIKTMP patients, the objectives in this chapter were to: 
a) Differentiate iPSC into MSCs (iPSC-MSCs)  
b) Determine whether iPSC-MSCs express typical MSC markers, and whether they 
possess the multi-lineage capacity to undergo osteogenic and adipogenic 
differentiation  
c) Determine whether there are differences in the expression of pro-fibrotic and 
adipogenic markers between patient and control cells  
 
 
 
 
 
 
 
 
Chapter 3 
 
62 
3.2 Materials and methods 
 
3.2.1 Deriving mesenchymal stem/stromal cells from iPSCs  
The iPSC-MSCs in this study were derived using a modified protocol by Itoh et al. (2013), 
where TGF-β2 was omitted and ascorbic acid was the primary molecule used to drive iPSCs 
towards the mesodermal lineage via EB formation and finally into mesenchymal 
stem/stromal cells (Fig. 3.1). Transforming growth factor (TGF)-β2 was omitted in the 
differentiation of iPSC to obtain progenitor cells of mesenchymal lineage for further 
differentiation into the affected tissue such as skeletal muscle, and to determine whether 
patient cells exhibited a myofibroblast phenotype without TGF-β treatment. 
Two patients and two control iPSC lines were manually passaged from the iMEF 
feeder layer as previously and transferred onto non-adherent 100 mm petri dishes for 
formation of EBs. The EBs were maintained in hESC medium (K/ODMEM; 20% KO-SR; 
1% NEAA; 1% GlutaMax; 0.05 mM β-mercaptoethanol) without bFGF and supplemented 
with 0.3 mM ascorbic acid (AA), and insulin-transferrin-selenium (ITS-A) supplement 
(Thermo Fisher Scientific, Waltham, MA, USA). The EBs were maintained in hESC medium 
(w/o bFGF) for six days and medium was changed every two days. Six days after EB 
formation the well-formed EBs were collected into 15 ml conical tubes and centrifuged at 
300 x g for two minutes. After centrifugation, the supernatant was removed and the EBs 
transferred onto gelatin-coated 6-well plates and maintained in high-glucose DMEM 
supplemented with 20% FBS, 1% Pen-strep and 0.3 mM ascorbic acid for 10 days, with 
medium change every 2-3 days. After 10 days, the cell outgrowths were passaged by first 
aspirating the differentiation medium and washing the cells twice with 1x PBS. The cells 
were passaged with 0.5 ml of 0.25% trypsin/EDTA per well and incubated at 37° C for five 
minutes. Thereafter 4.5 ml of growth medium was added to the cells for deactivation of 
trypsin/EDTA, collected and centrifuged at 2000 rpm for five minutes at room temperature 
(RT). Following centrifugation, the supernatant was removed, and the pellet was resuspended 
in one ml growth medium. The resuspended cells were thereafter added onto gelatin-coated 
culture dishes for expansion and formation of MSCs in DMEM supplemented with 10% FBS 
and 1% Pen-strep. The cells were maintained in culture and passaged every seven days up to 
passage six before characterisation for MSC markers. 
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3.2.2 Characterisation of iPSC-derived mesenchymal stem/stromal cells (iPSC-MSCs) 
3.2.2.1 Determining expression of MSC markers in iPSC-MSCs 
At passage six (P6), the derived iPSC-MSCs were characterised by qPCR analysis for 
expression of MSC markers. RNA extraction and qPCR (section 2.2.4.1.1 and 2.2.4.1.2, page 
45)  were performed to detect the expression of CD73, CD90 and alpha-smooth muscle actin 
(α-SMA) markers which are commonly expressed by MSCs. Adipose-derived MSCs which 
were kindly donated by Professor Michael Pepper (University of Pretoria, Pretoria, South 
Africa), were used as a positive control for characterisation of iPSC-MSCs as they are known 
to also express these markers.  
 
 
Figure 3.1 Derivation of iPSC-MSCs. The schematic diagram shows the step-wise approach used to 
derive MSCs from iPSCs. Adhered embryoid bodies (EBs) were maintained in basal medium supplemented 
with 20% FBS and ascorbic acid to induce mesenchymal differentiation. Fibroblast-like cells were 
maintained in culture for six passages prior to characterisation. The timeline shows the duration of each 
differentiation step for deriving iPSC-MSCs (protocol adapted from Itoh et al. 2013). (scale bar = 100 µm) 
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3.2.2.2 Osteogenic differentiation of iPSC-MSCs  
 To determine the multipotency of iPSC-derived MSCs, 1 x 105 cells/well were seeded 
onto gelatin-coated wells in a 6-well plate and were maintained in standard growth medium 
(DMEM; 10% FBS; 1% Pen-strep) until they reached confluence. The confluent iPSC-MSCs 
were maintained in standard growth medium supplemented with 50 µM ascorbate-2-
phosphate, 10 mM β-glycerophosphate and 1 µM dexamethasone, which activate expression 
of osteogenic transcription factors such as RUNX2 and synthesis of collagen (Langenbach & 
Handschel, 2013). Osteogenic differentiation was induced for 21 days, with fresh medium 
added every three days. Figure 3.2 shows the osteogenic cocktail used for differentiation and 
the timeline of differentiation. At day 21, the cells were either harvested for qPCR analysis to 
determine the expression of osteogenic markers and/or stained with Alizarin Red S stain to 
detect calcium deposition (Jaiswal et al., 1997; Kang et al., 2014; Pittenger, 1999). For qPCR 
analysis, the osteogenic markers used to detect successful differentiation were alkaline 
phosphatase (AP), RUNX2 and osteocalcin.  
 
 
 
 
 
 
Figure 3.2 Osteogenic differentiation. iPSC-MSCs were maintained in growth medium for 7 
days. From day 7 until day 21 the iPSC-MSCs were maintained in growth medium supplemented 
with the osteogenic cocktail indicated in the table. At day 21 the differentiated cells were stained 
with Alizarin red stain and compared with undifferentiated cells which were maintained in 
standard growth medium for 21 days.  
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Table 3.1: Primer sequences for osteogenic genes 
Gene Primer sequence NM Sequence Size (bp) 
AP (F) 5'-ATC TGA CCC TCC CAG TCT C-3’ XM_006710546.3 165 
AP (R) 5'-GAG TGA GTG AGT GAG CAA GG-3’ 
hRUNX2 (F) 5'-CCACCTCTGACTTCTGCCTC-3’  NM_001024630.3 108 
hRUNX2 (R) 5'-ATGAAATGCTTGGGAACTGC-3’ 
hOC/BGLAP (F) 5'-GGCAGCGAGGTAGTGAAGAG-3’ NM_199173.5 158 
hOC/BGLAP (R) 5'-CGATAGGCCTCCTGAAAGC-3’ 
 
3.2.2.2.1 Alizarin Red S (ARS) staining 
For detection of calcium deposition following 21-day of osteogenic differentiation, 
medium was aspirated, and the cells were washed twice with 1X PBS. After rinsing the cells 
with PBS, the cells were fixed with 10% formalin for 30 minutes at room temperature (RT). 
After fixing, the cells were washed twice with double-distilled water (ddH2O). One ml of 
Alizarin red stain (0.14%; pH 4.13) was thereafter added to the cells and incubated in the 
dark at RT for 1 hour (h). Following ARS staining, the cells were rinsed five times and 
thereafter viewed under the Evos XL Core (Life technologies) light microscope with a 20x 
objective. 
 
3.2.2.3 Adipogenic differentiation of iPSC-MSCs  
The derived iPSC-MSCs were further differentiated into adipocytes to determine their 
multipotency as MSCs are known to have the capacity to undergo into osteogenic, adipogenic 
and chondrogenic differentiation. For adipogenic differentiation, the iPSC-MSCs were 
cultured onto gelatin-coated 6-well plates at 5000 cell/cm2 for seven days and maintained in 
growth medium (DMEM; 10% FBS; 1% Pen-strep). On day seven growth medium was 
supplemented with the adipogenic cocktail containing 0.5 mM 3-Isobutyl-1-methylxanthine 
(IBMX) (Sigma-Aldrich, St Louis, MO), 10 µg/ml insulin (Thermo Fisher Scientific, 
Waltham, MA, USA), 1 µM Dexamethasone (activates expression of C/EBPα and PPARγ) 
(Sigma-Aldrich, St Louis, MO) and 100 µM indomethacin (Sigma-Aldrich, St Louis, MO). 
Adipogenic differentiation was induced from day seven until day 21, with medium change 
every 2-3 days (see Fig 3.3 for schematic presentation). The undifferentiated iPSCs-MSCs 
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were maintained in growth medium until day 21, with medium change every 2-3 days. 
Adipogenic differentiation was thereafter analysed by qPCR or Oil Red O staining. Adipose-
derived MSCs (AD-MSCs) were used as a positive control for characterisation of iPSC-
MSCs. Messenger RNA (mRNA) expression for early adipogenic markers peroxisome 
proliferator-activated receptor γ (PPARγ), CCAAT/enhancer binding protein α (C/EBPα), 
and late adipogenic markers fatty-acid binding protein-4 (FABP4) were analysed by qPCR in 
differentiated iPSC-MSCs. 
 
 
 
 
Table 3.2: Primer sequences for adipogenic genes 
Gene Primer sequence NM Sequence Size (bp) 
PPARγ (F) 5'-ATTGACCCAGAAAGCGATTC-3’  
NM_001354668.1 
 
154 
PPARγ (R) 5'-CAAAGGAGTGGGAGTGGTCT’ 
hCAAT/EBPα (F) 5'-GCAAACTCACCGCTCCAATG-3’  
NM_001287435.1 
 
247 
hCAAT/EBPα (R) 5'-TTAGGTTCCAAGCCCCAAGTC-3’ 
hFABP4 (F) 5'-GGGACGTTGACCTGGACTGA-3’  
NM_001442.2 
 
113 
hFABP4 (R) 5'-GGGAGAAAATTACTTGCTTGCTAAA-3’ 
Figure 3.3 Adipogenic differentiation. iPSC-MSCs were maintained in growth medium 
until confluence on day 7. Growth medium was medium supplemented with the 
adipogenic cocktail (see table) for adipogenic induction. At day 21 the differentiated cells 
were stained with oil red O stain which stain lipid droplets red and compared with 
undifferentiated cells, which were maintained in standard growth medium for 21 days.   
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3.2.2.3.1 Oil Red O staining in adipocytes derived from iPSC-MSCs 
 Following adipogenic differentiation, the cells were washed twice with 1x PBS and 
fixed for 10 minutes with 10% formalin at room temperature (RT). After 10 minutes, fresh 
10% formalin was added, and the cells were incubated for 1 hour (h) at RT. After 1 h, 
formalin was aspirated, and the cells were washed twice with distilled water and thereafter 
incubated with 60% isopropanol for five minutes. Thereafter, isopropanol was removed, and 
the cells were air-dried for five minutes followed by incubation with 60% Oil Red O (ORO) 
(Sigma-Aldrich, St Louis, MO) for 15 minutes. Following ORO staining, the cells were 
washed 4x with distilled water and air-dried prior to viewing at 200x magnification with the 
Evos XL Core Microscope (Thermo Fisher Scientific, Waltham, MA, USA). 
 
3.2.3 Analysis of fibrotic markers in iPSC-MSCs   
The iPSC-MSCs were cultured in growth medium (DMEM; 10% FBS; 1% Pen-strep) to 
determine if patients’ cells express high levels of key fibrotic markers, which are collagen 
type 1A1 (COL1A1), 3A1 (COL3A1) and α-SMA. Once the iPSC-MSCs reached confluence 
they were harvested for RNA extraction as previously described (section 2.2.4.1.1) and 
analysed by qPCR (section 2.2.4.1.2). Extraction of RNA and qPCR were performed as 
previously described, and expression of COL1A1, COL3A1 and α-SMA mRNA levels were 
measured and compared between patients and controls. 
 
3.2.3.1 Picrosirius Red (PSR) staining in iPSC-MSCs 
 Picrosirius red staining was performed to determine whether patient cells synthesised 
increased levels of type I and III collagen compared to controls. Briefly, patient and control 
iPSC-MSCs were seeded onto gelatin-coated 6-well culture plates at 0.1 x 106 cell/well. The 
cells were maintained in growth medium (DMEM; 10% FBS; 1% Pen-strep), with medium 
change every 2 days until the cells reached 80% confluence. At 80% confluence the cells 
were maintained in low serum (1% FBS) for 24 h. Following 24 h cell-culture in low serum, 
the cells were washed twice with 1x PBS and fixed with 1 ml Bouin’s solution and incubated 
at room temperature (RT) for 2 h. After fixation, the cells were washed twice with 1x PBS, 
followed by incubation with shaking in 1 ml of 0.1% Picrosirius red (PSR) stain for 2 h at 
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RT.  After 2 h incubation, the cells were washed 3x with 0.1% acetic acid and air-dried at RT 
for five minutes. Collagen staining imaging was captured at 200X magnification. 
 The PSR-collagen stain was eluted by incubating the cells with 0.1 N sodium 
hydroxide (NaOH) with shaking for 90 minutes at RT. The eluted stain was quantified using 
the spectrophotometer at the optical density of 540 nm. Rat tail collagen I was used as a 
standard.  
 
3.2.4 Western blotting 
3.2.4.1 Protein quantification  
Patient and control iPSC-MSCs were cultured to 90% confluence. Three-hundred µl 
of radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors were added 
to each 10-cm culture plate for cell lysis and collection. The lysate was centrifuged at 12 000 
rpm and 4 ºC for 20 minutes. The supernatant was collected into a fresh microfuge tube, and 
protein concentration was quantified using the Bicinchoninic acid assay (BCA) assay 
(Thermo Fisher Scientific, Waltham, MA, USA). Briefly, a 1:8 dilution was prepared for the 
BCA solution and bovine serum albumin (BSA), which was used as a standard. The samples 
were also prepared at 1:8 dilution in a 96-well plate. The 96-well plate was incubated at 37º C 
for 30 minutes and the absorbance was thereafter read at 562 nm using the RT-2100C 
microplate reader (Rayto Life & Analytical Sciences, Shenzhen, China). The standard curve 
and protein concentration were analysed on Microsoft Excel using the linear equation [(y = 
a*x + b) where: y = Protein concentration; x = Absorbance; a = Slope and b = Background 
Signal]. The protein samples were stored at -80º C for later use or long-term storage.  
 
3.2.4.2 Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 The SDS-PAGE gels were prepared using the BioRad electrophoresis apparatus 
(Biorad Mini PROTEAN©). Ten-percent resolving gels were prepared on 1.5 mm (thick) 
plates and 5% stacking gels were prepared for loading the samples (see appendix). Laemali 
sample buffer (2X) was added to each sample and boiled at 95º C for five minutes. Thirty 
micrograms of protein for each sample were loaded onto the gels and electrophoresed at 110 
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volts (V) in 1X running buffer for 90-120 minutes at room temperature. The loading control 
used was rabbit polyclonal anti-p38 (Cell Signalling Technology, Danvers, MA, USA) which 
is a 40 kDa protein. 
 
3.2.4.3 Nitrocellulose membrane electro-transfer  
 Following SDS-PAGE, the resolving gels and nitrocellulose transfer membrane 
(Amersham Biosciences, UK) were soaked in in 1X transfer buffer (see appendix) for 10 
minutes. The resolving gels and the transfer membranes were “sandwiched” between 
cassettes and placed in a running tank. The electro-transfer was performed at 100V and 4º C 
for 1 h.   
 
3.2.4.4 Chemiluminescence protein detection 
 Following electro-transfer, the nitrocellulose membrane was soaked in Ponceau stain 
for three minutes for detection of transfer efficiency. The membranes were thereafter washed 
3 x 5 minutes with shaking in Tris-buffered saline-0.1% Tween-20 solution (0.1% TBS-T). 
The membranes were incubated in blocking buffer in containing TBS-T and 5% fat-free milk 
for 1 h at RT with shaking.  The membranes were thereafter washed 3 x 5 minutes with 
shaking in 0.1% TBS-T. For detection of α-SMA protein (37 kDa) (Abcam, UK) one 
membrane was incubated in anti-α-SMA primary antibody (1:500) diluted in blocking buffer 
overnight at 4º C with shaking. The other membrane was incubated with anti-p38 primary 
antibody (1:5000) and used as a loading control.  
Following overnight incubation, the membranes were washed 3 x 5 minutes with 
shaking in 0.1% TBS-T and thereafter incubated for 2 h (RT) in horseradish peroxidase-
conjugated goat-anti rabbit secondary antibody (Biorad, Hercules, CA, USA) at 1:1000 for α-
SMA and 1:5000 for p38. The membranes were thereafter washed 3 x 5 minutes with shaking 
in 0.1% TBS-T and incubated in chemiluminescence reagent for 3-5 minutes and developed 
the blots in the dark using X-ray film for signal detection. The blots were thereafter scanned 
for densitometric readings and further analysis. 
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3.2.5 Statistical analysis   
Statistica Software version 13.2 (Dell Inc.) was used for statistical analysis of all data in this 
study. The qPCR results were analysed according to Schmittgen & Livak (Schmittgen & 
Livak, 2008) method, which was added to the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) guidelines (Bustin et al., 2009). The 
results are presented as mean ±SEM, and differences between two samples were analysed by 
Student’s t-test, independent by group or variable. To determine significant differences in 
three or more groups, Breakdown & one-way analysis of variance (ANOVA) was used, with 
Tukey honest significant difference (HSD) as the post-hoc test.  Data were considered 
statistically significant at p < 0.05. Graphs were plotted with GraphPad Prism version 5.0 
(GraphPad, San Diego, CA). 
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3.3 Results 
3.3.1. Characterisation of iPSC-derived MSCs (iPSC-MSCs) 
3.3.1.1 iPSC-MSCs express MSC markers 
The derived iPSC-MSCs were first characterised by their cellular morphology 
followed by the expression of typical MSC surface markers. The cell morphology of the 
newly derived iPSC-MSCs showed the typical fibroblast-like cell morphology as seen in 
adipose-derived MSCs (Fig 3.4A). Quantitative real-time PCR (qPCR) was performed to 
detect expression of typical MSC markers in iPSC-derived MSCs. As can be seen (Fig. 3.4B-
D), the iPSC-MSCs expressed high levels of CD73 (p < 0.001), CD90 (p < 0.05) and α-SMA 
(p < 0.05) compared iPSCs. Interestingly, low levels of CD90 expression were detected in 
iPSCs, which is not typically expressed in pluripotent stem cells.  These results indicate that 
the iPSC-MSC were successfully differentiated towards the mesenchymal lineage. Some 
variations were observed between the familial and non-familial controls with regards to 
CD90 expression (Fig. 3.4C) where the non-familial control showed higher expression of 
CD90 compared to the familial control as well as patient samples. This may have been due to 
differences in the genetic background of the non-familial control as genetic variation affects 
the expression of different genes in unrelated or non-isogenic samples.  
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Figure 3.4 Expression of MSC markers in iPSC-derived MSCs (iPSC-MSCs). (A) The cell morphology of derived iPSC-MSCs was compared to 
bona fide adipose-derived MSCs (AD-MSCs) (B-D) The expression of MSC-specific gene markers (CD73; CD90; α-SMA) in iPSC-MSCs was 
compared with undifferentiated iPSCs. Data are presented as mean ± SEM (n = 4). * p < 0.05; ** p < 0.001. 
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3.3.1.2 iPSC-MSCs stain positive for Alizarin red stain and express osteogenic 
markers 
 One of the key characteristics of mesenchymal stem/stromal cells is their trilineage 
multipotency. To determine whether iPSC-derived MSCs are multipotent, they were induced 
towards osteogenic differentiation by maintaining the cells in growth medium supplemented 
with 50 µM ascorbate-2-phosphate, 10 mM β-glycerophosphate and 1 µM dexamethasone for 
21 days, with medium change every 2-3 days. At day 21, the differentiated iPSC-MSCs were 
subjected to Alizarin Red S (ARS) stain for detection of mineralisation through calcium 
deposition. The successful differentiation of iPSC-MSC towards the osteogenic lineage was 
revealed by the orange-red ARS. The iPSC-MSCs that stained positive for ARS stain 
appeared orange-red and the undifferentiated iPSC-MSC showed a slightly reddish stain thus 
indicating non-mineralisation (Fig.3.5 A and B). Alizarin red staining in the familial control 
and Patient A was less extensive compared to the non-familial control and Patient B. Two 
biological repeats were performed for osteogenic differentiation and ARS stain and similar 
results were obtained. This was further confirmed by the expression of osteogenic markers, 
that the familial control and Patient A cells had low levels of RUNX2 a master transcription 
factor for osteogenic differentiation, and alkaline phosphatase (AP) which is an early 
osteogenic marker which is sustained till day 21. The non-familial control and Patient B 
indicated high levels of RUNX2 and AP (Fig 3.5Ci and Ciii), which is consistent with the 
high ARS staining compared to the familial control and Patient A. This variation in the 
familial control and Patient A may be due to clone variation. The expression of osteocalcin 
mRNA (Fig. 5Cii) was similar in both differentiated and undifferentiated cells. This finding 
is consistent with the finding by Jaiswal et al. (1997) who also showed that osteocalcin is 
expressed in similar levels in both differentiated and undifferentiated MSCs.  
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 Figure 3.5: Alizarin red staining and expression of osteogenic markers. (Ai; ii) iPSC-derived MSCs were differentiated towards the osteogenic lineage 
and stained with alizarin red S (ARS) stain. (Bi; ii) Alizarin red staining and microscopic imaging of ARS in differentiated and undifferentiated control 
iPSC-MSC samples. Alizarin red staining and microscopic imaging of in differentiated and undifferentiated patient iPSC-MSC samples. (Ci-iii) mRNA 
expression of osteogenic markers (AP, osteocalcin and RUNX2) was analysed in differentiated iPSC-MSCs and compared to undifferentiated cells. Two 
biological repeats were performed for osteogenic differentiation and ARS stain. Data presented as mean ± SEM (n = 2).     
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3.3.1.3 iPSC-MSC show limited Oil red O staining and low levels of adipogenic 
markers 
To determine the ability of iPSC-MSCs to differentiate towards the adipogenic 
lineage, they were maintained in growth medium supplemented with adipogenic cocktail (0.5 
mM IBMX, 1 µM dexamethasone, 100 µM indomethacin, and 10 µg/ml insulin) for 21 days. 
After 21 days of adipogenic induction oil red O (ORO) staining was performed. Adipose-
derived MSC (AD-MSCs) which were used as a positive control indicated positive staining 
of ORO and high expression of adipogenic markers (PPARγ; C/EBPα; FABP4) (Fig. 3.6A) 
compared to undifferentiated cells (Figure 3.6B). By day 21 of adipogenic differentiation, the 
iPSC-MSCs revealed smaller and fewer lipid droplets after ORO staining [Fig 3.6 C (i)]. 
Expression of PPARγ [Fig. 3.6C (ii)] and C/EBPα [Fig. 3.6C (iii)] mRNA, which are early 
adipogenic markers as well as FABP4 [Fig 3.6C (iv)] a late marker, indicated low or similar 
expression levels as undifferentiated cells. The qPCR data thus confirmed the low ORO 
staining indicating that expression of the key adipogenic genes were induced at very low 
levels. Three biological repeats were performed for the 21-day differentiation with similar 
findings, and two biological repeats were performed for the 30-day adipogenic induction. 
Extension of adipogenic differentiation in iPSC-MSCs to 30 days indicated a slight increase 
in adipocytes indicated by ORO staining (Fig 3.6D), however, high variation in the 
expression of adipogenic genes 30 days post-induction. These results demonstrate that iPSC-
derived MSCs have less adipogenicity compared to AD-MSCs 
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Figure 3.6 Analysis of adipogenic differentiation in iPSC-MSCs. Patient and control iPSC-MSCs were differentiated for 21 days and 
stained with Oil Red O (ORO). (A) Adipose-derived MSCs (AD-MSCs) show positive ORO staining of lipid droplets and (B) high 
expression of adipogenic genes (PPARγ, C/EBPα and FABP4) compared to undifferentiated cells. (Ci) Oil red staining and expression 
of adipogenic genes (Cii) PPARG; (Ciii) C/EBPα; (Civ) FABP4 in differentiated and undifferentiated patient and control cells at day-21 
of differentiation. (D) iPSC-MSCs showed a slight increase in lipid droplets following ORO staining after 30 days of adipogenic 
differentiation. Data are presented as mean ± SEM (n = 3).  
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3.3.2 Expression of pro-fibrotic markers in patient-derived iPSC-MSCs 
3.3.2.1 Patient-derived iPSC-MSCs do not express higher levels of pro-fibrotic 
markers than control cells 
 The hallmark of POIKTMP is multi-systemic fibrosis, specifically of the skin, skeletal 
muscle and tendons with lung fibrosis being the leading cause of death (Khumalo et al., 2006; 
Mercier et al., 2013). Since the mechanism by which the FAM111B mutation induces fibrosis 
in POIKTMP patients is currently unknown, we hypothesised that the mutation leads to the 
overexpression of pro-fibrotic markers and increases deposition of collagen type I and III. To 
test this hypothesis, endogenous expression of key pro-fibrotic makers (α-SMA; COL1A1, 
COL3A1) were analysed by qPCR in iPSC-MSCs. The aim was to determine if the patient 
iPSC-MSCs overexpress these pro-fibrotic markers similarly to systemic sclerosis (Gabrielli  
et al., 2009; LeRoy, 1974).  
When the mRNA expressions of COL1A1, COL3A1 and α-SMA were analysed in this 
study, there was no statistical difference between patients and controls (Fig. 3.7A). Protein 
analysis of α-SMA showed overall non-statistical significance between patients and controls 
(Fig. 3.7B). These results indicate that under the culture conditions of these experiments the 
patient iPSC-MSCs do not overexpress COL1A1, COL3A and α-SMA pro-fibrotic markers. 
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3.3.2.2 Patient cells reveal normal collagen levels following picrosirius red staining 
and quantification 
Since fibrosis is not only caused by high collagen expression but could have also been 
caused by a dysregulation in the breakdown of collagens and other ECM proteins. This would 
result in an accumulation of these proteins. Therefore, the next experiment was to determine 
if there are changes in total collagen content between POIKTMP patients and controls. 
Patient and control iPSC-MSCs were seeded onto gelatin-coated culture plates and 
Figure 3.7 Expression of fibrosis markers in patient and control iPSC-MSCs. (A) Endogenous 
mRNA expression for COL1A1; COL3A1 and α-SMA was measured in patient and control iPSC-MSCs. 
(B). Western blotting and densitometric analysis for α-SMA protein expression (shown in % relative to 
the familial control) was performed in patient and control iPSC-MSCs. Data are presented as mean ± 
SEM (n = 4). * p < 0.05; ** p < 0.01 
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maintained in standard growth medium till the cells reached 80% confluence. When 
confluent, they were maintained in DMEM supplemented with 1% FBS for 24 h and 
thereafter stained with Picrosirius red. Two biological repeats were performed for PSR 
staining and quantification. Picrosirius red (PSR) staining, which stains collagen indicated 
similar amounts of collagen between patients and controls (Fig 3.8A). The quantified PSR 
stain also demonstrated that patients and control iPSC-MSCs contained similar amount of 
collagen (Fig. 3.8B). These results indicate that the patient cells contain normal levels of 
collagen proteins. 
Overall, these results indicate that POIKTMP is distinct from other hereditary fibrotic 
disorders such as SSc, which show that patient fibroblasts and MSCs express high levels of 
these pro-fibrotic markers in vitro (LeRoy, 1974; Lu et al., 2017a; Vanneaux et al., 2013). It 
should be noted, in interpreting these experiments, that in vitro culture seems to upregulate 
the basal levels fibrotic proteins, such as collagens: this might mask any differences that 
might been seen between patient and control cells. 
 
 
Figure 3.8 Staining and quantification of collagen in iPSC-MSCs. (A) Picrosirius red staining of 
collagen in Patient and control iPSC-MSCs. (B) Spectrophotometric quantification of eluted Picrosirius 
red stain as a measure of total collagen in patient and control iPSC-MSCs. Data are presented as mean ± 
SEM (n = 2) (scale bar = 100 µm). 
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3.4 Discussion 
3.4.1. iPSC-derived mesenchymal stem/stromal cells demonstrate MSC characteristics 
with reduced adipogenicity  
Multi-systemic fibrosis is the primary phenotype in POIKTMP, and pulmonary fibrosis is the 
cause of death in the South African kindred. It was therefore valuable to determine, in cell 
specific assays, whether the FAM111B mutation results in an increasing the expression or 
accumulation of key fibrotic markers including COL1A1, COL3A1 and α-SMA.  
Most of the affected tissues in POIKTMP are of mesenchymal lineage, therefore, 
iPSCs were differentiated into mesenchymal stem/stromal cells (iPSC-MSCs) to determine 
expression of key pro-fibrotic markers in patient cells. Derivation of iPSC-MSCs was 
performed via embryoid body formation, with ascorbic acid and serum as the main molecules 
used to drive mesodermal/mesenchymal lineage differentiation. Characterisation of iPSC-
MSCs revealed that these cells have the fibroblast-like morphology and express typical MSCs 
markers (CD73, CD90 and α-SMA). Osteogenic and adipogenic differentiation in iPSC-
MSCs indicated that iPSC-MSCs possess adequate osteogenic differentiation and limited 
adipogenicity. Analysis of osteogenic differentiation also revealed some variation between 
samples. For example, the familial control and Patient A indicated moderate Alizarin red S 
(ARS) staining for detection of mineralisation in osteogenic cells, which was supported by 
the low expression of osteogenic markers (AP and RUNX2) in these samples. The non-
familial control and Patient B on the other hand, showed extensive osteogenic induction (Fig. 
3.5 B-C). These findings thus indicate that the variation between samples may be due to 
clone variation and not the POIKTMP condition as Patient A showed less osteogenic 
differentiation and Patient B showed high osteogenicity. Other clones for the familial control 
and Patient A need to be tested osteogenic differentiation.  
Limited adipogenic induction was observed in all iPSC-MSC samples. Following a 
21-day adipogenic induction, all iPSC-MSCs demonstrated less adipogenic differentiation 
with very small and few lipid droplets compared to adipose-derived MSCs (AD-MSCs) (Fig 
3.6 A-C). Furthermore, qPCR analysis indicated low expression of adipogenic genes 
(PPARγ; C/EBPα and FABP4) in differentiated iPSC-MSCs. Though there was a slight 
increase in adipogenesis after a 30-day induction, the areas of differentiation in iPSC-MSCs 
remained sparse. Similar findings were reported by Kang et al. (2015), who demonstrated that 
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iPSC-derived MSCs retain adequate osteogenic and chondrogenic differentiation capacity but 
less adipogenicity. Though a different method was used to derive MSCs from iPSCs in this 
study compared to a study by Kang et al. (2015), the same results were obtained in both 
studies, thus indicating that limited adipogenicity is a feature of iPSC-MSCs. Chondrogenic 
differentiation though not performed in this study was conducted by Dr Robea Ballo, who 
reported that iPSC-MSCs derived in this study indicated adequate chondrogenic 
differentiation (data not shown). Overall, the iPSC-MSCs demonstrated sufficient MSC 
phenotype and characteristics.  
 
3.4.2 Changes in the expression of key pro-fibrotic markers were not detected in patient 
cells carrying the FAM111B mutation  
Endogenous expression of pro-fibrotic markers was analysed in iPSC-MSCs to determine 
whether the FAM111B mutation increases expression of these genes thereby leading to 
fibrosis. The data in this study indicated that patient cells express similar levels of COL1A1, 
COL3A1 and α-SMA compared to controls. Protein expression of α-SMA also indicated 
similar levels between patients and controls, thus suggesting that patient iPSC-MSCs 
remained in a non-myofibroblast state. Picrosirius red staining and quantification also 
indicated similar levels of collagen deposition between patient and control cells, which 
confirmed qPCR and western blot data. These findings indicate that FAM111B mutation does 
not alter the expression of pro-fibrotic markers analysed in this study, thereby suggesting that 
fibrosis may be a secondary effect of the gene mutation. The data in this study further 
indicate that POIKTMP differs from conditions such as SSc, which have been shown to cause 
constitutive expression of pro-fibrotic markers in affected (LeRoy, 1974). 
Hereditary fibrosing poikiloderma studies have revealed variation in the phenotype 
caused by FAM1111B mutations. It is suggested that mutations located on codons 625, 627 
and 628 (see Table 1.2) have a severe phenotype and early onset of the disease (Takeichi et 
al., 2016). However, other cases with varying phenotype from the South African kindred 
have been reported by Seo et al. (2016) and Goussot et al. (2017). A study by Seo et al. 
(2016) showed that the FAM111B mutation (c.1261_1263delAAG, p.Lys421del) causes 
exocrine pancreatic dysfunction, and a study by Goussot et al. (2017) reported  a case of 
pancreatic cancer associated with another FAM111B mutation (c.1884T>A, p.Ser628Arg). 
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The fibrosis phenotype has been shown to be extensive in the South African kindred 
(Khumalo et al., 2006) while other cases have primarily reported muscle degeneration and 
elastic sclerosis in the skin (Mercier et al., 2013). These studies further expand the possible 
role of FAM111B in cellular processes. This chapter has shown that FAM111B does not alter 
the expression and pro-fibrotic genes as postulated, however, since wound healing is a 
complex process, the role of FAM111B cannot be completely excluded from this process. 
Since FAM111B has also been indicated to play a role in cell proliferation, though the 
mechanism has not been described (Aviner et al., 2015), it is therefore, suggested that 
FAM111B modulates cell proliferation during wound healing. The next chapter of this study 
will thus explore this hypothesis. 
Because no animal model exists for studying this condition due to lack of FAM111B 
homologues in Mus musculus species, the use of derived iPSCs for further differentiation into 
other affected cells types proves to be an advantage as derivation of other cell types may 
reveal new insights into the mechanism by which FAM111B induces fibrosis. For example, 
using iPSC-derived alveolar epithelial cells as another cellular model may indicate if derived 
alveolar cells from affected individuals continuously undergo epithelial-mesenchymal 
transition (EMT) that is known to occur during tissue repair and fibrosis (Coward et al., 2010; 
Li et al., 2016). Also, iPSCs can be used to derive organoids for skin and lung tissue, which 
could mimic the 3D structure and function of that specific cell type more effectively than 2D 
cultures (Dutta et al.). Studies have shown the successful derivation of 3D organoids for 
modelling of neurodegenerative diseases such as neural crest cell to model Alzheimer’s 
Disease (Raja et al., 2016).  Furthermore, the use of 3D matrices for creating an in vivo 
microenvironment could also improve the current models for studying fibrosis in vitro (Jeon 
et al., 2016; Xu et al., 2015). Application of these model systems would hopefully improve 
future work into understanding the mechanism by which the FAM111B mutation induces 
multi-systemic fibrosis in POIKTMP patients. 
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Chapter 4 
FAM111B mutation affects cell proliferation in poikiloderma patient-
derived iPSC-MSCs  
 
4.1 Introduction 
In normal tissue fibroblasts are in a quiescent state but during wound healing they are 
activated to proliferate and transdifferentiate into myofibroblasts resulting in collagen and 
ECM production (Wynn, 2008; Yeo et al., 2018). There is also recruitment of bone marrow-
derived mesenchymal stem/stromal cells that convert into myofibroblasts that further 
contribute to the synthesis of collagen and other ECM proteins (Chakraborty et al., 2014; 
Wynn, 2008). Upon completion of tissue repair the myofibroblasts are removed by apoptosis 
and senescence. However, the signals that lead to apoptosis or senescence have not been 
clearly defined (Desmoulière et al., 1995; Krizhanovsky et al., 2008). It has also been shown 
that the myofibroblasts that escape apoptosis and/or senescence revert to their inactive 
fibroblast state. For instance, a study by Desai et al. (2014) showed in adipose-derived MSCs 
that their exposure to TGF-β leads to myofibroblast formation and treatment with growth 
factors such as bFGF reverses the myofibroblast phenotype. Another in vitro study by 
Garrison et al. (2013) demonstrated that foetal and adult lung fibroblasts treated with TGF-β 
transdifferentiate into myofibroblasts and revert to their fibroblast state when treated with 
prostaglandin E2 (PGE2).  
In contrast to normal wound healing, during fibrosis, myofibroblasts evade apoptosis 
and persist in their active state, which results in further proliferation and ongoing collagen 
and ECM production (Horowitz et al., 2016; Vancheri et al., 2010). A study by van 
Spreeuwel et al. (2017), for example, showed that in cardiac fibrosis there is an increased 
number of resident fibroblasts which cause excessive production and deposition of collagen 
and other ECM proteins. A study on experimental idiopathic pulmonary fibrosis (IPF) study 
showed that primary fibroblasts obtained from patients with IPF proliferated faster compared 
to lung fibroblasts obtained from healthy individuals (Raghu et al., 1988). Furthermore, lung 
fibrosis studies using the bleomycin mouse model for fibrosis also indicated that there is an 
increase in the number of lung fibroblasts which correlates to increased collagen and other 
ECM proteins (Blaauboer et al., 2013; Chen et al., 2008; Löfdahl et al., 2018).  
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There have been a number of studies that have revealed that the increase in cell 
proliferation during fibrosis is caused by the upregulation of proteins involved in the cell 
cycle such as cyclin D1, which activates cell cycle progression from the G1 to S-phase. For 
example, a study by Watts et al. (2006) showed that a population of fibroblasts derived from 
lung biopsies of patients with IPF expressed higher levels of cyclin D1 via activation of the 
Rho A kinase pathway. Another study also indicated that alveolar epithelial cells obtained 
from patients with IPF differentiate into myofibroblasts via EMT and express high levels of 
cyclin D1 (Akram et al., 2014). These studies thus indicate that increased cell proliferation 
observed in fibrosis is also caused by cell cycle changes.  
As briefly discussed in the literature review (section 1.4), FAM111A and FAM111B 
have been shown to play a role in cell proliferation and cell cycle progression. Both proteins 
have been reported to be associated with the DREAM complex which regulates cell cycle 
repression and activation (Litovchick et al., 2007). The ChIP Enrichment Analysis (ChEA) 
data indicated that the FAM111B promoter specifically binds to E2F1 in breast cancer cells 
(MCF7) and to E2F4 in lymphoblastoid cells (http://amp.pharm.mssm.edu/lib/chea.jsp). 
E2F1 has been described to activate expression of target genes, while E2F4 has more recently 
been suggested to have dual ability to repress and activate expression of target genes (Lee et 
al., 2012). Since both transcription factors form part of the DREAM complex, they possibly 
activate FAM111B expression during cell cycle progression (Popov & Petrov, 2014; 
Sadasivam & DeCaprio, 2013).  
In support of this hypothesis, a study by Aviner et al. (2015) was the first to show that 
FAM111B is expressed in a cell cycle-dependent manner. Using multi-omic analysis 
(transcriptomics and proteomics) they showed that in synchronised HeLa S3 cellsFAM111B 
expression increases at the G1→S transition, with an mRNA peak at G1 and a protein peak at 
the S-phase, and low at the G2/M phase. Furthermore, their data indicate that FAM111B 
expression correlates with PCNA expression in these cells. Because FAM111B peaks at S-
phase, they propose that FAM111B may be involved in DNA replication or forms part of the 
S-phase machinery.  
Interestingly, cancer-associated studies have also shown a link between FAM111B 
and cancer progression. A study by Peng et al. (2008) reported that FAM111B (also known 
as the cancer-associated nuclear protein (CANP) mRNA expression is higher in human foetal 
tissue and cancer cells, compared to differentiating cells and adult tissues. They further 
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reported that FAM111B mRNA levels are higher in hepatic carcinoma cells compared to 
HepG2 cells. A separate study using integrated bioinformatic analysis of public microarray 
data revealed that FAM111B is among the top genes that are upregulated in lung squamous 
cell carcinoma (Zhang et al., 2017). These results overall suggest that in various types of 
cancer, FAM111B is upregulated and overexpressed.  A complementary approach was to ask 
whether FAM111B is reduced in cancer cells following treatment with anticancer agents.  In 
the first of such studies using a transcriptomic approach, Yue et al. (2015) showed that 
FAM111B was downregulated over 20-fold in a pancreatic cancer cell line (PANC-1) 
following dual treatment with metformin and aspirin. Another study by Baselet et al. (2017) 
indicated that the expression levels of FAM111B together with MKI67, which encodes a cell 
proliferation marker, were decreased in endothelial cells that were subjected to a single x-ray 
dose of ionizing radiation, which inhibits cell proliferation. These studies indicate that 
FAM111B is among the genes, including cell cycle genes which are altered during cancer 
treatment. It should be noted when interpreting these experiments, that one cannot distinguish 
between two possible interpretations: i.e. whether a decrease in the proliferation of cancer 
cells is a downstream consequence to a decrease in FAM111B expression, or whether 
FAM111B expression is decreased due to the global effect of anti-cancer drugs.  
Another important connector is that several studies have shown similarities in the 
pathogenesis of fibrosis and cancer (Kalluri, 2016; Schäfer & Werner, 2008; Vancheri et al., 
2010). Though distinct in their onset and progression, there are clear parallels as well as 
common cellular and molecular mechanisms that are activated in fibrosis and cancer (Schäfer 
& Werner, 2008). For instance, studies have shown that tumour stroma resembles the 
granulation tissue of wound healing, which also comprises of inflammatory cells and 
myofibroblasts (Balkwill et al., 2005). Furthermore, cancer has also been hypothesised to be 
an “overhealing wound” as malignant tumours have often been found to occur at sites of 
chronic injury caused by chronic inflammation (Schäfer & Werner, 2008). Also, it was 
previously postulated that chronic irritation and previous injuries are preconditions for 
tumorigenesis (Dvorak, 1986). Moreover, long-term inflammatory cells in chronic 
inflammation act as tumour promoters thus creating what is known as a neoplastic tissue with 
a microenvironment that is favourable for tumour growth and progression (Balkwill et al., 
2005). In neoplastic tissue there are also tumour-associated macrophages (TAMs) that 
acquire the type 2 (M2) macrophage phenotype which further induces secretion of anti-
inflammatory cytokines (IL-10 and TGF-β) to promote tumour proliferation, progression and 
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ECM deposition (Balkwill et al., 2005; Obermueller et al., 2004; Pollard, 2004). Activation 
of the EMT pathways has also been shown to contribute to tumour stroma which increases 
susceptibility to tumour formation and metastasis in liver fibrosis (Sawada et al., 2001; Tse & 
Kalluri, 2007). Additionally, as in fibrosis, tumour-associated myofibroblasts have been 
indicated to exhibit high proliferation and migratory phenotype thus inducing tumour 
invasion and metastasis (Liu et al., 2011; Spector et al., 2012). Moreover, the presence of 
myofibroblasts in cancer stromal tissues, similar to those in fibrotic tissues produce higher 
levels of collagen I; this regulates the expression of genes involved cell signalling and 
metabolism for tumour progression, apoptosis and invasion (Spector et al., 2012). Increased 
collagen and ECM production has also been associated with downregulation of E-cadherin 
(cell-cell adhesion marker) in cancer epithelial cells. It was previously shown in an in vitro 
study that pancreatic cancer cells (PANC-1) cultured on type I and III collagen result in 
downregulation of E-cadherin expression compared to PANC-1 cells that were cultured on 
fibronectin or type IV collagen (Menke et al., 2001). This study further showed that the loss 
of E-cadherin results in epithelial-to-mesenchymal morphology.  
Microarray studies have revealed further similarities in gene expression patterns 
between early wound healing and cancer. For example, Chang et al. (2004) indicated that the 
gene expression signature of serum-activated fibroblasts was similar to that of cancer cells as 
it included high expression of cell cycle genes (e.g. E2F1) and extracellular matrix 
remodelling genes (e.g. LOXL2) which are involved in cancer progression and metastasis. 
Importantly, in relation to the work in this thesis, there has also been an identification of 
mutations in genes associated with cell cycle progression in fibrosis and cancer. A study by 
Guyard et al. (2017), for example, identified by next-generation sequencing (NGS), 
mutations in p53, β-catenin (CTNNB1) and the phosphatase and tensin homolog (PTEN) 
genes from patients who presented with lung fibrosis-associated lung cancer. It is well 
established that mutations in the p53 tumour suppressor gene lead to aberrant DNA repair and 
deregulated cell cycle arrest causing tumorigenesis (Rivlin et al., 2011; Vancheri et al., 2010). 
β-catenin, which activates the Wnt signalling pathway during development is also involved in 
cell proliferation by activating transcription of cycling D1 (Olmeda et al., 2003). Mutations in 
the β-catenin gene (exon 3) have been associated with colorectal cancer (Ilyas et al., 1997; 
Johnson et al., 2005). A study by Kaler et al. (2012) showed that co-culture of human 
colorectal carcinoma cells HCT116 (which harbour the wildtype and mutant β-catenin 
alleles) with THP1 macrophages induce enhanced Wnt-signalling in the tumour stroma, thus 
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changing the anti-tumour properties of macrophages into tumour-associated macrophages. In 
fibrosis, it seems most likely, that mutations in β-catenin induce increased proliferation of 
myofibroblasts and expression of ECM proteins by activation of M2 macrophages that 
secrete growth factors which further activate the TGF-β pathway, leading to expression of 
collagen I and other ECM proteins (Enzo et al., 2015; Zhou et al., 2012).  Mutation on the 
PTEN gene which encodes a tumour suppressor lead to cancer caused by increased cell 
proliferation and downregulation of cyclin kinase inhibitor p21 (Sun et al., 1999). 
Furthermore, knockout of PTEN (PTEN -/-) in fibroblasts derived from IPF lung biopsies 
caused formation of myofibroblasts (White et al., 2006).  
Overall, these studies indicate that mutations in genes that are associated with cell 
proliferation and cell cycle progression potentially cause fibrosis and/or cancer. This link is 
important as mutations in the FAM111B gene are associated with fibrosis and cancer 
(Goussot et al., 2017; Mercier et al., 2013).  It is, therefore, plausible that FAM111B is also 
the link between fibrosis and cancer. This notion is supported by a case report by Goussot et 
al. (2017) which indicated that a FAM111B mutation causes pancreatic cancer instead of the 
fibrotic phenotype commonly observed in POIKTMP cases. These results suggest that 
description of the POIKTMP phenotype should be expanded to include cancer predisposition. 
In summary, the studies above have revealed tantalising evidence that FAM111B plays a 
role in cell proliferation and that increased cell proliferation during wound healing and tissue 
repair is also a key factor in chronic wound repair and fibrosis. To date there have been no 
studies to determine whether cells carrying a FAM111B mutation have an altered 
proliferation potential as compared with normal cells. The derivation of patient and control 
cells derived from iPSCs has enabled this question to be explored. The approach taken to 
address this hypothesis was therefore: 
a) To determine if there are differences in cell proliferation rates between patient and 
control iPSC-MSCs. 
b) To determine whether there is increased expression of FAM111B in rapidly dividing 
cells (iPSCs) compared to adult cells (dermal fibroblasts) and multipotent stem cells 
(iPSC-MSCs).  
c) To determine whether FAM111B expression is differentially expressed during cell 
cycle progression as indicated by Aviner et al. (2015), and if so, whether its 
expression is altered in patients compared to controls.  
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4.2 Materials & methods  
 
4.2.1 Growth rate of patient and control iPSC-MSCs  
To investigate the involvement of FAM111B in cell cycle regulation, a 6-day growth curve 
for patients and control iPSC-MSCs was performed. The iPSC-MSCs were seeded onto 
gelatin-coated 6-well plates at 3 x 104 cells per well to prevent myofibroblast morphology 
which MSCs exhibit when cultured on uncoated plastic dishes (Kanta, 2015). Each sample 
was seeded in duplicates for each day count and maintained in standard growth medium 
(DMEM; 10% FBS; 1% P/S). The cell counts were performed every 2 days for 6 days. 
Briefly, growth medium was aspirated, and cells were washed twice with 1X PBS, followed 
by a five minutes incubation with trypsin/EDTA at 37° C to dislodge the cells. 
Trypsin/EDTA was deactivated with two ml growth medium and 12 µl of medium containing 
cells was mounted onto a haemocytometer (Marienfeld Superior, Germany) for cell count. 
Cells were counted at their log-phase on days 0, 2, 4 and 6. Cell doubling time was calculated 
at the log phase using the following equation: DT = T ln2/ln (Xe/Xb) in which T is the 
incubation time in hours, Xb is the cell number at the beginning of the incubation time and 
Xe is the cell number at the end of incubation time (Aliborzi et al., 2016).  
 
4.2.2 Synchronisation of patient and control iPSC-MSCs 
For analysis of FAM111B expression in synchronised cells, iPSC-MSCs were synchronised 
using double thymidine block (Banfalvi, 2011). Because different cells have different 
properties, it is not a simple matter to decide how to the blocking should be conducted, it was 
thus necessary to optimise the blocking time and the concentration of thymidine. This was 
done using the control iPSC-MSCs. Briefly, 2x105 iPSC-MSCs were seeded onto gelatin-
coated 100 mm culture plates using standard growth medium (DMEM; 10% FBS; 1% P/S). 
When the cells reached 40-45% confluence, they were arrested at the G1/S phase by blocking 
with 4 mM thymidine (Sigma Aldrich, St Louis, MO) prepared in basal DMEM for 24 hours 
(h). After the first 24 h thymidine block, the cells were released from the G1/S arrest by 
removing growth medium and rinsing the cells twice with 1X PBS. Fresh growth medium 
was added for 12 h before the second thymidine block. Following the second 24 h block, the 
cells were washed twice with PBS and fresh growth medium for harvesting. For mRNA 
analysis, the cells were harvested at 0, 2, 6, 12 and 15 h timepoints, which coincide with the 
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G1/S, early S, late S and G2/M cell cycle phases. For mRNA analysis qPCR was performed 
as described below. The proliferating nuclear antigen (PCNA) which is known as a sliding 
clamp at the DNA replication fork (Dieckman et al., 2012; Moldovan et al., 2007) was used 
as a G1 and S-phase marker for qPCR analysis. Aurora kinase A (AURKA) which is 
involved in the regulation of centrosome maturation and spindle formation during mitosis 
(Marumoto et al., 2005; Nikonova et al., 2013) was used as a marker for cells analysed at the 
G2/M phase. Therefore, it is suggested that the pancreatic cancer phenotype in the POIKTMP 
case report by Goussot et al. (2017) is due to the FAM111B mutation in the affected person. 
 For FAM111B protein determination in synchronised iPSC-MSCs, 4 mM double 
thymidine block (24 h thymidine, 12 h release, 24 h thymidine) was performed to obtain a 
cell population arrested at the G1/S and S-phase. To obtain a cell population arrested at the 
G2/M phase, a single 24 h thymidine (4 mM) block was performed, followed by an 18 h 
nocodazole (150 ng/ml) block. Cells arrested at the M-phase were collected by shaking off 
the rounded cells and collecting them into a 15 ml tube and centrifuged at 1500 RPM for 
5min at RT. The supernatant was removed, and the cells were rinsed with 1X PBS, 
centrifuged and pooled with the adhered cells which were arrested at the G2-phase for 
analysis.   
 
4.2.3 Flow cytometry 
For validation of cell synchronisation, the familial control was prepared for flow cytometry 
post-thymidine and nocodazole block. For analysis of DNA content at the G1 and S-phase, 
the iPSC-MSCs were rinsed with twice 1X PBS and trypsinised using trypsin/EDTA for five 
minutes and thereafter collected and centrifuged at 1500 RPM for five minutes at RT. The 
cell pellet was resuspended in 2 ml 1X PBS for cell counting. Cells were fixed by adding 
eight ml of ice-cold 70% ethanol to the cell suspension and stored at -20° C for 1 h. After 1 h, 
the cells were centrifuged at 1500 RPM for five min at RT followed by removal of the 
supernatant and rinsing the cells with 1X PBS to remove excess ethanol. The cells were 
rinsed twice 1 ml PBS and after removal of the supernatant were incubated with 0.5 ml of 
FxCycle™ PI/RNase Staining Solution (Life Technologies) at RT for 30 minutes in the dark. 
The stained cell pellets were thereafter for distribution of DNA content by flow cytometry. 
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4.2.4 RNA isolation and analysis 
4.2.4.1 RNA extraction 
 For analysis of mRNA extraction, total RNA isolation from cells using the High Pure 
RNA Isolation Kit (Roche) per the manufacturer’s instructions. Briefly, 0.2 ml of 100% 
chloroform was added to every 1 ml of the cell lysates, vigorously mixed by inverting for 15 
seconds (s) and incubated at room temperature for 15 minutes. The lysates were thereafter 
centrifuged at 4 °C and 12 000 x g for 15 min. After centrifugation, the aqueous phase which 
contained RNA was transferred into new microfuge tube and equal volume of 70% ethanol 
was added to aqueous phase and mixed 10 times by pipetting up and down. The aqueous 
mixture was then transferred into a High Pure filter tube and 2 ml collection tube and 
thereafter centrifuged at 10 000 rpm for one minute. The flow-through was discarded and 
each sample was treated with 100 µl of DNase I for removal of genomic DNA contamination, 
and incubated at room temperature for 15 min. Following DNase I treatment, the samples 
were washed by adding 500 µl of Wash Buffer I and centrifuged at 10 000 rpm for one 
minute. The flow-through was discarded and the samples were washed again with 200 µl of 
Wash Buffer I and centrifuged as before. Following washes with Buffer I the samples were 
washed by adding 500 µl of Wash Buffer II and centrifuged at 10 000 rpm for one minute 
The flow-through was discarded and washed again with 200 µl of Wash Buffer II and 
thereafter centrifuged at 13 000 rpm for two minutes The flow-through was discarded and the 
samples were opened and incubated at room temperature for five minutes to allow 
evaporation of ethanol from the wash buffers. After five minutes, 30 µl of the Elution buffer 
were added to each sample and total RNA was measured using a nanodrop spectrophotometer 
(ND-1000, Thermo Fisher). RNA purity was measured at A260/A280 ratio. To determine 
RNA integrity one µg RNA was run on a non-denaturing 1% agarose gel containing ethidium 
bromide and electrophoresed at 100 volts (V) for 45 minutes The gel was viewed under UV 
light for detection of 28S and 18S ribosomal RNA bands. 
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4.2.4.2 cDNA synthesis 
For cDNA synthesis, 0.5-1 µg RNA from each sample was reverse transcribed by 
addition of Oligo (dT) primers and running the reaction in the PCR machine at 42° C for five 
minutes, followed by adding the cDNA mastermix (1 mM dNTPs; 2.5 mM MgCl2; 1x RT 
Buffer; 1 U/µl RNase inhibitor; 20 U M-MLV Reverse Transcriptase) [all reagents purchased 
from Promega except for dNTPs (Bioline)].  
 
4.2.4.3 Quantitative real-time PCR (qPCR)  
The quantitative real-time PCR (qPCR) Mastermix constituted of 200 ng of cDNA, 
0.2 µM of forward and reverse primers, 1X (5 µl) SYBR Green I Mastermix (Life 
Technologies) and water to the final volume of 10 µl per sample. The qPCR reaction was 
performed using the StepOne Plus machine (Applied Biosystems, Life Technologies) at 95 
°C denaturation for 15 s and 60° C annealing for one minute for 40 cycles. The results were 
analysed by relative quantitation using the delta delta (ΔΔ) Ct method, where samples were 
first normalised to β-glucuronidase (GUSβ) and/or β-actin housekeeping genes. Fold change 
(2-ΔΔCt) was analysed by determining differences between the normalised target sample and 
normalised calibrator (control sample). Human dermal fibroblasts (HDFs) were used as 
negative controls for the expression of pluripotency markers.  
 
Table 4.1: Primer sequences for FAM111B, PCNA and AURKA genes 
Gene Primer sequence NM Sequence Size 
(bp) 
Reference 
PCNA (F)  5’-AGGACCTGTTAAGGCTACA–3’ NM_182649 91 Aviner et al. 2015 
PCNA (R) 5’-CCAAGGTATCCGCGTTATC–3’ 
FAM111B (F) 5'-GACCGTAGTGTGTTTACAGCA-3' NM_001142704
.1 
171 https://pga.mgh.har
vard.edu/ FAM111B (R)  5'-GCACTTGAGAGGCATTCCTAAAT-3' 
AURKA (F) 5’-AGGACCTGTTAAGGCTACA–3’ NM_003600.3 104 Aviner et al. 2015 
AURKA (R) 5’-GAGCCTGGCCACTATTTAC–3 
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4.2.5 Western blotting 
4.2.5.1 Cell harvesting & protein quantification  
Patient and control iPSC-MSCs were culture to 90% confluence. Three-hundred µl of 
radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors were added to 
each 10-cm culture plate for cell lysis and collection. The lysate was centrifuged at 12 000 
rpm and 4º C for 20 minutes. The supernatant was collected into a fresh microfuge tube, and 
protein concentration was quantified using the Bicinchoninic acid assay (BCA) assay 
(Thermo Fisher Scientific, Waltham, MA, USA). Briefly, a 1:8 dilution was prepared for the 
BCA solution and bovine serum albumin (BSA), which was used as a standard. The samples 
were also prepared at 1:8 dilution in a 96-well plate. The 96-well plate was incubated at 37º C 
for 30 minutes and the absorbance was thereafter read at 562 nm using the RT-2100C 
microplate reader (Rayto Life & Analytical Sciences, Shenzhen, China). The standard curve 
and protein concentration were analysed on Microsoft Excel using the linear equation [(y = 
a*x + b) where: y = Protein concentration; x = Absorbance; a = Slope and b = Background 
Signal]. The protein samples were stored at -80º C for later use or long-term storage.  
 
4.2.5.2 Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE gels were prepared using the BioRad electrophoresis apparatus 
(Biorad Mini PROTEAN©). Ten-percent resolving gels were prepared on 1.5 mm (thick) 
plates and 5% stacking gels were prepared for loading the samples (see appendix). Laemali 
sample buffer (2X) was added to each sample and boiled at 95º C for five minutes. Thirty 
micrograms of protein for each sample were loaded onto the gels and electrophoresed at 110 
volts (V) in 1X running buffer for 90-120 minutes at room temperature. The loading control 
used was rabbit polyclonal anti-p38 (Cell Signalling Technology, Danvers, MA, USA) which 
is a 40 kDa protein. 
 
 
 
 
 
 
Chapter 4 
 97 
4.2.5.3 Nitrocellulose membrane electro-transfer  
Following SDS-PAGE, the resolving gels and nitrocellulose transfer membrane 
(Amersham Biosciences, UK) were soaked in in 1X transfer buffer (see appendix) for 10 
minutes. The resolving gels and the transfer membranes were “sandwiched” between 
cassettes and placed in a running tank. The electro-transfer was performed at 100V and 4º C 
for 1 h.   
 
4.2.5.4 Chemiluminescence protein detection 
Following electro-transfer, the nitrocellulose membrane was soaked in Ponceau stain 
(see appendix) for three min for detection of transfer efficiency. The membranes were 
thereafter washed 3 x 5 minutes with shaking in 0.1% TBS-T (see appendix). The membranes 
were incubated in blocking buffer in containing TBS-T and 5% fat-free milk for 1 h at RT 
with shaking.  The membranes were thereafter washed 3 x 5 minutes with shaking in 0.1% 
TBS-T. For detection cyclin B1 (55 kDa) (Cell Signalling Technology, Danvers, MA, USA) 
and FAM111B (55kDa) (Santa Cruz) proteins, the membranes were incubated in anti-cyclin 
B1 primary antibody (1:1000) and anti-FAM111B antibody (1:100) diluted in blocking buffer 
overnight at 4º C with shaking. The other membrane was incubated with anti-p38 primary 
antibody (1:5000) and used as a loading control.  
Following overnight incubation, the membranes were washed 3 x 5 min with shaking 
in 0.1% TBS-T and thereafter incubated for 2 h (RT) in horseradish peroxidase-conjugated 
goat-anti mouse secondary antibody (Biorad, Hercules, CA, USA) at 1:2000 for cyclin B1, 
donkey-anti-goat (1:2000) and goat-anti rabbit (1:5000) for p38. The membranes were 
thereafter washed 3 x 5 minutes with shaking in 0.1% TBS-T and incubated in 
chemiluminescence reagent for 3-5 minutes and developed the blots in the dark using X-ray 
film for signal detection. The blots were thereafter scanned for densitometric readings and 
further analysis. 
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4.2.6 Statistical analysis   
Statistica Software version 13.3 (Dell Inc.) was used for statistical analysis of all data in this 
study. The qPCR results were analysed according to Schmittgen & Livak (Schmittgen & 
Livak, 2008) method, which was added to the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) guidelines (Bustin et al., 2009). The 
results are presented as mean ±SEM, and differences between two samples were analysed by 
Student’s t-test, independent by group or variable. To determine significant differences in 
three or more groups, Breakdown & one-way analysis of variance (ANOVA) was used, with 
Tukey honest significant difference (HSD) as the post-hoc test.  Data were considered 
statistically significant at p < 0.05. Graphs were plotted with GraphPad Prism version 5.0 
(GraphPad, San Diego, CA). 
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4.3 Results  
 
One of the key characteristics of fibrosis is that in response to wounding, cells are stimulated 
to undergo proliferation by the growth factors that are released from the wounded tissue by 
invading inflammatory cells (Diegelmann & Evans, 2004).  It was therefore hypothesised that 
the iPSC-derived mesenchymal stem/stromal cells from poikiloderma patients might 
proliferate at a more rapid rate than the equivalent control cells, contributing towards the 
increase in fibrotic tissues. 
 
4.3.1 Patient-specific iPSC-MSCs show a higher cell proliferation rate compared to 
control cells  
To test this hypothesis, the first aim was to determine whether iPSC-MSCs from 
patients proliferated faster than those of controls. Briefly, the iPSC-MSCs were seeded at a 
density of 3 x 104 per well in gelatin-coated six-well plates and each sample was cultured in 
duplicates. The cells were manually counted every 2 days for 8 days. The experiments were 
carried out three times in duplicate and the combined results are presented in Figure 4.1. As 
can be seen, after 6 days there were approximately 2.5 times more patient cells (6 x 105) than 
controls (1.6 x 105). Doubling time calculations revealed that control cells had an average 
doubling time of 55 hours compared to patient cells, which had a doubling time of 33 hours. 
These results provide solid evidence that FAM111B protein does indeed play a role in 
regulating cell proliferation.  
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4.3.2 FAM111B expression in dermal fibroblasts, iPSCs and iPSC-derived MSCs 
The next aim was to determine a) whether the level of FAM111B expression is 
different between patient and controls cells and b) whether different cell types express 
different levels of FAM111B (Fig. 4.2). If so, this might give a clue as to what role or how 
FAM111B might be influencing cell proliferation.  In the first set of experiments, FAM111B 
mRNA levels were determined in three cell lines, dermal fibroblasts, iPSCs and iPSC-MSCs, 
as follows: Dermal fibroblasts and iPSC-MSCs were cultured on gelatin-coated culture plates 
and maintained in standard growth medium till they reached 90% confluence. The iPSCs 
were cultured under feeder-free conditions and analysed when they reached 90% confluence. 
Cells were then harvested and analysed for mRNA expression as previously described in the 
chapter 2 (sections 2.2.4.1). Of importance, it should be noted that all experiments were done 
at the same time or in the same run in order to minimize technical variations. Three biological 
repeats were performed with each biological repeat conducted as described. The results in 
Fig. 4.2 show that the iPSCs, somewhat surprisingly, showed higher FAM111B mRNA 
expression (p ≤ 0.001) compared to fibroblasts and iPSC-MSCs, with Patient A iPSCs 
showing the highest expression levels (Fig. 4.2A). The results further show that dermal 
fibroblasts have a lower expression of FAM111B mRNA compared iPSCs but slightly higher 
Fig. 4.1 Growth curve of patient and control iPSC-MSCs. Patients and controls iPSC-MSCs were 
cultured for 8-days and counted every two days to determine the growth rate Data presented as mean ± 
SEM. (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001  
iPSC-MSC Growth curve
0 2 4 6 8
0
2.0×105
4.0×105
6.0×105
8.0×105
Non-familial control
Familial control
Patient A
Patient B
Days
C
el
l c
ou
nt
*
 
*
 
**
 
Chapter 4 
 101 
levels when compared to iPSC-MSCs (Fig. 4.2A). The iPSC-MSCs showed lower FAM111B 
mRNA expression when compared to fibroblasts and iPSCs. The high levels of FAM111B in 
iPSCs is interesting because it is known that these cells have a faster cell cycle than cells of 
later lineages, including differentiated cells (Coronado et al., 2013; Kapinas et al., 2013).  
Next, FAM111B mRNA expression was compared between patients and controls 
(Fig. 4.2B). Patient primary skin fibroblasts showed slightly higher FAM111B expression 
compared to the familial and non-familial controls. The non-familial control showed 
significantly lower mRNA levels (p≤0.001) compared to patients and the familial control (see 
discussion) For iPSCs, FAM111B mRNA levels were similar between patients and controls 
with no statistical difference (n.s). When comparing FAM111B expression between patients 
and controls in iPSC-MSCs, there was no statistical difference between patients and controls 
though the non-familial control showed comparably low FAM111B levels. Furthermore, 
patient iPSC-MSCs had similar FAM111B levels as the familial control. Overall, the results 
suggest that a) iPSCs have a significantly higher FAM111B expression compared to dermal 
fibroblasts and iPSC-MSCs, and b) in these analyses of non-synchronised cell cultures, there 
is no statistical difference in FAM111B expression detectable between patients and controls.  
From these results one can conclude that a) differences in cell proliferation between 
patient and control cells are not due to the overall level of FAM111B mRNA which implies 
b) that the FAM111B mutation does not result in higher levels of gene expression or steady 
state levels of the protein. However, it is possible that FAM111B expression is cell-cycle 
regulated, and if so, the study of asynchronous population of cells would not reveal any 
differences. 
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Fig. 4.2 Analysis of FAM111B mRNA expression in different cells lines and between 
patients and controls. (A) FAM111B mRNA expression was analysed in fibroblasts, iPSC and 
iPSC-MSCs. (B) FAM111B expression was compared between patient and control iPSC-MSCs. 
Data presented as mean ± SEM (n = 4). * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. Non-significant 
data shown by n.s. 
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4.3.3 Optimising cell synchronisation in patient and control iPSC-MSCs using 
double-thymidine block 
Because there were no statistical differences in FAM111B RNA expression in non-
synchronised cells, it was recognised that a more targeted or fine-tuned approach would be 
necessary to analyse possible differences at different stages of the cell cycle, especially as 
Aviner et al. (2015) had recently shown that in HeLa cells that FAM111B was cell cycle 
regulated. In order to conduct analyses of synchronised cells it was first necessary to establish 
the conditions (doses of drugs, timing), to effectively synchronise the iPSC-MSCs. Firstly, I 
tested the reproducibility of the data obtained by Aviner et al. (2015) in synchronised HeLa 
cells. The HeLa cells were synchronised by double-thymidine block for 19 hours (h), with 
release for nine hours in between blocks. Cells were harvested at 2-h intervals for 14 h post 
the second thymidine block (Fig. S1). The data in the present study correlated with the 
findings of Aviner et al. (2015) that FAM111B mRNA expression in HeLa cells peaks at 14-
hours post-thymidine release, which is indicated to be the G1-phase. Similarly, PCNA and 
AURKA expression patterns were comparable to the those shown by Aviner et al. (2015) that 
PCNA (Fig. S1A) and FAM111B (Fig. S1C) peak at 14 h and AURKA peaks between 6- and 
8-h post-thymidine release (Fig. S1B). Thus, the synchronisation data of HeLa cells in this 
study showed reproducibility with this method and was therefore adopted for this current 
study.     
Synchronisation of iPSC-MSCs was initially performed using the parameters similar 
to those of Aviner et al. (2015). However, there were no clear peaks in PCNA and AUKRA 
mRNA expression when using this protocol. It was therefore deduced that this may have been 
due to a longer doubling time in iPSC-MSCs compared to HeLa cells which have a doubling 
time of 16 hours. To correct for this problem, optimisation experiments were first performed 
on one cell line (Familial control) to establish the best synchronization protocol and to 
determine synchronisation efficiency. A 30-h thymidine block (2 mM) was performed 
followed by a 15-h release and a final 30-h thymidine block for synchronisation of iPSC-
MSCs. The cells were thereafter harvested at 5-h intervals for 30 h. Careful analysis of the 
30-h timepoint showed two cell cycle rounds as PCNA (Fig. S2A) and FAM111B (Fig. S2C) 
expression peaked at 15- and 30- h, while AURKA peaked at 25-hours (Fig. S2B) post-
double thymidine block.  The iPSC-MSCs were thereafter synchronised by double thymidine 
block for 24 h and harvested at 3-h intervals up to 24 h after the second thymidine block to 
analyse a single cycle round. In this experiment, the results showed that the cell cycle marker 
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PCNA peaked at 3-,15- and 24-hours post-thymidine release (Fig. S3A). Aurora kinase A 
mRNA expression indicated a gradual increase, peaking at 6 h (Fig. S3B) and FAM111B 
mRNA peaked at 15- and 18 h post-double thymidine release (Fig. S3C). The results from 
these experiments indicated poor synchronisation as indicated by PCNA which peaked at 
different timepoints. It was therefore postulated that the 2 mM thymidine concentration was 
too low for synchronisation of iPSC-MSCs. The concentration was thereafter doubled to 4 
mM which improved synchronisation as indicated by flow cytometry data which measures 
DNA content (ploidy) during cycle progression, where diploid (2N) cells are detected at 
G0/G1 and tetraploid (4N) cells are detected at S- and G2/M phase (Fig. S4A-D). Cells were 
harvested at 0 h (G1/S), 2 h (S-phase), 6 h (G2/M) and 15 h (early G1-phase) post-double 
thymidine release. The 12 h timepoint was omitted in the optimised synchronisation protocol 
as it either showed a similar pattern of synchronisation with the 15-h timepoint as indicated 
by flow cytometry (Fig. S5) or it demonstrated large variations (high SEM), especially in 
AURKA mRNA expression between experiments (Fig. S6A). This pattern was observed in 
the three biological repeats performed. 
Using the optimised double thymidine (4 mM) blocking method, the iPSC-MSCs 
were arrested at the G1/S phase for 24 h, followed by a 12 h release and a second thymidine 
block (4 mM) for 23 hours was carried out (Whitfield et al., 2002). Following cell cycle 
arrest, the cells were released from the block and harvested at 0 h, 2 h, 6 h and 15 post-
thymidine treatment. Flow cytometric analysis (Fig. 4.3A) showed that in the untreated 
asynchronous control cells, 80% of the asynchronous cell population remained at the G0/G1 
phase. Typically, one would expect MORE cells to be in G0/G1 at time zero (straight after 
arrest) and drop thereafter, as cells move out of G1 into S/G2 and then rise again as cells go 
through mitosis and re-enter G1. However, in these experiments at zero hour, the number of 
cells in G1 DROPPED to 58%.  Thereafter, the number of cells in G1 stayed at the level of 
about 55-58% and rose again to 66% in 15 h.  The time zero result thus indicates that 
thymidine arrests the cells at G1/S and not G0/G1 (Bjursell & Reichard, 1973), and that the 
cells in G0/G1 follow the predicted pattern. The analysis of cells in S and /G2 are more 
informative in cell cycle progression.  In asynchronous cells, there are 13% of cells in G2 and 
6% in M. At 2 h, there was 17% of cells in G2 and 26% of cells in S-phase. At 6 h, there was 
an increase in the population of cells at the G2/M phase, followed by a decrease at 15 h. 
While these results are encouraging and suggest at least some of the cells have been 
effectively synchronised by the double-thymidine treatment, the results for time zero which 
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show a high population of cells arrested at G1 and S, and the very high levels of cells in G1 
throughout cell cycle progression make it difficult to provide firm conclusions. 
In the final set of experiments, cell synchronisation efficiency was therefore 
determined by analysis of cell cycle genes- PCNA and AURKA at timepoints 0, 2, 6 and 15 
h. PCNA is involved in DNA replication and its expression is typically increased at G1, 
peaking at S-phase and lowest at G2/M (Morris & Mathews, 1989).  In Figure 4.3B, PCNA 
expression in the familial control indicates unchanged expression levels in all the timepoints. 
The non-familial control also shows similar expression for PCNA between 0 and 2 h 
timepoints, with a slight decrease at 6 h and returning to similar levels at 15 h. Patient cells 
had a high expression of PCNA at 0 h, with Patient A showing a 1.7-fold increase compared 
to the controls, and Patient B showing a two-fold increase compared to controls. Patient A 
showed a 2.5-fold increase and Patient B a 3.8-fold increase in PCNA mRNA expression at 2 
h. At 6 h PCNA levels in Patient A and Patient B cells decreased by 50% with a further 
decrease at 15 h. The PCNA data thus indicates that at least some of the cells were 
successfully synchronised as it peaked at the G1/S and S phase where it is known to be high 
as it is involved in DNA replication. Furthermore, PCNA levels were relatively higher in the 
patient cells compared to controls (although no statistical differences were observed).  
Aurora kinase A (AURKA), which is involved in spindle formation during the mitotic 
phase was also analysed in synchronised iPSC-MSCs. In control cells, AURKA mRNA 
showed a gradual increase between 0 and 6 h, peaking at 6 h. At 15 h, there was a decrease in 
AURKA in the familial control and non-familial control (Fig. 4.3C). (It was observed that the 
non-familial control expressed slightly high AURKA levels compared to the familial control). 
Patient cells, similarly, showed a gradual increase of AURKA mRNA expression between 
time 0 and 6 h, peaking at 6 h. At 15 h both Patient A and Patient B showed a slight increase 
in AURKA levels (Fig. 4.3C). The AURKA expression further indicated measurable 
synchronisation as it peaked at 6 h which correlates with the G2/M phase.  
  Although the flow cytometric data (Fig. 4.3A) showed that a high population 
of synchronised cells remained at the G1 phase, changes in the expression of PCNA and 
AURKA (Fig. 4.3 B-C) in patient and control cells at each timepoint indicated changes as the 
cell cycle progressed. These results provide slightly more convincing evidence that at least a 
subpopulation of cells was synchronised by double thymidine block. The qPCR data show 
that expression of PCNA mRNA levels (Fig. 4.3B) coincides with the S-phase, which occurs 
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2 h post-thymidine block for a 4-6 h duration. As PCNA expression decreased at 6 h, it was 
also observed that AURKA mRNA levels peaked at 6 h (Fig. 4.3C), suggesting entry into the 
G2/M phase in both patients and controls. The data at 15 h indicate completion of the G2/M 
phase and entry into early G1 phase.  
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Fig. 4.3 Representative histograms of DNA content in synchronised cells by flow cytometry and 
mRNA expression of cell cycle genes. Patient and control iPSC-MSCs were synchronised by a 24 h 
double-thymidine block (4 mM), followed by release and harvesting of the cells at 0 h, 2 h, 6 h and 15 h 
post-thymidine block. (A) Flow cytometry shows cell population of the familial control at each cycle 
phase at the optimised timepoints. The different timepoints represent the G1/S phase (0 h), S-phase (2 h) 
G2/M phase (6 h) and early G1-phase (15 h). (B) PCNA mRNA and (C) AURKA mRNA expression were 
analysed at 0, 2, 6 and 15 h. Data presented as mean ± SEM (n = 3).  
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4.3.4 FAM111B mRNA expression is higher in synchronised patient cells compared to 
control cells 
To determine whether FAM111B levels of expression are altered in patient cells 
during cell cycle progression (as compared to control cells), the iPSC-MSCs were 
synchronised by double-thymidine block as previously described and were harvested at 0 h, 2 
h, 6 h, and 15 h timepoints after release from thymidine block. Real-time qPCR was 
thereafter performed to determine FAM111B mRNA expression in these synchronised cells.  
The results reveal that FAM111B mRNA expression peaked at 2 h (Fig. 4.4) and at 6 h there 
was a decrease in FAM111B expression followed by a slight increase at 15 h.  
Patient cells showed significantly higher FAM111B mRNA levels than controls, with 
Patient A indicating a six-fold (p ≤ 0.01) higher level and Patient B showing a five-fold (p ≤ 
0.01) increase in mRNA levels compared to control cells at 0 h (Fig. 4.4). At 2 h, FAM111B 
expression peaked to 7-fold (p < 0.05) in the patient cells compared to controls. At 6 h 
FAM111B mRNA levels decreased but remained significantly high (p < 0.05) in patient cells 
compared to controls. At 15 h, mRNA levels were similar between patient cells and the 
familial control. The non-familial control on the other hand, showed significantly low 
FAM111B mRNA levels at 15 h (p < 0.05) (Fig. 4.4), possibly due to variations in genetic 
background.  The 12 h timepoint was omitted in this experiment as it demonstrated large 
variations (high SEM) in FAM111B mRNA expression in the patient cells and the non-
familial control after three biological repeats (Fig. S6B). This suggests a technical error 
which masked whether there is statistical difference between patient and control cells at this 
timepoint.The overall data showed that a) FAM111B mRNA is temporally expressed in 
synchronized cells, peaking at the S-phase which is represented by the 2 h timepoint in this 
study; and b) FAM111B mRNA expression is very much higher in patients cells compared to 
controls between 0 h and 6 h timepoints. Interestingly, FAM111B expression pattern appears 
to be similar to the PCNA expression pattern, where both genes were increased at 2 h (S-
phase) and decreased at 6 h (G2/M) (Fig 4.3 B) particularly in the patient cells, which 
suggests that FAM111B is involved in DNA replication.  
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4.3.5 Detection of FAM111B protein in patient and control cells 
 The next step was to determine if FAM111B protein expression correlated with 
mRNA expression. To analyse FAM111B protein expression at the different phases of the 
cell cycle the thymidine-nocodazole method was used. Briefly, to obtain cells arrested at the 
G1/S and S-phase double-thymidine (4 mM) block was performed as described in section 
4.2.2. To obtain cells arrested at the G2/M phase, the iPSC-MSCs were treated for 18 h with 
nocodazole (150 ng/ml) after a single 24 h thymidine block. Nocodazole, which arrest cells at 
G2/M phase by inhibiting formation of mitotic spindle (Banfalvi, 2011) was added to obtain a 
higher cell population at the G2/M for protein quantification. Flow cytometric data of the 
familial control was used to confirm efficient synchronisation in iPSC-MSCs following cell 
synchronisation by thymidine-nocodazole block (Fig. 4.5A). As with the flow cytometry data 
in Figure 4.3A, a high percentage of cells (55-58%) remained at the G1-phase as shown in 
Figure 4.5A.  The percentage of cells at early (2 h) and late (4 h) S-phase were at 25% and 
15%, respectively. Flow cytometry data further showed that 31.69% of the cell population 
was arrested at the G2/M phase following nocodazole block (Fig. 4.5).  
Fig. 4.4 FAM111B mRNA expression in patient and control iPSC-MSCs. 
Synchronised cells were analysed for FAM111B mRNA expression at time 0 h, 2 h, 6 h 
and 15 h, which represent the G1/S, S and G2/M phases of the cell cycle.  Data presented 
as mean ± SEM (n = 3) * p < 0.05; ** p < 0.01; *** p < 0.001 
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Western blot analysis of cyclin B1 (CCNB1), which increases during the G2/M phase 
was further performed to confirm synchronisation of both patient and control cells by 
indicating a high expression at the G2/M-phase compared to the early S- and late S-phase. 
The densitometric graph indicates that cyclin B1 protein levels were slightly higher in the 
patient cells at early S-phase, decreased at late S-phase and increased at G2/M as expected 
(Fig. 4.5 B). Three biological repeats were performed in this experiment. Though cyclin B1 
protein levels in the synchronised iPSC-MSCs were slightly increased at G2/M, with Patient 
B indicating higher expression compared to controls and Patient A (though not statistically 
significant), the data indicates that a population of cells were synchronised, and also that 
some cells may have escaped cell cycle arrest even after nocodazole block which arrests cells 
at G2/M phase.    
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Fig. 4.5 Flow cytometric analysis of DNA content and protein expression of cyclin B1 in iPSCs-MSCs synchronised by thymidine-
nocodazole block (A) Familial control iPSC-MSCs were used optimise and determine synchronisation efficiency by flow cytometry at G1/S, early 
S-phase, late S-phase and G2/M-phase (n = 2). (B)  Cyclin B1 (CCNB1) protein expression was analysed by western blotting (blots and graph) in 
synchronised patient and control cells Anti-p38 antibody was used a loading control. Data presented as ± SEM (n = 3). 
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Next, FAM111B was analysed by western blotting in synchronised cells to determine 
whether the mRNA levels (Fig. 4.4) correlate with protein levels. In particular the aim was to 
1) determine whether there are higher levels of FAM111B protein in patient versus control 
cells, and 2) whether there is any detectable difference in pattern of FAM111B expression 
compared to controls.  The currently available anti-FAM111B antibodies do not detect the 
predicted molecular size of 72 kDa for FAM111B, including the antibody used in this study, 
possibly due to posttranslational modifications that occur during protein synthesis (Umar et 
al., 1996). The available antibodies commonly show clear detection of FAM111 B protein 
with the molecular weight of 55 kDa, which is size that was detected by the antibody used in 
this study (sc-246547).  Densitometric analysis was used to measure the ratio of protein 
levels expressed in patient cells relative to the familial control for quantification of 
FAM111B protein levels detected by western blotting. The densitometric data indicate that 
FAM111B protein levels are similar at the G1/S and S-phase (2 h and 4 h) (Fig 4.6A). 
FAM111B protein levels are slightly higher in the early S-phase (2 h) and lower in the G2/M 
phase, however, no statistical differences were observed. Slight differences were also 
observed between patients and controls where patient cells expressed high levels of 
FAM111B protein in the early S-phase (2 h) compared to controls. Interestingly, FAM111B 
levels were reduced in patient cells compared to controls at the G2/M phase though no 
statistical difference was observed. Overall, these western blot results thus do not reveal a 
correlation in FAM111B mRNA (Fig. 4.4) and protein expression (Fig. 4.6A). It should be 
noted however, that there were variations in FAM111B protein levels between the 
experimental runs as indicated by the western blots in Figure 4.6B (i-iii). The variations 
observed in the western blots may be due to a lag in protein synthesis; but they may also be 
attributed to some of the challenges experienced with western blotting where the 
housekeeping protein levels are elevated in some experimental runs as observed in this study 
where p38 levels varied as shown in Figure 4.6 B (i) and (ii).  
The overall FAM111B results reveal temporal expression patterns and statistical 
differences in mRNA expression between patient and control cells (Fig. 4.4). Though 
changes in FAM111B protein expression pattern were subtle, they appeared to be similar to 
the mRNA expression pattern (Fig 4.6A), particularly in the early S-phase represented by the 
2 h timepoint. However, other synchronisation methods such as serum starvation (Achille et 
al., 2011; Davis et al., 2001) should be applied to confirm the findings in this study. Also, the 
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application of proteomics should be used to overcome some of the limitation and challenges 
experienced with western blotting  
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Figure 4.6 FAM111B protein expression in synchronised iPSC-MSCs. Patient and control iPSC-MSCs were synchronised by thymidine-
nocodazole block. Double thymidine (4 mM) block was performed for isolation of cells arrested at the G1 and S phase. Cells at the early S-phase 
were harvest 2 h post-thymidine release and cells at the late S-phase were harvested 4 h post-thymidine release. Cells arrested at the G2/M were 
collected after 18 h of nocodazole (150 ng/ml) treatment. Anti-FAM111B antibody was used to detect FAM111B protein expression between patients 
and controls. (A) Graphical representation of relative FAM111B expression following normalisation with anti-p38 antibody which was used a 
loading control. Graph presented as ± SEM (n =3). (B i-iii) Western blots indicating FAM111B protein expression between patients and controls.  
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4.4 Discussion 
 
During the course of this study, reports were published on the involvement of FAM111B in 
cell proliferation and cell cycle progression (Aviner et al., 2015). These reports led to the 
hypothesis that the FAM111B mutation may promote fibrosis by modulating the cell 
proliferation. The aim in this chapter was therefore, to determine whether patient cells 
proliferated at a different rate compared to control cells, and whether the mutation in the 
FAM111B gene alters its level of expression in the patient cells. 
 A standard growth curve was performed to determine the proliferation rate of patient 
and control cells, and notably, patient cells showed higher cell proliferation rate compared to 
control cells, with the average doubling time of 33 hours in patient cells versus 55 hours in 
control cells. Studies have indicated varying doubling times for mesenchymal stem/stromal 
cells derived from bone marrow, adipose and/or umbilical cord tissue ranging from 40 to 50 
hours (Heo et al., 2016; Mennan et al., 2016). The control iPSC-MSCs in this study indicate 
similar doubling times as the primary mesenchymal stem/stromal cells as well as iPSC-MSCs 
reported by other investigators (Diederichs & Tuan, 2014).  The differences in the growth 
rate of patient cells thus suggests that the FAM111B mutation is associated with the 
modulation of cell proliferation in this condition. It would have been of interest to determine 
if dermal fibroblasts showed similar trends between patients and controls, however, this was 
not possible because of the limited supply of patient dermal fibroblasts. Skin biopsies will 
need to be obtained to address this gap.  
The thymidine block protocol used to synchronise cells in culture works by increasing 
the intracellular pool of deoxy-thymidine triphosphate (dTTP) which results in the inhibition 
of deoxy-cytidine diphosphate (dCDP) thereby inhibiting DNA replication (Bjursell & 
Reichard, 1973; Uzbekov, 2004). Double thymidine block is used as the first thymidine block 
arrests cells which are at the G1/S boundary and the second thymidine block arrests cells 
which have escaped the first block (Tobey et al., 1966; Uzbekov, 2004).  It has also been 
shown that thymidine blocks nucleolar RNA which prevents ribosomal RNA synthesis. The 
advantage of thymidine is that it is a reversible inhibitor, therefore, upon release the 
synchronised cells progress into the S-phase to complete at least one full cell cycle (Banfalvi, 
2011; Chen & Deng, 2018). Expression of cell cycle-regulated genes is analysed in 
synchronised cells at specific timepoints which represent a duration of each phase for one cell 
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cycle upon thymidine release (Banfalvi, 2011). However, since double-thymidine block 
arrests DNA and ribosomal RNA synthesis it is therefore recommended that it not be used to 
synchronise cells with cell cycle duration longer than 16-18 hours (Uzbekov, 2004).  
After carrying out a double thymidine block of iPSC-MSCs in this study, flow 
cytometry data showed that a low percentage of cells progressed through the cell cycle and at 
least 60% of the cell population remained at G1. These results, therefore, demonstrate that 
this method was inefficient to synchronise iPSC-MSCs. There are a number of possible 
explanations for this: 1) it may have been due to an inappropriately low thymidine 
concentration of 4 mM which was used in this study. Investigators commonly use thymidine 
concentrations of 2 mM to 5 mM, particularly in HeLa cells and other cancer cells (Aviner et 
al., 2015; Banfalvi, 2011; Whitfield et al., 2002). Higher thymidine concentrations of 10 mM 
have been previously used to synchronise other cells such as CHO cells (Tobey et al., 1967). 
Therefore, higher thymidine concentrations may be needed to synchronise iPSC-MSCs for 
future work. 2) Studies have also reported that some synchronised cells lose their synchrony 
post-thymidine release, which reduces the number of synchronous cells that complete the cell 
cycle. This may have also contributed to the low synchronisation of iPSC-MSCs in the 
current study (Darzynkiewicz et al., 2011; Pederson & Robbins, 1971). 3) Synchronisation 
methods such as serum starvation and other chemical inhibitors such as nocodazole (arrest 
the cells at the G2/M-phase) and aphidicolin (arrests cells at G1) have also been used in other 
studies (Uzbekov, 2004). Synchronisation of MSCs has been previously performed in other 
studies, for example, Achille et al. (2011) synchronised bone marrow-derived MSCs (BM-
MSCs) by serum starvation for 20 hours and harvested the cells between 10 and 32 hours 
after serum addition. Their study indicated that these cells have an extended cell cycle of over 
24 hours as the G1-phase lasted 14-15 hours, the S-phase lasting 8-9 hours and G2/M phase 
lasting 3-4 hours. Furthermore, they showed that BM-MSCs enter the G1-phase 15 hours 
post-serum addition and enter the S- and G2/M phases 24- and 27 hours post-serum addition 
respectively. Another study using serum starvation showed that human dermal fibroblasts and 
adipose-derived MSCs enter the S-phase 20 hours- and the G2/M phase 24 hours post-serum 
addition (Chen et al., 2012). These studies, therefore, suggest that serum starvation may be a 
more suitable method for synchronising cells with a longer doubling time and/or longer cell 
cycle duration.  
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The double-thymidine block has also been reported to synchronise a low percentage 
of cells compared to serum starvation as the cells are captured at fixed timepoints by this 
method thus leading to a loss of subtle shifts in gene expression during cell cycle progression 
(Bjursell & Reichard, 1973). Furthermore, there have been debates that whole-culture 
synchronisation cannot be performed as synchronisation only aligns a small population of 
cells (Cooper et al., 2008). Another study by Cooper et al. (2006) also argues that chemical 
synchronisation by nocodazole only arrests cells at G2 prior to mitosis and therefore produce 
a mixed population of cells that have G2-DNA content and G1-DNA due to some cells 
escaping synchronisation, further masking the expression of cell cycle genes. These studies 
therefore indicate that there are limitations to the respective synchronisation methods, hence 
specific methods need to be applied for specific cell types that have a lengthy cell cycle 
duration.  
Although the above studies suggest that serum starvation is the preferable method to 
synchronise even whole-cell culture, especially mesenchymal cells, there are currently no 
studies that have investigated the cell cycle duration of iPSC-derived MSCs. Furthermore, 
there is no current data which compares cell cycle duration between primary MSCs and 
iPSC-MSCs. Future work will, therefore, address this gap in order to optimise 
synchronisation of iPSC-MSCs and as to verify whether there is actual correlation between 
FAM111B mRNA and protein expression.         
Despite the evident problems with synchronization of the iPSC-MSCs, there was 
useful information that could be gleaned from the cell cycle experiments. Analysis of 
FAM111B expression in synchronised patient and control iPSC-MSCs showed that 
FAM111B mRNA expression is temporally expressed, peaking at 2-hours (S-phase) as well 
as at 15-hour (G1 phase) timepoints. Though there was slight variation in the peak of 
FAM111B mRNA expression between this study and the findings by Aviner et al. (2015), 
who showed that FAM111B mRNA peaks at the G1-phase. This variation may have been due 
to the different cell types and analytical methods used for both these studies. Aviner et al. 
(2015) measured FAM111B mRNA expression by RNA-seq in HeLa cells, while the current 
study measured relative FAM111B mRNA expression in synchronised iPSC-MSCs using by 
quantitative real-time PCR. Furthermore, the inconclusive protein data in this study limited 
further analysis of FAM111B between the current study and the findings by Aviner et al. 
(2015). However, the findings in this study are in line with the findings by Aviner et al. 
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(2015) that FAM111B mRNA expression is associated with the G1→S cell cycle 
progression, peaking the at S-phase and that FAM111B is co-expressed with PCNA 
expression which also peaked at 2 hours (S-phase). The elevated levels of expression of 
FAM111B at S phase are in line with ChEA data (http://amp.pharm.mssm.edu/lib/chea.jsp), 
which shows that the FAM111B promoter region contains a binding site for the E2F-1 
transcriptional activator known to be involved in the regulation of cell cycle transition into 
the S-phase. A recent study by Melling (2018) showed that the FAM111B promoter activity 
is increased in synchronised human lung carcinoma cell line (H1299) that were transfected 
with plasmids expressing E2F1 and E4orf6/7 which is a viral (adenovirus) analogue to human 
p107. Protein interaction assays such the chromatin immunoprecipitation (ChIP) assay could 
be performed to determine whether there is FAM111B-E2F1 interaction at the G1 and S-
phase to confirm the abundance of FAM111B protein in patient cells compared to controls. 
Furthermore, a report by Peng et al. (2008), stated that FAM111B/CANP levels are higher in 
foetal tissue and cancer cells compared to differentiating and adult cells. Foetal and cancer 
cells are known to exhibit higher cell proliferation rates compared to normal adult cells.  
Though different cell lines were used in this study, the data corroborates the report by Peng et 
al. (2008) as the results in this study showed that iPSCs, which have high proliferation rate 
express significantly higher levels FAM111B mRNA compared to dermal fibroblasts and 
iPSC-MSCs. These results further support the findings that FAM111B mRNA in 
synchronised iPSC-MSCs is temporally expressed and that patient cells express significantly 
higher levels than normal.  
Protein quantification was also performed to determine whether there is a correlation 
between FAM111B mRNA and protein expression. However, there was no correlation 
between mRNA and protein expression nor were there any statistical differences in protein 
expression between patient and control iPSC-MSCs. Given that it was clear that not all cells 
were adequately synchronised, one cannot draw any conclusions from these results. These 
experiments will be repeated once the cell cycle duration and the effective synchronisation 
method for iPSC-MSCs are established.  
While inefficient cell synchronisation may be the main conceivable reason for the 
differences in FAM111B mRNA and protein expression, other factors which may affect 
protein expression should also be considered, such mRNA-protein ratio as well as the 
specificity and/or effectiveness of the antibody used in this study. Studies have shown that 
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there are variations in transcription and translation rates which affect protein abundance (Lin 
& Amir, 2018; Liu et al., 2016). It has also been indicated that the mRNA-protein 
relationship is influenced by modulation of mRNA translation by the binding of non-coding 
RNAs (e.g. miRNA) on the regulatory elements of the transcript (Ebert & Sharp, 2012; Liu et 
al., 2016). The ubiquitin-proteasome pathway (UPP) has also been shown to influence protein 
levels and half-life independent of the mRNA levels. Furthermore, the delay in protein 
synthesis also contributes to the non-correlation with mRNA. For instance, a study by 
(Jovanovic et al., 2015) showed that mRNA levels of immune genes in mouse dendritic cells 
are elevated 3 hours after stimulation with lipopolysaccharide (LPS) while protein levels 
were elevated only 12 hours post-LPS stimulation. Another factor that could be considered to 
cause the differences in FAM111B mRNA and protein expression relates to the antibody 
used in this study. The Human Protein Atlas (www.proteinatlas.org) reported in their 
detection of FAM111B that the antibody staining of FAM111B in human tonsil tissue was 
inconsistent with RNA expression. Though the present study used a different antibody (sc-
246547) compared to the Human Protein Atlas (HPA038637) similar findings were observed. 
Lastly, it is also important to note that though data by Aviner et al. (2015) showed similar 
pattern of FAM111B mRNA and protein expression in HeLa cells, their study also indicates 
that certain cell cycle genes with high mRNA and translation do not show similar protein 
data, and further state that protein expression of these cell cycle genes is not reflected by 
steady-state protein accumulation. Clearly, future work will include optimising antibody 
detection and specificity.   
As mentioned above, the FAM111B protein levels may be due to posttranslational 
modifications such as ubiquitination which is known to modulate protein expression during 
cellular processes such as cell cycle progression (Liu et al., 2016).  Interestingly, ubiquitin 
binding sites have been identified on FAM111B and are reported to be localised on lysine (K) 
382, K429 and K62 (www.genecards.org). Functional studies, however, are needed to 
confirm activity on these ubiquitin sites. It should also be noted that gene mutations in some 
hereditary disorders may also show equivalent mRNA and/or protein expression as the 
wildtype. For example, a study by Devine et al. (2011) indicated that the protein levels of the 
mutant LRRK2 protein which causes autosomal dominant Parkinson’s disease, were similar 
between patient and control fibroblasts. Another study indicated that protein expression of the 
mutant Four and a half LIM domain protein 1 (FHL1), which causes Reducing Body 
Myopathy (RBM) due to poor myotube differentiation, was similar to the wildtype in induced 
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C2C12 mouse myoblast cells. In this condition, the mutant gene causes protein aggregates 
that inhibit normal myotube differentiation (Wilding et al., 2014). These studies thus indicate 
that though comparable protein levels can be observed between affected and unaffected cells, 
the pathogenesis of these conditions may be caused by protein modifications which are not 
detected by protein quantification.  
The data in this chapter demonstrates that patient cells exhibit a higher proliferation 
rate than control cells, and that elevated FAM111B mRNA levels may be associated with 
increased cell proliferation as recent studies have indicated that FAM111B is be involved in 
cell proliferation, though the mechanism of action is undefined. Future work will include 
investigating FAM111B protein expression in synchronised cells using the serum starvation 
method which may yield better results compared to the thymidine method used in this current 
study. Posttranslational modification (e.g. ubiquitination) assays and immuno-detection 
assays will also be performed to determine FAM111B localisation during cell cycle 
progression, and whether there is modulation of the ubiquitin proteasome system in 
FAM111B degradation. Future work will, furthermore, focus on FAM111B protein 
expression, activity and regulation as it will reveal the mechanism by which the mutation 
causes POIKTMP for clinical application in the affected persons.   
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Chapter 5 
General discussion and conclusion 
 
5.1 Summary of key findings 
Mutations in the FAM111B gene are associated with hereditary fibrosing poikiloderma with 
tendon contractures, myopathy and pulmonary fibrosis (POIKTMP). Since the putative 
function of FAM111B has not been described, this study aimed to investigate its involvement 
in fibrogenesis in a South African family carrying an autosomal dominant FAM111B 
mutation (c. 1861 T>G p. Tyr621Asp.). While it was hypothesised that FAM111B influences 
expression of pro-fibrotic genes, the findings in this study revealed that patient cells carrying 
the FAM111B mutation express normal levels of pro-fibrotic markers (COL1A1, COL3A1 
and α-SMA). Collagen content also indicated to be unaffected in the patient cells, thereby 
confirming the expression data. These results, therefore, indicate that FAM111B does not 
directly induce fibrosis via the dysregulation of pro-fibrotic markers.   
 Recent studies have indicated that FAM111B is among the uncharacterised proteins 
involved in cell proliferation and cell cycle progression (Aviner et al., 2015; Baselet et al., 
2017). To determine the basis of cell cycle modulation in this condition, a growth curve was 
performed to determine the proliferation rate between patient and control cells. The results 
showed that patient cells have over 2-fold cell proliferation compared to the control cells. 
Cell cycle experiments were therefore, performed to determine whether there is an 
association between FAM111B expression and cell cycle progression. The results revealed 
that FAM111B mRNA expression is cell cycle-regulated, peaking at the S-phase. Most 
importantly, they showed that patient cells express significantly high FAM111B mRNA 
levels compared to control cells in a cell cycle-dependent manner. Protein data were, 
however, inconclusive as the iPSC-MSCs indicated poor synchronisation for protein analysis. 
This may have been caused by the synchronisation method and/or the cell type used in this 
study. Taken together, this study has firstly, revealed that the cells derived from the South 
African patients carrying a FAM111B mutation have higher proliferation rate than the 
unaffected control cells. Secondly, though further experimentation is required in 
synchronised cells for protein analysis, mRNA data in this study indicate strong evidence that 
FAM111B is cell cycle-regulated and that it is highly expressed in the patient cells compared 
to controls. In summary, the data in this study suggest that the FAM111B mutation modulates 
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cell proliferation in persons with POIKTMP, which plausibly contributes to the phenotype in 
this condition. 
 
5.2 Creating in vitro cell models to elucidate FAM111B function 
Hereditary fibrosing poikiloderma (POIKTMP) in the South African family presents 
primarily with fibrosis in skeletal muscle, skin and lungs (Khumalo et al., 2006; Mercier et 
al., 2013). Based on the findings in this study the FAM111B mutation alters cell proliferation 
in the patient cells, but it is unclear how the mutation causes myopathy or tendon 
contractures. Fibrosis in skeletal muscle has been indicated to be caused by the continuous 
cycle of myofiber degeneration and regeneration, followed by excessive proliferation of 
fibroblasts as well as increased production of ECM proteins (Serrano & Munoz-Canoves, 
2010). In the patients with POIKTMP there is also muscle fragmentation that is replaced by 
fatty infiltration. Fatty infiltration is suggested to be caused by differentiation of 
fibro/adipogenic progenitor cells that are found in the interstitial space of skeletal muscle 
(Uezumi et al., 2011). It is probable that the FAM111B mutation contributes to the 
continuous cycle of muscle degeneration and fibrosis via fibro/adipogenic progenitors as they 
are able differentiate into fibroblasts and/or adipocytes during muscle repair, however, further 
studies need to be performed. Tendon contractures which are described as thickening of the 
tendons due to increased collagen deposition (Nolan, 1992) may be a secondary effect of this 
condition as their aetiology is unclear in literature. 
The current in vitro study used the iPSC-derived mesenchymal stem/stromal cells to 
investigate their proliferation and expression of pro-fibrotic factors as they have the potential 
to differentiate into myocytes as well as myofibroblasts under specific conditions (Desai et 
al., 2014; Xu et al., 2017). The limitation of this cellular model is that it could not recapitulate 
some of the fibrotic features observed in POIKTMP due to time constraints and the 
complexity of fibrosis (Mercier et al., 2013). Also, a 2D monolayer culture system was used 
in this study which has its limitation in mimicking the 3D in vivo microenvironment or 
complete disease modelling (Antoni et al., 2015; Duval et al., 2017). Furthermore, no 
chemical or mechanical insults were applied to iPSC-MSCs such as treatment with TGF-β or 
scratch assays to induce in vitro “wounding healing” or “fibrosis” to determine cell 
proliferation and fibrogenesis in these experimental conditions.  Improving this in vitro 
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model will provide greater insights into understanding the role of FAM111B during wound 
healing and fibrosis.  
The patient-derived iPSCs provide an infinite source for creation of in vitro tissue-
specific models for studying POIKTMP. The unknown function of FAM111B thus requires 
that iPSCs be further differentiated into other cell types that are affected in this condition to 
gain more insight into the onset of this fibroproliferative condition. Firstly, it is crucial that a 
3D culture system be used to mimic the in vivo milieu. Studies have shown that culturing 
human MSCs in hydrogel scaffolds stimulated with CTGF or TGF-β leads to their 
differentiation into myofibroblasts and increase production of ECM proteins (Xu et al., 
2017). Furthermore, differentiation of iPSC-MSCs into skeletal myocytes to investigate the 
onset of myopathy in this condition may also reveal the role of FAM111B in myocyte 
degeneration and fatty infiltration observed in POIKTMP. In addition, the Protein Atlas 
database (www.proteinatlas.org) has indicated that FAM111B expression is high in tissues of 
the endodermal lineage such as the pancreas, lung and prostate; these are some of the tissues 
that are affected in POIKMTP cases or prostate cancer linked to FAM111B (Akamatsu et al., 
2012; Goussot et al., 2017; Mercier et al., 2013; Takeichi et al., 2016); therefore, cellular 
modelling must also be directed towards these cell types to gain more understanding into the 
function of FAM111B. The derived patient-specific iPSCs could also be differentiated into 
3D skin and/or lung organoids under the 3D culture system (Ho et al., 2018; Miller et al., 
2019; Zuppinger, 2016). Recent studies have shown that 3D cell culture models develop 
tissue stroma and the heterogenous cell type found in the specific tissue (Dutta et al.). For 
instance, a study by (Hohwieler et al., 2016) showed that iPSC-derived pancreatic organoids 
formed mature acinar/ductal structures which also produced enzymes such as carbonic 
anhydrase. Another study by Dye et al. (2015) demonstrated that iPSC-derived lung 
organoids presented with epithelial structures that resembled the proximal airway and were 
also associated with mesenchymal cells which expressed α-SMA.  
There are still challenges in the creation of iPSC-derived in vitro models that mimic 
molecular changes at different stages of disease progression (Miller et al., 2013). Creation of 
these in vitro models is not only expensive, but it is also laborious and requires further 
troubleshooting to obtain a culture model that best mimics the structure and function of the 
specific tissue (Dye et al., 2015; Miller et al., 2019). Furthermore, there is also a challenge of 
self-organisation of organoid cell cultures as they do not always undergo uniform self-
organization (Ho et al., 2018). Moreover, it is also important to determine the lifespan of the 
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derived cell types and to match it to the primary cells as it is known that cellular 
reprogramming also alters the epigenetic signature of the reprogrammed cells. For example, 
iPSC-MSCs have been shown to exhibit similar characteristics as primary MSCs (Diederichs 
& Tuan, 2014; Frobel et al., 2014; Kang et al., 2015). They have also been shown to maintain 
a distinct epigenetic signature and acquire rejuvenation-associated gene signature compared 
to primary MSCs (Frobel et al., 2014; Spitzhorn et al., 2019). A study by Frobel et al. (2014) 
showed that redifferentiation of iPSCs that were derived BM- MSCs into iPSC-MSCs acquire 
moderate age-related DNA methylation compared to BM-MSCs and were estimated to be 
younger than the donor MSCs. In contrast, a recent study by Fernandez-Rebollo et al. (2019) 
indicated that iPSC-MSCs acquire similar changes in morphology as primary MSCs and 
display similar senescence-associated metabolomic phenotype. Furthermore, they reach 
growth arrest at cumulative population doubling (CPD) of 17 compared to primary MSCs 
that reached growth arrest at CPD of 21. Therefore, it is important to determine the aging of 
the cell type used for disease modelling. Another challenge is aging the iPSC-derived disease 
models as they “age” at a different pace as primary cells.  
Creation of an isogenic lines in this study is required for future work to eliminate the 
genetic background of non-isogenic cell lines which contributes to the variation of the results 
observed in this study. The clustered regularly interspaced short palindromic repeat-Cas9 
(CRISPR-Cas9) system is a gene editing tool which can be used to create isogenic cell lines 
by performing a homolog-directed repair (HDR) where the Cas9 endonuclease is directed to 
the target DNA locus by guide RNAs to repair the target mutation (Ran et al., 2013). Gene 
editing of patient-derived cells by the CRISPR-Cas9 system will therefore, allow for 
comparison of the wildtype and mutant cells from the same donor and further reveal some of 
the subtle phenotypic differences that may have been masked by the genetic background of 
non-isogenic donor cells (Bassett, 2017; Grobarczyk et al., 2015). The generation of 
FAM111B isogenic cell lines will further yield conclusive findings such as whether the 
FAM111B mutation alters expression of pro-fibrotic markers since no differences were 
observed when compared with the non-isogenic control cells. Furthermore, the creation of 
patient-derived isogenic iPSCs will contribute to understanding the fibrotic phenotype 
affecting the different cell types as well as its mechanism in different disease models that will 
be derived for this condition.   
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5.3 Functional characterisation of FAM111B 
Further characterisation of the FAM111B protein is also required as gene mutations 
may cause molecular modifications during protein expression and folding. Bioinformatic data 
have, for instance, indicated that there are ubiquitination sites on the FAM111B protein and 
are localised on lysine (K) 382, K429 and K62 (www.genecards.org). It has also been 
indicated that FAM111B forms part of the ubiquitin-mediated proteolysis pathway (UMPP) 
(Guo et al., 2011) and that FAM111B is frequently mutated in renal cell carcinoma 
(Rydzanicz et al., 2013). The FAM111B mutation in this study is located at the loop region 
(p. Tyr621Asp.)  of the catalytic domain (Mercier et al., 2013), therefore it is likely that it 
affects the catalytic activity of this protein. Based on the current findings that the mutation 
induces increased cell proliferation in patient cells, this suggests a gain-of-function mutation 
as hypothesised by Mercier et al. (2013). A gain-of-function mutations exert effects which 
the wild-type gene does not (van Oijen & Slootweg, 2000). It is, therefore, possible that the 
FAM111B mutation in the South African family acquires new function in proliferating cells. 
Further experiments such as in vitro wounding or stress assays need to be performed as the 
gain-of-function phenotype in patient cells may lead to increased cell proliferation. 
Furthermore, since FAM111B is described as a serine/cysteine protease it is also likely that 
the mutation may lead to autoactivation or inhibit inactivation of the catalytic site leading to 
POIKTMP, as observed in gain-of-function mutations on the cationic trypsinogen enzyme 
which causes hereditary pancreatitis (Sahin-Tóth & Tóth, 2000). Moreover, the FAM111B-
fibrosis and FAM111B-cancer link should be further explored as it may also reveal the role 
of FAM111B in fibrosis and cancer. For, instance, a study by Fernandez-Retana et al. (2017) 
showed that FAM111A and FAM111B form part of the degradome-related genes which are 
upregulated in cervical cancer as they are also involved in the breakdown of the extracellular 
matrix for cancer metastasis.  
   
5.4 Potential treatment for POIKTMP  
 The standard treatment for fibrotic diseases such as systemic sclerosis, hepatic fibrosis, 
idiopathic pulmonary fibrosis (IPF) and nephrogenic systemic fibrosis is targeted downstream 
kinases in the TGF-β and PDGF receptor signalling pathway (Daniels et al., 2004; Kay & 
High, 2008). For example, Imatinib mesylate inhibits tyrosine kinase activation to prevent 
binding of TGF-β to SMAD-independent receptors (e.g. PI3K/Akt/ c-Abl) as well as PDGF 
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signalling. Imatinib has been shown to particularly target the non-receptor tyrosine kinase-
cellular Abelson (c-Abl) as well as the non-canonical TGF-β pathway (Kay & High, 2008).  
Most of these therapeutic drugs such as Pirfenidone aim to target TGF-β and its 
pathway. Although some improvement has been observed, it should be noted that TGF-β 
plays an essential role in cellular processes such as proliferation, cell migration and 
differentiation; therefore, its inhibition may have long-term negative consequences. Some 
studies have therefore reported that the timing of treating fibrosis using TGF-β inhibitors is 
crucial as treating early may worsen the condition while treating later may greatly improve 
the condition (Edgley et al., 2012). Some promising studies have demonstrated that targeting 
the EMT process during fibrosis may be effective in treating fibrosis. For example, a study by 
Kim et al. (2017) demonstrated that the use of chromones which are present in plant flavones 
can downregulate EMT-associated genes. This study demonstrated that Eupatilin, a chromone 
derivative successfully downregulated lymphocyte infiltration, collagen I, periostin and α-
SMA expression as well as overall ECM deposition in IPF lung fibroblasts and hepatic 
stellate cells in vitro (Kim et al., 2017). Corticosteroids which function as anti-inflammatory 
agents to prevent the activation of pro-inflammatory factors have also been used to treat 
idiopathic pulmonary fibrosis (Walter et al., 2006). These therapeutic agents, however, have 
proven to be ineffective for long-term treatment of fibrosis.  
Since FAM111B is associated with fibrosis and cancer (Fernandez-Retana et al., 
2017; Mercier et al., 2013; Yue et al., 2015), it is of interest, based on the findings in this 
study, if the repurposing of cancer-drugs can be used to treat POIKTMP as it induces 
increased cell proliferation in the affected persons. Recent studies have indicated that co-
treatment of cancer-associated fibroblasts with cisplatin and pirfinedone leads to increased 
apoptosis and reduced cancer progression in non-small cell lung cancer (NSCLC) cell lines 
and prostate (Mediavilla-Varela et al., 2016). Furthermore, treatment of pulmonary fibrosis 
with histone deacetylase (HDAC) inhibitors such as Suberanilohydroxamic acid (SAHA) 
which is used to treat T-cell lymphoma was shown to reduce inflammation in IPF lung cells 
by inhibiting biosynthesis of Leukotriene B4 (LTB4) enzyme required for chemotactic 
activity of leukocytes in mouse acute lung infection model (Lu et al., 2017b). Another study 
indicated that treatment of IPF lung cells with UCN-01, (7-hydroxystaurosporinean), an anti-
cancer drug that is currently tested in phase II clinical trial (http://clinicaltrials.gov) increases 
expression of the Forkhead box O3 (FoxO3) transcription factor. This transcription factor 
was found to be downregulated in fibroblasts obtained from human IPF lung and those from a 
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mouse bleomycin model. Treatment of the cells with UNC-01 leads to increased FoxO3 
protein levels which indicated to reduce cell proliferation and expression of pro-fibrotic 
markers such as COL1A1, COL3A1 and α-SMA (Al‐Tamari et al., 2017). These studies, 
though in early stages thus indicate that anti-cancer drugs can be repurposed for treatment of 
fibrosis by also targeting cell proliferation which is also observed in the POIKTMP condition.  
 
5.5 Conclusion and Future work  
This study revealed that FAM111B mutation increases proliferation of patient cells. It further 
showed that FAM111B mRNA is increased in the patient cells. However, protein data for 
FAM111B expression during cell cycle progression was inconclusive. Therefore, 
determination of the cell cycle duration in the derived iPSC-MSCs is important for 
determining whether there are differences in the expression of FAM111B protein in patient 
cells. 
 Future work will also focus on developing the 3D disease model(s) to elucidate the 
function of FAM111B. Together with the UCT FAM111B group, future work will also focus 
on protein characterisation and enzymatic activity, particularly during cell cycle progression 
as the current data indicate its involvement in DNA synthesis. Furthermore, FAM111B 
expression and its role in cancer cells will be explored as it may perform similar function in 
POIKTMP.  
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Figure S1: Synchronisation of HeLa cells with double-thymidine (2 mM) block. HeLa cells 
were arrested at G1/S using by double-thymidine (2 mM) block for 19 h with a 9-h release. (A) 
PCNA, (B) AURKA and (C) FAM111B mRNA expression levels were measured at 2, 4, 6, 8, 
10, 12 and 14 h post-thymidine release. Data presented as mean ± SD (n =2). 
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Figure S2: 30-hour synchronisation of control (familial) iPSC-MSCs with double-thymidine 
block (2 mM). Control iPSC-MSCs were arrested by double-thymidine (2 mM) block for 30 h 
with a 15-h release. mRNA expression of (A) PCNA, (B) AURKA and (C) FAM111B were 
analysed relative to asynchronous cells (G0) phase at 4-5 h intervals for 30 h post-thymidine 
block. (n =1). 
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Figure S3: 24-hour synchronisation of control (familial) iPSC-MSCs with double-thymidine 
block (2 mM). Control iPSC-MSCs were arrested by double-thymidine (2 mM) block for 24 h 
with a 12-h release before the second thymidine block. mRNA expression of (A) PCNA, (B) 
AURKA and (C) FAM111B were analysed at 3-h intervals for 24 h post-thymidine block. Data 
presented as mean ± SD (n =2). 
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Figure S4: Flow cytometry of synchronised control (familial) iPSC-MSCs with 2 mM or 4 mM 
double-thymidine block. Control iPSC-MSCs were treated with 2 mM or 4 mM of thymidine for 24 h 
with a 12-h release before the second thymidine block. DNA content of synchronised cells was 
measured at (A) 0 h, (B) 2 h, (C) 6 h and (D) 15 h for the respective thymidine concentrations (2 mM 
and 4 mM) used. Data presented as mean ± SD (n =2).  
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Figure S5: Flow cytometry analysis of synchronised control (familial) iPSC-MSCs at 6 h, 12 h and 
15 h. Control iPSC-MSCs were treated with 4 mM of thymidine for 24 h with a 12-h release before the 
second thymidine block. DNA content in synchronised cells was compared at 6 h, 12 h and 15 h post-
double-thymidine release. Data presented as mean ± SD (n =2).  
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 Figure S6: Expression of AURKA and FAM111B mRNA in synchronised patient and control 
iPSC-MSCs. The iPSC-MSCs were arrested by double-thymidine block for 24 h with a 12-h release 
before the second thymidine block. DNA content in synchronised cells was compared at 6 h, 12 h and 
15 h post-double-thymidine release. (A) AURKA and (B) FAM111B mRNA expression were analysed 
at 0, 2, 6, 12 and 15 h. Data presented as mean ± SEM (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001 
Supplementary Data 
 173 
 
NATIONAL  HEALTH LABORATORY  
Human Genetics  - Groote Schuur  
Tel  No:  021   4044 509   Cyt ( o )  021   40 44449   (M olecular ) 
Fax No:  021 4044530   021 40 444 72   
Practice No: 5200296  
Labno  SCG0022205  /2014)  (05/03 
Ref  R-17 
DR  BALLO  
www.m:ulhtb.11cL1c.za  
Age(Sex)  
Ref  Dr  
DoB  Not stated  
DR BALLO  
OrganisationKaryotyping  Ballo 
Hosp No  
SERVICE  
PO Box 3.J55S  
Groote Schuur  
7 935   
Page  1 of  1   
RM  ,  6.01 LEVEL  6   
ANATOMY  BUILDING  
UCT,  MEDICAL SCHOOL  
OBSERVATORY  
Taken  
  7925 
Specimen  
Tests  ordered  
Report  
HFPl.2 / Fa mi l i al  c o ntr ol 
No  Date  Rcv'd27/02/14 14:50  
17 /03/14  13:41   
LABORATORY  REPORT   
Stem Cell Collection  
Bld  Chr  
BLOOD  CHROMOSOME ANALYSIS  
Chromosome analysis  of  10 metaphase  cells  revealed  the  karyotype:  
46 ,XX  consistent  with  a  normal  female  pattern.  
No gross  structural abnormality  was detected on  Giemsa  banded  
metaphases.  Chromosomal changes  which  may  be  clinically  significant  
such as  subtle rearrangements or micro-deletions may  not  be detected  
in  some metaphase spreads.  
The  chromosome  band  resolution  is  approximately    400 g-bands.  
This  test  was performed at  NHLS Cytogenetics,  C21,  New  GSH  
Tel:  021     404 4509 
Information  regarding Genetic  Services is available at  
Tel:    021 406 6304   / 021 404  6235   
Authorised by :   T Ruppelt  Medical  Technologist  Test(s):  Bld Chr  
End  of Laboratory Report  --- 
Supplementary Data 
 174 
 
Supplementary Data 
 175 
 
NATIONAL  HEALTH LABORATORY  
Hunwn Genetics  - Groote Schuur  
Tel  No:  021   40 44 509   ( Cyto)  021   40   44449 ( Molecular) 
Fax No:  021 4044530   021 4044472   
P r actice No: 5200296  
Labno  SCG0023775  (15 / 08 / 2014)   
Ref  R-20  
DR R  BALLO  
wwi,i,·. tn.1<11:?b. 11Ct..1c.z.1  
Patient  
Age(Sex)  
Ref Dr  
HF P2.5/P atient  A  
DoB Not stated  
DR R BALLO  
OrganisationKaryotyping  Ballo  
Hosp  No  HFP2.5/P atient  A  
SERVICE  
PO Box 3.J555  
Groote Schuur  
7 935   
Page  1 of    1 
RM  6.01 ,  LEVEL  6   
ANATOMY  BUILDING  
UCT,  MEDICAL  SCHOOL  
OBSERVATORY  
Taken  No  Date  Rcv'dl2/08/14  15:45   
  7925 
Tests  ordered  Bld  Chr  
BLOOD  CHROMOSOME  ANALYSIS  
Report  /08/14 10:16  26 
LABORATORY  REPORT   
Chromosome  analysis  of 10  metaphase  cells  revealed  the  karyotype:  
46 ,XY,  consistent  with  a  normal  male pattern.  
No gross  structural  abnormality  was detected on  Giemsa  banded  
metaphases.  Chromosomal changes  which  may  be  clinically significant  
such  as  subtle rearrangements  or micro-deletions may  not  be detected  
in  some metaphase spreads.  
The  chromosome  band  resolution  is  approximately 500  g-bands.  
This  test  was  performed  at  NHLS  Cytogenetics,  C21,  New GSH  
Tel: 021 404 4509  
Information  regarding  Genetic  Services is  available at  
Tel:  021   406   6304   /  021 404   6235   
Authorised  by  :   N Jano  Medical Technologist  Test(s):  Bld Chr  
--- End  of  Laboratory  Report  --- 
Supplementary Data 
 176 
 
NATIONAL  HEALTH LABORATORY  SERVICE  
Human Genetics  - Groote Schuur  
Tel  No:  021404450 9   ( Cyt o )  02140 44449   ( Molecular ) 
Fax No:  021 4044530   0214 044472   
Practice No: 5200296  wi,i,·w.ma<IJ,lb.11ct.ac.z..1  
Labno  SCG0024875  /2014)  (20/11 
Ref  R-22 
DR R BALLO  
Patient  
Age(Sex)  
Ref Dr  
HFP 3.4 /Pa tient  B  
DoB Not stated  
DR R BALLO  
OrganisationKaryotyping  Ballo  
Hosp No  
POBox34555  
Groote Schuur  
  7935 
Page    1 of    1 
RM  6.01 ,  LEVEL  6   
ANATOMY  BUILDING  
UCT,  MEDICAL  SCHOOL  
OBSERVATORY  
Taken  
7925   
Specimen  
Tests  ordered  
Report  
HFP3.4/Pa tient  B  
No  Date  Rcv'dl7/ll/14 15:30  
12 /12/14  13:59   
LABORATORY  REPORT   
Stern Cell Collection  
Bld Chr  
BLOOD  CHROMOSOME  ANALYSIS  
Chromosome  analysis  of  10   rnetaphase  cells  revealed  the  karyotype:  
46 ,XX  consistent with  a  normal female pattern.  
No  gross  structural  abnormality  was  detected  on  Giernsa  banded  
metaphases.  Chromosomal  changes which  may  be clinically  significant  
such  as  subtle  rearrangements  or  micro-deletions  may  not  be detected  
in some  melaphase  spreads.  
The  chromosome band resolution is approximately 400  g-bands.  
This  test was  performed at NHLS  Cytogenetics,  C21,  New  GSH  
Tel:  021   404   4509   
Information  regarding Genetic Services is  available  at  
Tel:  021   406 6304 /  021 404 6235   
Authorised  by  :   N  Jano  Medical Technologist  Test(s):  Bld  Chr  
--- End  of  Laboratory  Report  --- 
